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ABSTRACT
Kaposi's sarcoma (KS)-associated herpesvirus (KSHV), also called human
herpesvirus 8 (HHV8), has been been identified in all epidemiological forms of KS as
well as in tissue obtained from primary effusion lymphoma (PEL) and Multicentric
Castleman's disease (MCD). The KSHV genome contains several putative
oncogenes, suggesting that viral infection may induce cellular transformation and
tumorgenesis.
Herpesviruses encode a number of different surface glycoproteins, which are involved
in virus-host interactions. Studies have shown that the viral glycoproteins H and L
form a complex that plays an essential role in viral attachment and cell to cell fusion.
Both glycoproteins have been identified in KSHV and were expressed in mammalian
cells. Expression studies revealed that KSHV gH and gL exhibit similar features to
those seen in other herpesviruses. However, KSI-IV gL appears to traffic
independently and may function in cell to cell fusion processes even when expressed
alone.
KSI-IV de novo infections are rare and the lack of a reliable cell culture system has
delayed pathogenesis studies. As part of this thesis the hepatoma cell line HepG2 has
been shown to allow limited KSHV infection, as judged by nested PCR. Studies have
shown that infection leads to increased apoptosis, although viral replication could not
be detected. Furthermore, Epstein Barr Virus (EBV) appeared to modulate the ability
of KSHV to infect HepG2 cells.
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Finally, a microtitre plate assay has been established for the quantification of the
KSHV genome. A comparison of plasma and serum samples obtained at the same
time point showed that plasma is more reliable in testing for KSHV, the DNA copy
number in serum samples being reduced up to 10 fold. In conclusion, this new assay
is a potentially useful tool for both diagnostic proposes and research studies.
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1. Introduction
Kaposi's sarcoma was originally described in 1872 by the dermatologist Moritz
Kaposi as a multiple pigmented sarcoma affecting elderly Mediterranean men
(Kaposi, 1872). To date several epidemiological forms have been classified. In
recent years the general prevalence of this vascular tumour in the USA and UK
was low, at 0.05 per 100 000 of the population (Biggar et al. 1984). However,
with the emergence of the HIV epidemic, the incidence of KS increased. In 1990,
approximately 30% of HIV infected gay men suffered from KS during their illness
(Jacobson et a!. 1990).
Kaposi sarcoma lesions are histologically complex and evolve over time, from a
patch or plaque-like lesion at early stages to nodular lesions characteristic of
disease progression. Several hypotheses regarding the pathogenesis of this
vascular tumour have been suggested, including both infectious agents and
cytokine mediated processes. In 1994 a study by Chang and colleagues found a
novel herpesvirus present in KS tissue (Chang et a!. 1994). Since its discovery this
virus, now known as KS associated herpesvirus (KSHV) or human herpesvirus 8
(HHV8), has been the focus of many studies regarding its role in the pathogenesis
of Kaposi's sarcoma.
1.1 Kaposi's Sarcoma (KS)
1.1.1 Epidemiological forms of Kaposi's sarcoma
Kaposi's sarcoma is a multifocal vascular neoplasm involving the skin, visceral
organs and lymph nodes. The lesions are complex and contain distinctive
proliferating spindle cells, activated endothelial cells and infiltrating inflammatory
24
cells (Roth et a!. 1992). The classic form of KS predominantly affects elderly
male patients of southern European heritage (Franceschi and Geddes, 1995). The
tumour is also frequently described in patients from Israel, mainly in the Jewish
population (Iscovich el a!. 1998b; Iscovich et a!. 1998a) and in other Middle
eastern countries. Disease progression in classic KS patients occurs over a period
of several years. In patients suffering other forms of KS, including endemic KS of
I-IIV negative individuals in central regions of Africa, iatrogenic KS, and AIDS-
associated KS, the disease is more aggressive. In HIV infected individuals the
underlying immunsuppression leads to a fulminant disease starting with skin
lesions and often affecting systemic organs (lung, liver, gut spleen) (Beral, 199 Ia;
Beral, 1991b). KS is the most common AIDS-associated malignancy and has been
a leading cause of morbidity among AIDS patients (Beral eta!. 1990).
The endemic form of KS can be found in some equatorial countries of Africa.
Here, KS is described in both young and elderly HI V-negative patients. Before the
HIV epidemic KS was common in some areas of Sub Saharan Africa. With the
advent of AIDS a 20 fold increase in the incidence of KS in Uganda and
Zimbabwe was observed (Cook Mozaffari et a!. 1998; Chang et a!. 1 996b) and KS
has become one of the leading malignancies in sub-Saharan Africa. Disease
progression is more aggressive than for classical KS, in particular for children
where lymph node involvement is common. Endemic KS leads to the majority of
death in young patients (Ziegler and Katongole Mbidde, 1996).
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Finally, the incidence of this vascular tumour has increased among renal transplant
recipients and other patients receiving immunosupressive therapy. This form is
known as post-transplant KS or iatrogenic KS (Beral, 199 Ia).
1.1.2 Histology of KS
Kaposi's sarcoma is characterised by bundles of spindle-shaped cells and
endothelial-lined vascular spaces with lymphocytic infiltrates. Commonly red
blood cells percolate in the spaces between the spindle cells (Cockerell, 1991).
These spindle cells produce pro-inflammatory and angiogenic factors that are
likely to play an important role in the recruitment of additional cells to the
sarcoma (Ensoli eta!. 1991). Also, KS cells are highly dependent on inflammatory
cytokines in culture. This observation led to the hypothesis that KS pathogenesis
may be influenced by inflammatory cytokines and angiogenic factors (Nakamura
eta!. 1988; Ensoli eta!. 1992).
KS is not a typical sarcoma, in that multiple lesions may appear simultaneously at
several locations, but may disappear completely over time. As mentioned earlier
KS starts as a patch or plaque-like lesion at early stages and develops into the
nodular lesions characteristic of later stage disease. In early stages small irregular
endothelial-lined spaces, surrounded by normal blood vessels and inflammatory
infiltrates of lymphocytes can be detected. As the disease progresses the number
of spindle shaped cells increase throughout the dermis and form slit like vascular
channels containing erythrocytes (patch stage). In the final, nodular stage, the
lesions are characterised by sheets of spindle cells.
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KS cells represent a heterogeneous population, as indicated by the variety of
surface markers. The cells identified by histology are mainly activated endothelial
cells mixed with fibroblasts, smooth muscle cells and cells of dentritic and
monocytic origins (Regezi et a!. 1993; Roth et a!. 1992). The clonality of KS is
frequently discussed, as the exact tumor cell type is controversial. Especially in
early lesions spindle cells are a minority. Spindle cells are usually not prominent
until late stage disease. Recent studies have demonstrated that spindle cells belong
to an endothelium lineage that expresses the vascular endothelium growth factor
receptor-3 (VEGFR-3), a marker of lymphatic vessels (Dupin et al. 1999). Other
studies analysing inactivation pattern of the X chromosome, a marker for
clonality, revealed both a monoclonal and polyclonal pattern (Rabkin et a!. 1995;
Delabesse et a!. 1997). KS may be initially a non-clonal proliferation, but may
sometimes develop into a clonal malignancy with metastases during advanced
disease (Rabkin et a!. 1997).
1.1.3 Pathogenesis of KS, chemokines and viruses
Kaposi's sarcoma lesions produce high levels of cytokines both in vivo and in
culture. Several cytokines and growth factors have been implicated in the
proliferation of KS spindle cells, including oncostatin M (Miles et a!. 1992),
platelet derived growth factor (PDGF) , Interleukin I 1 (IL-I 3) (Sturzl et a!. 1995),
Interleukin 6 (IL-6) (Miles et a!. 1990), Interleukin 8 (IL-8) (Sciacca et a!. 1994),
basic fibroblasts growth factor (bFGF) (Ensoli et a!. 1994a; Ensoli et a!. 1994b),
vascular endothelial growth factor (VEGF) (Comali et a!. 1996), macrophage
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chemotactic protein-I (MCP-I) (Barillari et a!. 1992), and the Human
Immunodeficiency Virus-I (HIV-1) Tat protein (Ensoli et a!. 1990). Data from
gene expression studies further support their involvement in KS pathogenesis as
angiogenic properties of IL-6, bFGF and IFN gamma could be demonstrated in
vitro (Sciacca et a!. 1994; Comali et a!. 1996). In particular IL-6 has been shown
to enhance proliferation of KS cells in culture (Miles et a!. 1990). As disease
progression in HI V-associated KS is more aggressive, it has been suggested that
proteins encoded by HIV may influence tumour growth. Observations showed that
the transcription activator protein, Tat, in combination with bFGF, stimulate the
proliferation of KS associated spindle cells in vitro and can induce KS-like lesions
in mice (Ensoli et al. 1994b). This HIV encoded protein also induces cellular
genes that are pro-proliferative and pro-inflammatory (MCP-1, IL-6) in KS and
possibly enhance the recruitment of leukocytes to KS lesions (Kelly eta!. 1998)).
While in vitro and animal models strongly suggested that cytokines and growth
factors play an important role in the development of KS (Ensoli et a!. 1992),
epidemiological data implicated a sexually transmitted cofactor (Beral et a!.
1990). AIDS patients with Kaposi's sarcoma are predominantly gay or bisexual
men, rather than patients who acquired the virus through heterosexual contact,
haemophiliacs or intravenous drug users (Beral, 1991b). These findings favour an
infectious agent or co-factor in the development of KS. Infectious agents such as
cytomegalovirus (CMV) (Giraldo et a!. 1972) human herpesvirus 6 (HHV-6),
human papilloma virus (HPV), BK virus and other viral or bacterial pathogens
have all been linked to KS (Monini eta!. 1996b; Wang eta!. 1993). However, in
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1994 a research group in New York detected herpesvirus-like DNA from biopsies
of AIDS-associated KS using a subtractive DNA hybridisation technique known
as representational difference analysis (RDA) (Lisitsyn, 1995; Chang et a!. 1994).
The technique relies on cycles of subtractive hybridisation and polymerase chain
reaction to enrich and isolate nucleotide sequences which differ between KS
affected tissue and unaffected surrounding cells. Two subgenomic BamHl
fragments of DNA, designated KS33O Bam and KS63 1Bfl were isolated. Subsequent
computer-assisted homology searches revealed that these novel sequences were
related to the minor capsid and tegument protein genes of the lymphotropic y
-herpesviruses Epstein Barr (EBV) and Herpesvirus saimiri (HVS) (Chang et a!.
1994, Albrecht et a!. 1992; Baer et a!. 1984). More recently, similarities between
this newly identified herpesvirus and the rhesus monkey rhadinovirus (RRV)
(Searles et a!. 1999; Desrosiers et a!. 1997) as well as macaque retroperitoneal
fibromatosis virus isolates Mn and Mm (Rose et a!. 1997) have also been
described. Further characterisation of this newly identified agent, named Kaposi's
sarcoma-associated herpesvirus or human herpesvirus 8, confirmed its
classification as a member of the gamma-2 herpesvirus family (genus
Rhadinovirus) (Moore el a!. 1996b). Visualization of herpesvirus like particles by
electron microscopy provided additional evidence for the viral origin of these
sequences (Said et a!. I 996b).
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1.2 Family of Herpesviridae
Herpesviruses have the capacity to establish latent infections in their host, with the
genome persisting in the nucleus. Hence these viruses are frequently reactivated in
AIDS patients and following immunosupressive therapy for organ transplantations
or cancer.
The Herpesviridae are a family of enveloped virions, approximately 120-200nm
in diameter, comprising an inner core that is surrounded by an icosahedral capsid,
and a lipid-bilayer, the envelope. The number of glycoproteins embedded in this
viral envelope varies for each herpesvirus, for example HSV encodes at least 11
glycoproteins.
The herpesvirus genome is a linear double stranded DNA molecule, which
circularises upon release from capsids into the nuclei of infected host cells
(Furlong et a!. 1972). During latency only a small subset of genes is expressed to
maintain the viral genome and maintain a persistent infection (Croen, 1991).
Herpesviruses encode a large number of enzymes involved in nucleic acid
metabolism, DNA synthesis and the processing of proteins. Many of these genes
are not essential for viral replication and presumably encode other functions, such
as cellular growth control, pathogenicity, supression of the host immune response
or maintenance of viral latency (McGeoch, 1989). Viral gene expression is both
highly complex and tightly regulated, with sequential transcription and translation
of immediate early, early and late genes (Roizman, 1993). One may generalize
that viral immediate early genes are responsible for the activation of lytic genes
and that early synthesised proteins regulate the transcription of later genes
(Chevallier Greco eta!. 1986; Countryman and Miller, 1985; Nicholas et a!. 1991;
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Whitehouse eta!. 1998). During lytic infection the virus induces the shut down of
host cell protein and nucleic acid synthesis to produce its own progeny virions.
Usually herpesviruses have characteristic cytopathic effects (CPE), such us the
formation of multinucleated giant cells (VZV, HCMV), swollen, rounded cells
(HSV), or intranuclear inclusion bodies (HSV, HCMV) (White and Fenner, 1994).
The classification of the herpesviridae into three subfamilies was based originally
on these biological properties. However, with the increasing number of sequences
available from each herpesvirus the taxonomy will in future be based more on
DNA sequence similarity, genome arrangements and the conservation of particular
genes.
1.2.1 Alphaherpesvirinae
This subfamily includes the herpes simplex viruses I and 2 (HSV- I; HSV-2) and
varicella-zoster virus (VZV). Recurrent HSV-1 infection is generally associated
with labial herpes, whereas HSV-2 is mainly responsible for genital herpes. VZV
causes chickenpox during childhood and herpes zoster (shingles) on reactivation
in adults.
These viruses have a variable host range and a relatively short reproductive cycle.
In culture viral growth is rapid and leads to destruction of the infected cell.
Latency is primarily established in sensory neurons.
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1.2.2 Betaherpesvirinae
The human cytomegalovirus (HCMV), human herpesvirus 6 (HHV6) and human
herpesvirus 7 (HHV7) are members of the beta herpesvirinae subfamily. CMV
infection is acquired subclinically during childhood but can cause severe damage
in immunocompromised adults. Also, during pregnancy primary CMV infection
can lead to severe congenital abnormalities in the fetus. Reactivation of latent
CMV infection is one of the most common opportunistic infection in HI V-infected
patients and can lead to death.
HHV6 and I-IHV7 infect children in the first two years of life and are associated
with exanthem subitum (Levy, 1997). An association of HHV6 with
encephalopathy have been suggested but this is still under investigation.
Biologically, betaherpesvirinae show a long reproductive cycle in vitro and
produce large, often multinucleated, cells (cytomegalia). Latency is established in
secretory glands, lymphoreticular cells, the kidney and other tissues.
1.2.3 Gammaherpesvirinae
Herpesviruses of the subfamily gammaherpesvirinae are involved in the
pathogenesis of several lymphomas or carcinomas. Representatives of this group
exhibit oncogenic potential and are associated with B- and T-cell lymphomas.
Viruses replicate and persist in lymphoblastoid cells (Roizman, 1993). Members
include the Epstein Barr virus (EBV), the squirrel monkey virus, herpesvirus
saimiri (HVS) and others. On the basis of sequence similarity, the newly identified
herpesvirus KSHV has been classified as a gammaherpesvirus, most closely
related to the gamma-2-herpesviruses. Other gammaherpesvirus subgroup with
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sequence similarities to KSHV are the murine herpesvirus 68 (MHV68) and the
recently identified retroperitoneal fibrosis herpesvirus (RPHV). Both viruses are
capable of inducing tumours in animals. Table 1.1 lists the known gamma
herpesviruses that are related to KSHV.
Virus	 Host	 Associated tumor
Epstein Barr Virus	 Humans	 Burkitt's lymphoma
(EBV)	 Hodgkin's disease
Nasopharyngeal carcinoma
_____________________ _____________________ Post-transplant lymphoproli ferations
Herpesvirus saimiri	 New World monkeys 	 T cell lymphoproliferations
(1-IVS)	 ______________ _______________________
retroperitoneal fibrosis Old World monkeys	 Retroperitoneal fibrosis
herpesvirus(RPHV) ____________________ _________________________________
Murine herpesvirus 68 Mice 	 Lymphoproliferations
(MHV68)	 ______________ _______________________
Table 1.1: Gammaherpesviruses that are related to the newly identified Kaposi's
sarcoma associated herpesvirus (KSHV)
Epstein Barr Virus causes infectious mononucleosis, in certain geographic areas
the virus has been linked to a number of malignant lymphomas, including
Burkitt's lymphoma (BL) in Sub Sahara Africa and naso-pharyngeal carcinoma
(NPC) in East Asia (Kieff, 1996). In vivo EBV is able to infect B lymphocytes as
well as epithelial cells. In vitro EBV infection is largely restricted to primate B
lymphocytes; epithelial cells can be infected but infection is abortive and the virus
is lost on passage. Most knowledge of EBV pathogenesis is based on culture
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systems using B lymphocytes, where the virus transforms resting B lymphocytes
to proliferate indefinitely in culture (for review see Kieff, 1996). These
lymphoblastoid cell lines (LCL) are similar to antigen-driven B cells and are used
successfully for the production of human monoclonal antibodies (Gorny et al.
1998; Liu et aL 1993). For example, PBMCs derived from HIV-infected
individuals can be transformed with EBV in vitro. The resulting LCLs are then
screened for antibody production and, to maintain them in vitro fused to a mouse
myeloma cell line (Gorny et a!. 1998). Fusion with a second LCL is a second
popular method of immortalization (Foung eta!. 1984).
The latency pattern of LCL has been described, so far 11 viral genes have been
identified which play a role in persistent infection and transformation: two small
non-polyadenylated RNAs (EBERI; EBER2); six nuclear antigens (EBNA 1, 2,
3A, 3B, 3C, LP) and three integral membrane proteins (LMPI, 2A, 2B) (Kieff,
1996). Studies with recombinant viruses showed that EBNA2, EBNA3A,
EBNA3C and LMP1 are essential for the immortalization process (Cohen and
Kieff, 1991; Kaye et a!. 1996). The EBNAI gene is involved in episome
maintenance. In addition the EBNA2 gene determines differences between EBV
type 1 and type 2 in transforming B cells (Kieff, 1996; Hammerschmidt and
Sugden, 1988). A more detailed description of these EBV gene products is given
later in the chapter with the appropriate KSHV counterpart.
Herpesvirus saimiri (HVS) is the prototype of rhadinoviruses, the second
subgroup of the gammherpesvirinae. This virus is found in the peripheral blood
mononuclear cells of healthy squirrel monkeys. HVS is apathogenic in its natural
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host but can cause fulminant T cell lymphomas in other species, including New
World monkeys (Fleckenstein et a!. 1982). Furthermore, HVS can immortalize
peripheral blood lymphocytes of both simian and human origin (Biesinger et a!.
1992). Some human CTL lines have been established by infecting human T cells
with HVS (Berend eta!. 1993; Lacey eta!. 1998) A number of genes of HVS are
not found generally among the herpesvirus family. These genes exhibit significant
homology with cellular proteins, including complement control proteins, cyclins
and seven transmembrane 0 protein coupled receptors (Albrecht et a!. 1992). The
newly identified herpesvirus KSHV is a close relative of HVS that infects humans
(Chang et a!. 1994). Its genome contains all the open reading frames that are
conserved throughout the herpesvirus family together with a high number of
unique genes that may be important in angiogenesis, cellular growth control and
regulating antiviral immunity (Russo et a!. 1996).
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1.3 Kaposi's sarcoma associated herpesvirus (KSHV)
1.3.1 Detection of the KSHV genome in KS
Since its first description in 1994, KSHV/1-IHV8 DNA sequences have been
detected by polymerase chain reaction in all epidemiological forms of the disease,
in both fresh biopsies and in the vast majority of paraffin embedded material
(Boshoffet a!. 1995; Moore and Chang, 1995; Schalling et a!. 1995; Dupin eta!.
1995; Ambroziak et a!. 1995; Whitby et al. 1995). By using in-situ PCR KSHV
can be detected in all stages of the disease from early patches to nodular lesions
(Kennedy et a!. 1998; Dupin et al. 1999). Using a monoclonal antibody specific
for the KSHV nuclear antigen (anti-LANA), only 10% of cells in early KS lesions
harbor the virus (Dupin et a!. 1999). The amount of cells staining positive for
LANA increases to 90% as disease progresses. These findings support a direct role
for the virus in the etiopathogenesis of KS (Dupin et a!. 1999). In KS lesions
KSHV sequences have been localized to spindle and endothelial cells and to
monocytes. Prior to extensive spindle cell formation herpesviral sequences are
limited to the flat endothelial cells of the lesion (Boshoffet a!. 1995; Staskus et a!.
1997; Sturzl eta!. 1997; Rainbow et a!. 1997). The viral genome is maintained as
an episome and at least one copy per cell can be detected (Decker et a!. 1996;
Chang eta!. 1994). The majority of spindle cells seem to be latently infected, with
a sub population supporting lytic replication (Davis el a!. 1997; Staskus et a!.
1997; Orenstein et a!. 1997; Rainbow et a!. 1997; Zhong et a!. 1996). Several
attempts to establish an in vitro culture system for KSHV using spindle cells
isolated from KS have been unsuccessful. Spindle cells have a limited life in
tissue culture and even well established KS cells lose the viral genome upon
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passage (Aluigi et al. 1996; Ambroziak et a!. 1995).Also non-involved tissue from
KS patients, including skin, lymphoid tissue, prostate, semen, saliva and PBMC,
has been shown to harbor KSHV DNA (Harrington, Jr. et a!. 1996; Koelle et a!.
1997; Mesri et a!. 1996; Rainbow et a!. 1997; Staskus et al. 1997; Monini et a!.
1996a; Dupin eta!. 1995; Howard et a!. 1997). Furthermore, in-situ hybridization
to detect the minor capsid protein mRNA has shown that monocytic cells are
productively infected with KSHV. However, not all monocytes stained positive
and therefore transmission of virus from spindle cells to monocytes was thought to
be rather unlikely (Blasig et a!. 1997). It has also been demonstrated that the virus
replicates in PBMCs of KS patients (Decker eta!. 1996). PCR studies of PBMCs
from healthy individuals have found the virus to be uncommon (Gao et a!. 1996b;
Kedes et a!. 1996). In contrast in areas at high risk for KS, KSHV has been
detected at a high frequency (Sirianni et a!. 1997). It has also been demonstrated
that the detection of KSHV in the peripheral blood of HIV infected patients
precedes KS development and is strongly correlated with increased KS risk (Gao
eta!. 1996a; Whitby eta!. 1995).
1.3.2 KSHV and other lymphoproliferative diseases
Besides KS, KSHV sequences have also been associated with other
lymphoproliferative disorders and multiple myeloma. Viral sequences have been
consistently found in primary effusion lymphoma (PEL) and multicentric
Castleman's disease (MCD) (Cesarman et a!. 1995a, Cesarman et a!. 1996a;
Nador eta!. 1996; Gaidano eta!. 1996; Soulier eta!. 1995). KSHV has also been
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associated with multiple myeloma. These findings are rather controversial, as
several groups were unable to confirm this association.
1.3.2.1 Primary effusion lymphoma
Primary effusion lymphoma (PEL), also called body cavity based lymphoma
(BCBL), is a rare form of AIDS-associated B cell lymphoma and was initially
recognised in HIV infected individuals (Nador et a!. 1996; Knowles et a!. 1989). It
is seen predominantly in patients with advanced stages of immunosupression
(Komanduri et a!. 1996) but cases in HIV negative patients have been reported
(Said et a!. 1996; Nador et al. 1996).
The lymphoma is characterised by malignant effusion in pleural and abdominal
cavities (Jaffe, 1996), usually without significant tumor mass or
lymphadenopathy. Tumor cells are derived from a B cell lineage, as indicated by
clonal immunoglobulin rearrangements and plasma differentiation markers. The
majority of cells are co-infected with EBV and KSHV (Cesarman et a!. 1995b;
Gessain, 1997). However, some cases have been reported where only KSHV is
present (Carbone et a!. 1996; Arvanitakis et al. 1996). Compared to the
endothelial and spindle cells in KS lesions, KSHV DNA sequences have been
reported to be 50 times more abundant in PEL tumor cell lines (Cesarman et a!.
1995b; Knowles et a!. 1989). Analyses have shown that PEL cells are infected
with multiple episomal copies of KSHV, 50 to 150 copies per cell have been
detected, whereas KS cells may contain less than one copy per cell (Cesarman et
a!. 1995b). Unlike Burkitts lymphoma PEL cells lack c-myc rearrangement when
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KSHV is present (Nador et a!. 1996). Several B cell lines have been established
from PEL patients and from the peripheral blood of PEL patients to study the
pathogenesis of KSHV as well as to perform sero epidemiological studies. It is
likely that these B cells may be similar to EBV transformed lymphoblastoid cell
lines (LCL) and produce antibodies, although this has not yet been described.
Some of these established B cell lines are positive for only KSHV (e.g. BCP-1,
Boshoffet a!. 1998) others are dually infected (e.g. HBL-6, Gaidano eta!. 1996)
The majority of these B cells are latently infected with KSHV, with approximately
2% of cells spontaneously entering the lytic replication cycle to produce infectious
virions (Renne et al. 1996; Miller et a!. 1997; Zhong et a!. 1996). Several research
groups have shown that the addition of phorbol ester or sodium butyrate to
KSHV-infected PEL cell lines leads to the activation of viral gene expression
(Renne et a!. 1996; Moore et a!. 1996a). As shown by Miller and colleagues in
dually infected PEL cells (here the BC-I cell line) the replication of each virus can
be differentially induced by chemicals such as TPA (EBV) or n-butyrate (KSHV)
(Miller et a!. 1997). In co-infected cell lines the expression of EBV latent proteins
is restricted to EBNA-1 and low levels of LMP-2 (1-lorenstein eta!. 1997; Szekely
et a!. 1998). There are three stages of EBV latency, each type characterised by the
expression of certain latent antigens. Burkitt's lymphoma is an example for
latency type I, where EBNAI (essential for EBV replication) is expressed and
lymphoma cells show c-myc translocation. In contrast, the transforming genes
LMPI and EBNA2 are only expressed in type 'H and type III latency stages.
Therefore the expression pattern seen in PEL cells corresponds to EBV latency
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type I. It has been suggested that EBNA-1 and KSHV in combination might have
the same transformation potential as EBNA-1 with c-myc translocation in
Burkitt's lymphoma cells (Boshoff et a!. 1998). Overall the interaction and
specific roles of EBV and KSHV in PEL is poorly understood.
1.3.2.2 Multicentric Castelman Disease (MCD)
Multicentric Castelman disease, also called multicentric angiofollicular
hyperplasia, is an atypical lymphoproliferative disorder described by Castelman in
1956 (Castleman et a!. 1956). The disease is characterised by generalised
lymphadenopathy and immunological abnormalities. Two histological forms can
be distinguished; the hyaline-vascular variant and the plasma variant. Patients with
MCD tend also to develop non-Hodgkin's lymphoma or KS. The factors involved
in MCD development have not yet been established. However, high levels of IL-6
have been found and suggested to play an important role in disease development
(Leger Ravet eta!. 1991).
KSHV has been detected in 50% of the plasma variant when HIV-infected, but
HI V-negative cases have been reported (Soulier et a!. 1995). In particular PBMCs
from MCD patients have been shown to harbour the virus (Soulier et al., 1995).
Recently, large immunoblastic cells belonging to the B-cell lineage have been
found to harbor the viral latent nuclear antigen (LANA) (Dupin et a!. 1999).
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1.3.2.3 Multiple Myeloma
The identification of KSI-IV sequences in bone marrow stroma cell cultures from
patients with multiple myeloma has been controversial. Some groups have
detected viral sequences by PCR, RT-PCR and in situ hybridisation methods
(Rettig et a!. 1997; Said et a!. 1997b; Brousset et a!. 1997; Agbalika et a!. 1998).
Furthermore, using serological assays, antibodies against lytic and latent KSHV
antigens could be detected in multiple myeloma patients (Gao et al. 1998).
However, others could not confirm these findings and further serological studies
were unable to identify KSHV antibodies (Yi et a!. 1998; Parravicini et a!. 1997;
Tisdale et a!. 1998; Masood et a!. 1997). Given these conflicts a link between
KSHV and multiple myeloma remains to be established.
1.4 Epidemiology of KSHV
Polymerase chain reaction and serological studies have been used to define the
epidemiology of the newly identified herpesvirus KSHV. However, the exact
prevalence is still unclear, as different serological assays show high inter-assay
variability with low-titre sera from non-KS patients. Current knowledge suggests
that KSHV is not ubiquitous in Northern Europe, North America and some parts
of Asia, but is relatively common in Southern Europe (Italy, Greece) and Africa
(Calabro et a!. 1998; Gao et a!. 1 996b; Kedes et a!. 1996; Mayama et a!. 1998;
Simpson et a!. 1996; Whitby ci a!. 1998).
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1.4.1 Establishment of serological assays
Several serological assays detecting antibodies to KSHV lytic or latent antibodies
have been developed. In particular the latent nuclear antigen LANA (Gao et a!.
1996a), encoded by open reading frame 73 (Rainbow et a!. 1997; Kellam et a!.
1997) has been widely used to analyse KSHV sero-prevalence. Antibodies to
LANA can be detected by western blot or by indirect immunofluorescence assays
(IFA) using an noninduced PEL cell line (Gao eta!. 1996b; Kedes et a!. 1996). In
IFA, KSHV positive serum gives a characteristic nuclear 'stippling' pattern due to
the presence of anti-LANA antibodies (Kellam et a!. 1997). Antibodies directed
against LANA have been found in 80-85% of AIDS associated KS, and in more
than 90% of classical KS, but only in 0-3% of US and UK blood donors (Gao et
aL 1996b; Kedes et al. 1996; Simpson eta!. 1996; Calabro eta!. 1998; Lennette et
a!. 1996; Chandran et a!. 1998). Other assays are based on cell extracts derived
from chemically-induced B lymphoid cell lines, and mainly detect viral structural
proteins. Their sensitivity and specificity is reported in US blood donors of
between 0% (Smith et aL 1997) to 25% (Lennette et a!. 1996). However, it has
been demonstrated that serological cross reactivity with other viral proteins, for
example the EBV structural proteins, can occur (Andre et a!. 1997) making these
assays potentially less reliable.
Enzyme linked immunabsorbent asays (EIA) have been established using virions
purified from chemically-induced PEL cell lines (Whitman eta!. 1997).
Several recombinant viral proteins have been generated and tested in serological
assays. The viral open reading frame 65 encodes a capsid related protein which is
able to detect antibodies in 75-80% of AIDS KS patients and in 85-90% of
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patients with classical KS. Only 1-3% normal blood donors in the UK and 5% in
the US tested positive with this assay (Simpson et a!. 1996). Recently, a
polypeptide encoded by KSHV ORF8.1 has been described as frequently
recognized by KS patient sera on Western Blots with induced PEL cells.
Antibodies to K8.l could be detected in 80-90% of 16/20 KS patients, whereas
control sera did not show any cross reactivity (Li eta!. 1999). Combining all these
different latent and lytic antigens may be an option for use in diagnostic assays. A
study comparing the reactivity of different latent (LANA) and lytic (0RF65;
K8.1) viral antigens in IFA and western blot analyses showed that a combination
of both assays may be a more reliable way of detecting KSHV antibodies (Zhu et
a!. 1999). In addition several monoclonal antibodies have now been produced,
including anti-0RF73, and anti-ORF8.1, these will be useful tools in future
serological analyses as well as in studies of the pathogenesis of KSHV (Raab eta!.
1998; Kellam et al. 1999; Chandran eta!. 1998).
1.4.2 Sero-epidemiology in the general population and in HIV infected
individuals in Western Countries
In the general population of North America, the UK and Japan KSHV sero
prevalence in blood donors may be no greater than 1% (Gao et a!. I 996a; Gao et
a!. 1996b). Depending on which antibody detection method has been applied, the
prevalence rates among UK or US blood donors range from 0 to 3% (anti-LANA),
3-5% (anti-ORF65) and 0 to 25% when detecting undefined structural antigens
(IFA) (Chandran et a!. 1998; Lennette et a!. 1996; Whitman et a!. 1997). These
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findings have been supported by PCR studies using PBMCs, samples from
lymphoid tissue and semen samples from healthy semen donors. KSHV was not
detected in PBMCs from UK, US and French healthy control individuals (Whitby
ci a!. 1995; Moore et a!. 1996c; Lefrere ci a!. 1996). In contrast the sero
prevalence of KSHV is higher in some populations at risk for sexually transmitted
diseases, with the highest prevalence in homosexual male groups (Gessain, 1997).
Among HIV infected individuals antibodies against LANA can frequently be
detected in homosexual patients (35%) as well as in 70-85% of HIV infected
patients with KS (Kedes eta!. 1996; Miller eta!. 1996; Gao eta!. 1996b; Lennette
ci a!. 1996; Simpson ci a!. 1996). The KS incidence in HIV infected patients
increases with age and is higher in male patients. Furthermore patients who
reported homosexual intercourse with other males have significantly elevated risks
for KS, both in Europe and the US (Kedes et a!. 1996; Melbye ci a!. 1998). In
contrast, groups with low risk for the development of KS (blood donors, HIV-
positive women, intravenous drug users and haemophiliacs) show correspondingly
low rates of sero-positivity (1-3%) (Kedes ci a!. 1997a; Simpson ci a!. 1996).
Studies examining seroconversion and the presence of viral DNA in blood from
1-IIV-infected gay men with no evidence of KS, have demonstrated that patients
found to have KSHV are at a higher risk of developing KS in the future (Gao eta!.
1996a; Moore ci a!. 1996c; Whitby et a!. 1995). Overall, the high prevalence of
KSHV among HIV infected homosexuals, together with the low rate of sero-
positivity among other HIV risk groups, supports the hypothesis of a causative
role of KSHV in KS.
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1.4.3 Sero-epidemiology in Mediterranean Europe and Africa
High proportions of normal sera from those parts of the world associated with the
classic and endemic forms of KS show a high detection rate of antibodies against
LANA or 0RF65. In Italy and Greece the virus is relatively abundant in the
general population, reflecting the higher incidence of classic KS (5-20% in Italy
and Greece) (Gao et a!. 1996b; Kedes et a!. 1996; Glenn et a!. 1999). Also in
semen samples from Italian semen donors the prevalence of KSHV is high (13-
23%) (Blackbourn and Levy, 1997).
In Africa and the Middle East infection without disease is widespread. Up to 60%
sero-positivity in Africa has been reported when using IFA on non-induced PEL
cells. However, there are substantial regional variations, East and Central Africa,
including Republic of the Congo, Uganda and Zambia have more cases of
endemic KS than other parts of the continent. In Central Africa antibodies against
LANA have been detected in more than 80% of the population (Kedes et a!.
1996). In Uganda analysis of KS tumor lesions indicated a universal presence of
KSHV DNA. Furthermore 85% of PBMCs of KS patients were positive when
tested by PCR (Purvis eta!. 1997). The transmission route of KSHV is different in
Africa compared to Northern Europe and the US. While in Northern Europe and
the US KSHV is more likely to be acquired through sexual contact after puberty
(Melbye et aL 1998; Martin et a!. 1998), in Africa, KSHV sero-positivity is
common among children from East and South Africa (Mayama et a!. 1998;
Kasolo et a!. 1997). Since the AIDS epidemic the incidence of KS has risen
explosively. KS is now the most frequently reported tumor in several African
countries (Wabinga eta!. 1993), especially in Uganda, where childhood KS has
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risen more than 40 fold (Ziegler and Katongole Mbidde, 1996). Studies suggest
that vertical as well as horizontal transmission among children in Africa may play
an important role in the route of infection (Angeloni el a!. 1998). Usually the
mother of an KSHV positive child will be positive as well. How the virus is
transmitted to children is unknown, (possibly during child birth or breast feeding).
It has been shown that saliva from PCR positive samples may contain infectious
virus (Vieira et a!. 1997). An interesting situation has been reported in The
Gambia where KSHV infection is very common, but KS is rarely seen. Some
cases have been described in AIDS patients infected with HIV-1 (Ariyoshi et a!.
1998).
In summary, a consistent correlation between KSHV sero-prevalence and high-
risk KS groups can be demonstrated (Gao et a!. 1 996a; Gao et a!. I 996b; Kedes et
a!. 1996; Smith et a!. 1997; Whitby eta!. 1995). Also the detection of anti-LANA
sero-positivity closely reflects the risk of developing KS in the future. KSHV does
not seem to be ubiquitous in the general population, unlike most other herpesviral
infections (Simpson eta!. 1996; Neipel eta!. 1998). Currently, KSHV seems to be
confined to those populations at risk for developing KS.
1.5 KSHV morphology and genomic organisation
1.5.1 Morphology of KSHV
KSHV has morphological features typical of herpesviral capsids (see figure 1.1).
Electron microscopy using induced primary effusion lymphoma cell lines revealed
both intranuclear herpesvirus nucleocapsids and complete cytoplasmic virions.
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Figure 1.1: A KSHV particle from a primary effusion lymphoma cell line
showing typical herpesvirus morphology, including core, envelope and tegument.
Reprinted from Schulz, 1997.
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Capsids are I lOnm in diameter and surrounded by an envelope. Within the
nucleus a nucleocapsid with an electro dense core can be detected (Said et a!.
1997a; Renne et a!. 1996). Similar morphological features typical of herpesviruses
have also been observed in spindle cells from KS lesions (Orenstein et a!. 1997;
Said et a!. I 997a).
1.5.2 Genomic organisation of KSHV
The genome of gammaherpesviruses exhibit a common structure. Large colinear
genomic blocks, encoding typical herpesviral proteins (DNA polymerase,
thymidylate kinase, capsid proteins), are interspersed by regions containing virus
type-specific open reading frames (ORF) (Kieff, 1996). These unique open
reading frames are predominantly involved in physiological processes and
determine the pathogenesis of each virus. In figure 1.2 a schematic picture of the
KSHV genome is shown. The complete sequence of KSHV has been determined
from a BCBL derived cell line, BC-I (Russo et a!. 1996) as well as from a KS
biopsy specimen (Neipel et a!. 1997). The genome is a 190-kb double stranded
DNA molecule consisting of a central, low-GC content, long unique region (LUR)
of 140.5kb which is flanked each side by non coding tandemly repeated units.
Each repeat is approximately 800bp in size and high in GC content (85%,
HDNA). The genomic organisation of KSHV is very similar to other
rhadinoviruses (Renne et a!. 1996; Russo et a!. 1996; Neipel et a!. 1 997b). Within
the LUR 89 ORFs have been identified, 66 have sequence similarity to HVS open
reading frames, the nomenclature for individual genes correspond to the HVS
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Figure 1.2: Structure of the KSHV genome. The central long unique region (LUR) is
flanked by tandem repeats. The LUR contains at least 89 open reading frames, most
of the genes have homologs in other herpesviruses. The conserved gene blocks (open
boxes) are interspersed by non-conserved areas (gray boxes) contain genes with
homology to other rhadinoviruses (v-cyclin, LANA, vGPCR) but also open reading
frames unique to KSHV that have no similarity with other known viral genes. These
15 unique open reading frames have been designated with a K prefix (Ki-KI 5).
In the bottom of the picture genes with potential influence in KSHV pathogenesis
are enlarged. Black arrows indicate homology with cellular genes; gray arrows
symbolize homology with cellular genes and genes found in Herpesvirus saimiri,
open arrows represent genes that are unique for KSFIV. Reprinted from
Neipel and Fleckenstein, 1999. For a more detailed genetic map see Neipel et a!.
1997.
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genome. KSHV shares the genomic block organization of other herpesviruses
(Kieff, 1996). In KSHV the conserved genes are arranged in four or five blocks
and include major structural proteins, DNA synthetic enzymes, glycoproteins and
a viral proteinase and assembly protein. These genes are required for replication
and assembly of new virus progeny (Unal et cii. 1997; Russo et a!. 1996). Between
these blocks are non-conserved regions that show homology to other
rhadinoviruses, e.g. the v-cyclin, LANA or VGPCR. In addition 15 open reading
frames have been identified in KSI-IV that are unique and show no similarity with
other known viral genes. These unique open reading frames have been designated
with a K prefix (K1-K15).
A general feature observed in DNA viruses is the presence of open reading frames
with significant homology to cell cycle regulatory and signalling proteins as well
as proteins that can interfere with the immune system (Murphy, 1994). These
genes are mainly unspliced and may have been captured from the host cell during
viral evolution. In KSHV this 'piracy' of eukaryotic genes seems to be more
extensive than is seen in any other herpesvirus (Moore et a!. I 996a). The KSI-IV
genome is equipped with several genes which encode proteins that allow the virus
to escape cellular responses to viral infection.
On infection the host activates a number of anti-viral immune responses, including
cell cycle arrest, apoptosis and mobilization of the immune system. KSHV has
evolved proteins that have immunomodulatory functions such as Cytokines
(vMIP-I; vMIP-II) (Moore ci al. 1996a, Bohoffei a!. 1997) and a homolog to
Interleukin-6 (vIL-6) (Nicholas et a!. I 997b; Moore et a!. I 996a; Neipel ci a!.
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I 997a). Other proteins deregulate cell cycle mechanisms by interfering with
receptor-mediated signal transduction pathways, including a homolog to the seven
transmembrane cytokine receptor CXCR2 (vGPCR) (Cesarman et a!. 1996b), a
homolog to the interferon regulatory family (vIRF) (Gao et a!. 1997; Moore et a!.
1996a), and a D-type cyclin (v-cyc) (Cesarman et a!. I 996b). A number of viral
gene products also have transforming properties, e.g. open reading frame Ki (Lee
et a!. 1998b) and kaposin (K12) (Muralidhar et al. 1998). In addition 0RF73,
which encodes LANA, which has possible cellular growth-promoting activities
(Kellam et a!. 1997). To effectively suppress or delay apoptosis KSHV carries a
bcl-2 homolog (v-bcl-2, ORF16) (Cheng eta!. 1997; Sand eta!. 1997; Nicholas et
a!. 1997a) and a protein with anti-apoptotic function (vFLIP, ORFKI3). Also viral
homologs of cellular complement-binding proteins CD2I/CR2 (ORF4) (Russo et
a!. 1996) and an NCAM-like adhesion protein (ORFI4) (Russo et a!. 1996) have
been detected. The plethora of possible interactions between these proteins makes
modeling the pathogenesis of KSHV problematical.
Apart from the proteins that may play a role in oncogenesis, several other proteins
have been identified within the KSHV genome with importance for viral
replication. Some examples include the processivity factor-9 (ORF59) that binds
the viral DNA polymerase (ORF9) to allow synthesis of extended stretches of
DNA without dissociation from the DNA template (Lin et a!. 1998) and K8.1, a
positional analog to
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HVS ORF5I, which encodes a glycoprotein expressed in lytic replication and
present at the surface of infected cells and virion particles (Raab et a!. 1998; Li et
a!. 1999).
1.5.2.1 Transcription pattern of viral genes
In PEL cells as well as KS biopsies only a small sub-population of cells actively
replicates the virus, whereas the majority of cells retain KSHV as a latent episome
(Renne et al. 1996; Russo et a!. 1996). In these latently infected cells a subset of
genes is expressed that appear to maintain the latent state of the virus (Miller eta!.
1997; Sand et a!. 1998; Staskus et a!. 1997). However, the lytic replication cycle
can be induced in cell lines derived from primary effusion lymphoma by chemical
stimuli such as TPA and n-butyrate. According to their transcription pattern three
to four broad types of viral gene transcription have been identified: latent,
immediate early, early and late (Sand eta!. 1998; Sun et a!. 1999). LANA and the
anti apoptotic protein vFLIP are expressed constitutively and their expression was
not induced by the chemicals that induce lytic replication. During latency three
transcripts have been detected. Latent transcript I (LT1) and latent transcript 2
(LT2) are differentially spliced homologous mRNAs and encode a cluster of genes
suggested to have oncogenic properties (oncogenic cluster) (Sand et a!. 1998;
Dittmer et a!. 1998). The third latent transcript has not been characterized. LTI
encodes 0RF73 (LANA-I), 0RF72 (v-cyc) and ORFKI3 (vFLIP), while LT2
only encodes 0RF72 and ORFKI3. Studies have revealed that the promoter
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controlling the transcription of both transcripts is regulated in a cell-cycle
dependent manner (Sand et aL 1999).
In gamma herpesviruses some viral immediate early genes that can activate the
transcription of lytic genes have been determined (Chevallier Greco ci a!. 1986;
Nicholas eta!. 1991; Whitehouseet a!. 1998). So far two KSHV proteins that can
regulate lytic expression have been identified. The ORF K8 encodes a protein
belonging to the basic-leucine zipper (bZIP) family of transcription factors (Lin et
a!. 1999). This viral protein, designated K-bZIP, shows homology to the EBV
BZLF1 (ZEBRA) gene. BZLFI also contains a leucine zipper motif, which
mediates binding to a group of target sequences (BZLF 1-responsive elements) that
are found in a number of EBV early promoters (Rooney et a!. 1989). When
overexpressed BZLF 1 can reactivate latent EBV to enter the lytic cycle, indicating
that it is a key factor in the reactivation and replication of EBV. In KSHV K-bZIP
is a homodimerizing protein; its leucine zipper structure is generated through
multiple splicing and transcription events and follows the kinetics of an early lytic
gene (Lin et a!. 1999). The gene product encoded by open reading frame 50 has
also been identified as an immediate early gene that can activate early and late
lytic gene expression from the latent viral genome (Lukac ci a!. 1998; Sun et a!.
1998). This gene is a homolog of Rta, a transcriptional activator encoded by EBV
(Sun et a!. 1998). Among the gamma-herpesvirus family Rta proteins are well
conserved (Albrecht et a!. 1992; van Santen, 1993). These proteins are known to
bind DNA specifically, but they may also interact with DNA indirectly via other
proteins (Gutsch et a!. 1994). KSHV/Rta has been shown to activate lytic cycle
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gene expression in KSHV when PEL B cells were transfected with cloned
KSHV/Rta and an increase of polyadenylated (PAN) RNA, mRNA for viral IL-6
was seen and an increase in the number of cells expressing capsid antigens could
also be detected (Sun eta!. 1998).
Early genes are transcribed without chemical stimulation in PEL cells but can be
induced to a higher transcription level. A number of virally encoded cellular
homologs (vIL-6, vMIP I, vMIP II), the antiapoptotic gene vBcI-2, and the
putative cytokine receptor vGPCR have been shown to behave as eaily lytic genes
(Sand et al. 1998). The most abundant lytic cycle transcript was the
polyadenylated RNA. PAN RNA (nut-i) does not appear to encode a protein
(Zhong et a!. 1996; Sun et a!. 1996) but can associate with ribonuclear proteins
(Zhong and Ganem, 1997). Late gene expression is indicated by e.g. the small
viral capsid antigen (sVCA), the lytic immunogenic glycoprotein 8.1 and
primarily by structural and replication genes that are transcribed to high levels
only in response to chemical induction.
The pattern of mRNA expression in PEL cells is consistent with the transcription
pattern observed in KS biopsies (Sun eta!. 1999).
1.5.2.2 Variability of the genome
Overall the viral genome derived from B cells or spindle cells differ only 0.4%
from each other (Neipel et a!. 1997; Russo et a!. 1996). Based on sequence
comparison of 0RF26 and 0RF75 among different KSHV samples three distinct
subtypes A, B and C have been described which differ by 1 to 1.5% at the
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nucleotide level (Zong et a!. 1997). However, the ORFKI displays unusual high
levels of genetic variability, resulting in four major genetic subtypes A, B, C and
D. These clades differ by 15 to 30% at the amino acid level in this gene (Nicholas
Ct a!. 1998; Zong et a!. 1997; Zong et a!. 1999) and show distinctive ethnic and
geographic association that are thought to have arisen during the migrationary
divergence of modern humans in Paleolithic times (Zong et al. 1997). Most AIDS
associated KS cases in the US are Al, A4 or C3 variants, whereas classical KS
cases from the Middle east, Asia, Europe and the US are classified as C2 variants.
Recently sequence analysis of six other loci across the KSHV genome, including
three segments in the central conserved portions and three at the extreme right-
hand confirmed this division into three or four clades (Poole eta!. 1999).
1.6 Viral Equipment of genes for latency, transformation and
tu morgenesis
As mentioned above KSHV encodes a number of proteins that bear homology to
cellular genes/proteins involved in cell growth control, signal transduction
pathways and other regulatory processes (Boshoffet a!. 1997; Neipel et a!. I 997b;
Nicholas et a!. 1997a). KSHV has evolved several strategies to overcome cellular
defense mechanisms both to establish a latent infection and to produce virions.
The identification of homologs to proto-oncogenes and cytokines provides
evidence that KSHV is likely to be a transforming virus. In contrast to EBV,
KSHV modifies the cell signaling and regulation pathways by introducing
exogenous genes from its own genome, whereas EBV-encoded proteins induce the
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expression of cellular proteins, leading to immortalization and transformation of
cells (Arvanitakis et a!. 1995; Birkenbach et a!. 1993). There is a similarity
between genes encoded by KSHV and those induced by EBV. The Epstein Bar
nuclear antigen (EBNA) and the Latent membrane protein (LMP) induce human
interleukin-6, cyclin D, a G protein coupled receptor, cellular bcl-2, and the
complement-controlling protein CR-2. Both viruses seem to have developed
different strategies to achieve the same goal of overcoming cell cycle arrest,
apoptosis and activation of cellular immunity.
1.6.1 Latent nuclear antigen and latent membrane protein
Serological studies using sera from KSHV infected individuals showed that
infection with KSHV is associated with the development of antibodies to a nuclear
antigen. Typically, a punctuate nuclear immunofluorescence pattern can be
observed with KSHV positive PEL cells when reacted against sera from KSHV
positive patients (Lennette et a!. 1996; Gao et a!. 1996b; Kedes et a!. 1997b;
Kellam et a!. 1997; Rainbow et a!. 1997). Screening of cDNA libraries with KS
positive sera identified the latent nuclear antigen (LANA or LNA-1) as the
product of 0RF73 (Kedes et a!. I 997b; Kellam et a!. 1997). LANA is transcribed
as a single polycistronic message with two other growth promoting or anti
apoptotic proteins, namely v-cyc and vFLIP (Kellam et a!. 1997; Rainbow et a!.
1997). Several studies demonstrated its presence in all tissues and cell types
associated with KSHV infection (Dupin et a!. 1999; Kellam et a!. 1997). The
protein is expressed as a large polypeptide with numerous repeated blocks of
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acidic residues; the number of repeats can vary for different isolates (Rainbow el
a!. 1997). The immunogenic nature, physical structure, nuclear localization and
latent expression suggest that the protein is analogous to EBV Epstein Barr
nuclear antigens (EBNA). These nuclear antigens play a pivotal role in the
maintenance and replication of the EBV episome and in cell transformation. At
least 11 EBV genes are expressed in latent infection (EBNAs 1-6, LMP-i-3, and
EBER I and 2), although only EBNA and LMP proteins are required for B cell
transformation. EBNAs also transactivate a number of host and viral genes
involved in the regulation of cellular physiology and growth (Farrell, 1995; Kieff,
1996). LANA seems to associate with different nuclear features compared to
EBNA, as shown by confocal microscopy in coinfected cells (Szekely eta!. 1998).
LANA and KSHV DNA colocalize to mitotic chromosomes, indicating a possible
role in the persistence of the KSHV episome (Ballestas eta!. 1999).
The recently identified third latent transcript, LT3, is thought to code for a family
of transmembrane proteins with similarities to EBV latent membrane protein-2A
(LMP2A) and latent membrane protein-i (LMP1) (Sand et a!. 1998; Glenn et a!.
1999, Poole et a!. 1999). Corresponding sequences have been localized to the
extreme right region of the KSHV genome, between 0RF75 and Terminal Repeats
(TR), sequence analysis of several KSHV isolates has identified two highly
diverged alternative allelic forms. This region, referred to as ORF-K15,
encompasses complex spliced latent state genes and transcription was up regulated
after phorbol ester treatment (Poole et a!. 1999; Glenn el a!. 1999). The encoded
protein, named Latency associated membrane protein (LAMP) contains several
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sequence motifs, including TNF receptor-associated factor (TRAF) binding sites,
as well as up to 12 transmembrane domains and, presumably, a cytoplasmic
domain (Glenn eta!. 1999). These features are reminiscent of both EBV LMP2A
and LMPI. Transfection studies indicate that the KSHV protein is localized on the
cell surface and intracellular membrane. Furthermore, association between the
LAMP cytoplasmic domain and TRAF-1, -2 and 3 have been observed.
In EBV, LMPI exhibits a variety of activities in target cells, including
transforming properties in rodent fibroblasts (Wang et al. 1985), induction of
phenotypic changes in epithelial cells and inhibition of epithelial differentiation in
vitro (Fahraeus et a!. 1990). Moreover LMPI is essential for B-cell
immortalization (Kaye eta!. 1996), induces up regulation of antiapoptotic proteins
(such as bcl-2, Bcl-xL) (Henderson et a!. 1991; Young et a!. 1997) and increases
cytokine production.
Downstream signaling is mediated via cytoplasmic domains which interact with
molecules of the TRAF family (Devergne eta!. 1996; Kaye et a!. 1996; Mosialos
et a!. 1995; Eliopoulos eta!. 1999) and the presence of a TRADD (TNF receptor-
associated death domain) (Izumi and Kieff, 1997).
EBV LMP2A is known to be expressed in nasopharyngal carcinoma as well as
latently in B cells of asymptomatic individuals. It has been suggested that LMP2A
plays an important role in maintaining viral latency (Longnecker et a!. 1993). As
the KSHV encoded LAMP shows similarity to both LMP1 and LMP2A it may
possess features of both EBV proteins.
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1.6.2 Viral proteins targeting cellular proliferation or inducing transformation
1.6.2.1 0RF72 (v-cyc)
KSHV 0RF72 is part of the "oncogenic cluster" in KSHV and encodes a D type
cyclin homolog (v-cyc) with functions similar to cellular cell cycle control
proteins (Cesarman et a!. 1996b; Chang et a!. 1996a). Some other rhadinoviruses
(HVS, MHV68) and some oncogenic retroviruses also possess homologues to D-
type cyclins (Nicholas et a!. 1992; Virgin, eta!. 1997).
Cyclins are involved in the regulation of cellular proliferation. Cellular cyclins
associate with cellular kinases (cdk) forming an active complex. These complexes
modulate progression of the cell into S-phase by phosphorylating cell cycle
control proteins, including members of the retinoblastoma suppressor protein
related family (pRB) and histones. Several cyclins have been described which
associate with different kinases to promote the progression of cells through the
division cycle. Each cyclin/cdk pair performs at a distinct stage of cell cycle
progression, forming a complex regulated network (Morgan, 1997).
Cellular cyclin D is required for progression through the Gi cell cycle checkpoint,
controlled by the tumor suppresser protein retinoblastoma associated protein
(pRB). The cyclin/cdk complex phosphorylates pRB and ablates its ability to bind
certain transcription factors, resulting in transcription activation and progression
of the cell into the S phase (Whyte, 1995). Tumor viruses, like SV4O, HPVI6 and
adenovirus have all evolved mechanisms to subvert the host cell cycle through
direct binding to pRB and its subsequent inactivation (Jansen Duff, 1996). Others
inactivate pRB indirectly, e.g. HTLV-1 or EBV. EBV encodes proteins (EBNA-
LP, EBNA-2) that induce cyclin D2 overexpression (Sinclair et a!. 1995;
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Arvanitakis et a!. 1995) which subsequently will inhibit pRB and p53 (Zacny et
aL 1998). This inhibition of pRB has been attributed to the need for a virus to
induce S-phase DNA synthesis in order to expand virion production. KSHV cyclin
is expressed during latency and has been shown to be a functional cyclin capable
of directing phosphorylation and inactivation of the retinoblastoma tumor
suppressor protein as well as phosphorylation of histone Hi via cdk6 activation
(Chang eta!. 1996a; Godden Kent eta!. 1997; Li eta!. 1997; Moore eta!. 1996a;
Moore and Chang, 1998). Studies also demonstrated that v-cyc can overcome the
G1-S block mediated by pRB in SAOS2 cells (Chang et a!. 1996a). These cells
have a homozygous deletion for pRB and upon co transfection of pRB and v-cyc
continuous growth can be established. However, in contrast to cellular D type
cyclin, viral cyclin in association with cdk6 can also phosphorylate histone Hi (Li
et a!. 1997; Godden Kent et a!. 1997; Mann et a!. 1999). Unlike cellular cyclins,
v-cyc is resistant to certain cdk inhibitory proteins, e.g. the p27 (Kip) inhibitor is
phosphorylated by v-cyc and in combination with cdk6 triggers p27
destabilization (Ellis et a!. 1999; Swanton et a!. 1997). This possibly allows the
secondary transactivation of other p27-sensitive cyclin/cdks. Inactivation of p27 is
a common feature in oncogenic virus infection, such as by adenovirus and human
papillomavirus (Zerfass Thome eta!. 1996; Mal eta!. 1996).
Expression of viral cyclin has been detected in latently infected PEL cells as well
as in KS spindle cells (Sturzl et a!. 1999). In KS lesions v-cyc is present in 1% of
spindle cells in early patches and in approximately 60% of the spindle cells in late
60
nodular lesions. Interestingly, v-cyc could also be detected in the peripheral blood
of AIDS patients with KS (Davis eta!. 1997).
So far v-cyclin has not yet been shown to have transformation abilities, but the
viral cyclin may act in concert with other potential viral oncogenes and contribute
to overall oncogenesis. Furthermore, deregulation of cdk activation has been
implicated in the development of cancer (Bates and Peters, 1995).
1.6.2.2 ORFKJ
Viral gene products exhibiting mitogenic and transforming properties have been
identified in several gamma herpesviruses. These proteins are positioned at the
same location in their respective genomes but do not share amino acid sequence
similarity (Russo et a!. 1996; Jung and Desrosiers, 1991). In the T cell specific
oncogenic virus HVS two proteins have been associated with host cell
transformation, the saimiri transformation associated protein (STP) and the
tyrosine kinase interacting protein (TIP). STP is sufficient to immortalize primary
T lymphocytes in vitro and induce lymphoma in marmosets (Duboise et a!. 1998).
TIP is associated with ras and the protein kinase C pathway (Lund et a!. 1997). In
KSHV no genes with sequence homology to the transforming genes TIP and STP
have been identified. However, the open reading frame KI, the positional
homolog to the HVS transforming protein SIP, has been shown to induce
morphological changes and alter growth of rodent fibroblasts. Furthermore, a
recombinant HVS containing ORFKI instead of SIP, immortalized primary I
lymphocytes and induced lymphoma in common marmosets (Lee et a!. I 998b).
61
The structure of the KI protein product is similar to lymphocyte receptors, and a
functional immunoreceptor tyrosine-based activation motif has been identified.
Furthermore, this cytoplasmic domain was found to induce cellular activation (Lee
eta!. 1998a).
1.6.2.3 ORFKJ2 (kaposin A)
A latency associated 0.7-kb transcript (T0.7) is expressed abundantly in all forms
of KS, as well as in PEL cells (Zhong ci a!. 1996; Sturzl et a!. 1997; Renne et a!.
1996). It encodes two small open reading frames as well as ORFI2, also known as
kaposin (Russo et a!. 1996; Neipel eta!. 1997b). The T0.7 mRNA can be found in
KS tissue of all stages (Staskus et a!. 1997). In gene expression studies ORF12
was shown to be able to induce tumorgenic transformation (Muralidhar ci a!.
1998).
1.6.2.4 0RF74 (vGPCR, vIL8R)
The KSHV open reading frame 74 encodes a 0 protein coupled receptor
(Cesarman et a!. 1996b; Russo et a!. 1996) with homology to the human
chemokine receptors CXCR1 and CXCR2 (Murphy and Tiffany, 1991; Holmes et
a!. 1991).
Human chemokine receptors are a family of G protein-coupled receptors (GPCR),
that are involved in the chemotaxis of leukocytes to other cells (Strader ci a!.
1995). The receptors couple extracellular stimuli to cell responses through guanine
nucleotide binding proteins and can be subdivided according to their agonist-
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specificity into two groups: C-X-C chemokine specific receptors binding, e.g.
interleukin 8 (IL-8), and C-C chemokine receptors, which are specific for MIP-la,
MIP-1, RANTES (Baggiolini eta!. 1994). These two families of chemokines are
discussed more fully below (section 1.6.5.2). However, the viral GPCR is able to
interact with both CC and CXC chemokines, although it binds IL-8 with the
highest affinity (Arvanitakis et a!. 1997). In vitro studies have shown that the
receptor exhibits an agonist-independent activity resulting in a constitutively
active signaling molecule that can influence both proliferation and angiogenesis
(Cesarman et a!. 1996b). Overexpression of recombinant vGPCR induces
tumorgenic transformation in rodent cells and vGPCR transformed NIH3T3 cells
efficiently formed tumors in mice (Bais et a!. 1998). KSHV 0RF74 is primarily
expressed during lytic replication (Kirshner et a!. 1999) and plays an important
role in neoangiogenesis and inflammatory cell infiltration (Bais et a!. 1998).
Signaling is mediated through the phosphoinositide-inositoltriphosphate-protein
kinase C (PLC) pathway (Arvanitakis et a!. 1997) and JNKISAPK as well as the
p38-MAPK protein kinase pathway. In infection it initiates a program of cellular
gene expression that culminates in the synthesis and release of vascular
endothelial growth factor (VEGF) (Bais et a!. 1998). This growth factor and its
receptor are regulators of angiogenesis. KS spindle cells express high levels of
VEGF receptor and VEGF-3 (Jussila ci a!. 1998). Hence, VEGF has been
regarded as a key factor in KS pathogenesis.
Although it has been demonstrated that the vGPCR is constitutively active, some
chemokines and chemokine variants have been shown to modulate its activity
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level. Inhibition of signaling has been observed for the viral encoded chemokine
vMIP-II (CC chemokine), the cellular stromal cell derived factor-I-alpha (SDF-
Ia, a CXC chemokine that can block HIV-I infection) and Interferon Gamma-
inducible protein 10 (IP-lO) (Geras Raaka eta!. 1998b; Geras Raaka eta!. 1998a;
Gershengorn et a!. 1998). In contrast, other chemokines have been shown to
increase the level of signaling (Gershengorn et a!. 1998). GPCRs homologs have
also been identified in HVS (Ahuja and Murphy, 1993) and CMV, which encodes
several GPCR homologs as lytic genes (Vieira eta!. 1998; Welch eta!. 1991).
In summary, the KSHV vGPCR, with its transformation potential and coristitutive
signaling ability, may be another viral oncogene. Furthermore, as a GPCR, I-HV-1
gpl2O may bind and signal through this receptor, which may contribute to the
relatively aggressive disease course in HIV/KSI-IV co-infection.
1.6.3 Viral proteins and Interferon signaling
KSHV encodes four open reading frames that show homology to the transcription
factors of the interferon regulatory factor (IRF) family (Li eta!. 1998; Moore eta!.
1 996a; Burysek et a!. 1999; Russo et a!. 1996). So far two of these interferon
regulatory factors (vIRFs) have been analysed, vIRF-1 and vIRF-2 (Gao et a!.
1997; Li et a!. 1998; Burysek et a!. 1999). Interferons are a family of
multifunctional cytokines with antiviral activities which interact with cell surface
receptors, resulting in the synthesis of groups of cellular proteins (David, 1995).
Stimulation of interferon synthesis is regulated at a transcriptional level and
activation of interferon genes is mainly mediated by two families of
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transcriptional factors, the NF-KB family and the interferon responsive factors,
which include IRF-1, IRF-2, IFN-consensus sequence binding protein (ICSBP),
and the IFN-alpha stimulated factor 3 gamma (Fujita et a!. 1988; Harada et a!.
1989). These transcriptional factors recognize a conserved cis-acting DNA
element located within the promoter of this target genes (David, 1995). IRF-1 is a
transcriptional activator, and IRF-2 its antagonistic repressor. Both have been
identified as regulators of IFN-alpha and IFN-inducible genes (Harada et al.
1993). Studies have shown that the KSHV IRF-1 can function as a repressor on
promoters which contain IFN-sensitive response elements. Expression of
recombinant vIRF- I (K9) dramatically repressed transcriptional activation
induced by IFN-cz, I and y (Zimring et a!. 1998). It has also been demonstrated
that vIRF-1 can induce transformation in rodent fibroblasts, which when injected
into mice form tumors (Gao et a!. 1997; Li et a!. 1998; Zimring et a!. 1998).
Furthermore, vIRF-1 plays an important role in regulating KSHV gene expression
(Li et a!. 1998). The second viral IRF (vIRF-2) has a different pattern of
expression and properties from vIRF-1 (Burysek et a!. 1999). The vIRF-2 interacts
with cellular transcription factors and its expression can not be detected after
chemical treatment of PEL cells (Li eta!. 1998; Burysek eta!. 1999). Both vIRFs
show possible mechanisms which may interfere with IFN-mediated antiviral
activity or deregulate the host immune system. Furthermore, vIRF-1 also has
transforming properties and hence can be classified as another KSHV oncogene.
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1.6.4 Viral proteins exhibiting anti-apoptotic properties
1.6.4.1 ORFJ6 (vbcl-2)
Programmed cell death (Apoptosis) is a common feature of mammalian cells and
is important for embryonic development and the maintenance of homeostasis of
multinuclear organisms (Vaux et a!. 1994). This cellular self-destruction can also
serve as a defense mechanism against viral infections to eliminate the infected
cells, thereby slowing down viral spread. Viruses have evolved mechanisms to
inhibit this host response to facilitate persistent infection or prolong the survival of
lytically infected cells (Lewis et a!. 1996; Crook et a!. 1993). In contrast, others
induce apoptosis and contribute to the resulting disease and mortality by
destroying cells, e.g. apoptosis of CD4 cells and neurons in AIDS pathogenesis
(Ameisen, 1995).
During some viral infections the tumor suppressor protein p53 is up regulated and
activates apoptosis mediating proteins (the bcl-2 family) (Sato et cii. 1994; Boyd et
a!. 1995). The bcl-2 protein family is characterised by the ability to modulate cell
death, some promote cell death (Bax, Bak) whereas others inhibit apoptosis (bcl-2,
bcl-xL) (Reed, 1996). Cellular bcl-2 has been implicated as a proto oncogene in
the pathogenesis of human follicular lymphomas and other cancers (Cleary and
Rosenberg, 1990; Cleary, 1991) via its anti apoptotic effect. Studies revealed that
the bcl-2 protein interacts with other proteins with which it shares amino acid
homology and overcomes bax-mediated apoptosis (Sato et al. 1994).
Homologs of bcl-2 have been identified in a number of y-herpesviruses, including
EBV (BHRFI) and HVS (ORFI6). The bcl-2 homolog encoded by EBV is
dispensable for the transformation of B lymphocytes but is able to block cell
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differentiation in epithelial cells (Dawson eta!. 1998). The ORFI6 of KSHV has
been shown to encode a bcl-2 homolog (Russo et a!. 1996; Neipel et a!. 1997b)
and its expression during the lytic replication cycle has been demonstrated (Sand
et a!. 1997). Its apoptosis suppressor activity has been proven using the Sindbis
virus vector system (Cheng et a!. 1997) and the viral protein is able to block
apoptosis as efficiently as cellular Bcl-2 and Bcl-xl. However, KSHV bcl-2 does
not homodimerize or heterodimerize with other bcl-2 family members, thereby
escaping the regulatory effects of other cellular bcl-2 family proteins (Cheng et a!.
1997).
1.6.4.2 ORFK1 3/73 (vFLIP)
It has been suggested that apoptosis can be mediated through the activation of the
ICE-like family of cysteine proteases (caspases) (Henkart, 1996). Initially the
tumor suppressor p53 may up regulate the expression of the so called "death"
receptors (CD95, TNFR-1, TRAMP) along with their ligands (Nagata, 1997;
Bodmer et a!. 1997; Kitson et a!. 1996). For example, CD95 (also called Fas or
Apo-1) triggers a cell to apoptose, together with its ligand CD95L, in response to
virus specific cytotoxic T lymphocytes (Thome et al. 1997). Death receptors
belong to the TNF receptor superfamily and encode a cytoplasmic death domain
(DD) which interacts with the death domain of adapter proteins (FADD, TRADD)
(Nagata, 1997). FADD then associates via its death effector domain (DED) with
the ICE-like protease FLICE, leading to the assembly of a receptor (CD95)-
associated death inducing signalling complex (DISC) (Kischkel et a!. 1995).
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Finally DISC-associated FLICE initiates proteolytic activation of other ICE
protease family members, which in turn leads to programmed cell death (Muzio et
a!. 1996; Medema et a!. 1998).
The KSHV ORFK13/71 encodes an inhibitory protein that interferes with this
pathway (Thome et a!. 1997). Homologs have been identified within several
gamma herpesviruses (EHV-2. BHV-4, HVS, KSHV). These FLICE inhibitory
proteins (vFLIPs) contain two DED domains which interact with the FADD
adapter protein, thereby inhibiting the recruitment and activation of the protease
FLICE (Thome et a!. 1997). Studies showed that cells expressing vFLIPs are
resistant to death receptor mediated apoptosis (Bertin et a!. 1997; Thome et a!.
1997). Similarly, tumor cells such as melanomas and hepatomas do not respond to
CD95L-mediated apoptosis (Hahne et aL 1996). Thus, vFLIPS may not only
promote viral persistence but also contribute to the transformation capacity of
KSHV and other gamma herpesviruses.
1.6.5 Viral cytokines and chemokines that support KS pathogenesis
As described earlier, the development of KS was suggested to be dependent on
inflammatory cytokines and growth factors. Interestingly, KSHV encodes a
number of cytokines that have been implicated in disease progression.
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1.6.5.1 ORFK2 (vIL-6)
Before the discovery of KSHV the cytokine interleukin 6 (IL-6) was thought to
play an important role in the development and progression of the human diseases
with which KSHV has now been associated. AIDS-KS cell lines have been
reported to secrete high amounts of IL-6 and to contain a large number of IL-6
receptors (Miles et a!. 1990). Furthermore, IL-6 was described to support the
proliferation of KS cells in vitro (Miles eta!. 1990). Elevated levels of IL-6 have
also been detected in MCD lesions and in KS patient sera (Ishiyama ci a!. 1994).
Recently, IL-6 has been shown to be important as an autocrine growth factor for
PEL cells (Asou eta!. 1998).
Human IL-6 normally functions in the regulation of the immune system and other
tissues. It activates acute phase genes and is involved in the stimulation of B cells
(IhIe, 1995). IL-6 binds to gpl3O, a part of the IL-6 receptor, and signals through a
variety of transcription factors, including STAT (IhIe, 1995). Human IL-6 has
been implicated in a variety of B cell neoplasms. The KSHV genome encodes an
IL-6 homolog (ORFK2) which is expressed in approximately 50% of latently
infected BCP-1 cells and in primary ascitic PEL, suggesting constitutive
expression in latently infected PEL cells (Asou ci a!. 1998; Moore et a!. 1996).
However, vIL6 is only expressed by a minority of cells within the KS lesion, but
can be found in hematopoietic cells and lymph nodes of KS patients (Moore et a!.
1996a; Parravinci et a!. 1997). KSHV encoded IL-6 is functional in a number of
11-6 dependent bioassays, as it promotes survival of IL-6 dependent cell lines
(Burger ci a!. 1998; Moore et a!. I 996a; Nicholas ci a!. I 997a). Although there are
functional similarities to human IL-6, there are receptor binding differences (Wan
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et a!. 1999). Biologically, vlL-6 triggers the Janus Tyrosine Kinases/ signal
transducers and activators of transcription (JAK/STAT) pathway via interactions
with the IL-6 receptor as demonstrated in 1-lepG2 cells. However, the gpl3O signal
transduction subunit alone is sufficient for viral IL-6 signaling (Molden et a!.
1997). The low expression rate of vIL-6 in KS lesions suggests that vIL-6 plays a
more indirect role in KSHV pathogenesis; perhaps in a paracrine manner.
1.6.5.2 ORFK4, K4. 1, K5 (vMIP-I and vMIP-II)
Chemokines have an important role in leukocyte migration and activation as well
as hematopoeisis (Mackay, 1996). Furthermore, several chemokine receptors have
been identified as co factors for HIV entry into CD4 cells and some CC and CXC
chemokines can block HIV entry into T cells, including the MIP/RANTES family
(Cocchi et a!. 1995; Dragic et a!. 1996). As described before (section 1.6.2.4)
there are two groups of pro-inflammatory chemokines; the CC chemokines (MIP-
ict, MIP-113, MIP-2, MIP-3 and RANTES), and the CXC chemokines such as IL-8
and SDF-1 (Baggiolini et al. 1994). The activity of these small soluble proteins is
mediated through GPCRs. MIP-1 proteins are chemoattractants for monocytes, I 3
acting preferentially on CD4+ T lymphocytes and I a also on B lymphocytes and
cytotoxic T cells (Schall et a!. 1993). KSHV encodes three proteins with
homology to cellular CC chemokines: vMIP-I; vMIP-lI and vMIP-III (Moore et
a!. 1996a; Russo et a!. 1996; Neipel et a!. 1997b; Nicholas et a!. 1997a). These
virally encoded chemokines bind to both CC and CXC chemokine receptors,
unlike cellular chemokines (Boshoffet a!. 1997). Both vMlP-I (ORFK6) and
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vMIP-II (ORFK4) show sequence similarity to human chemokine MIP-Ia (Moore
et a!. 1996a), whereas vMIP-llI (ORFK4.1) is less homologous. Studies
demonstrated l-IIV-1 inhibitory activity for vMIP-1 and vMIP-2; vMIP-1 directly
via interaction with the CCR5 chemokine receptor (which binds human
MIP/RANTES) and vMIP-2 by association with CCR3 (which binds eotaxin)
The latter one has also been reported to bind to other chemokine receptors and
may or may not be associated with chemoattraction of e.g. eosinophils (Moore et
a!. 1996a; Kiedal eta!. 1997; Boshoffet a!. 1997). Furthermore, vMIP-lI has been
shown to bind the KSHV G protein coupled receptor and inhibits signaling (Geras
Raaka et al. 1998a). Less is known about vMIP-I, this viral chemokine binds
specific to the CCR8 chemokine receptor and induces signaling. These receptors
are predominantly expressed on T helper 2 lymphocytes, indicating that vMIP-I
may influence the host immune response (Endres et a!. 1999; Dairaghi el a!.
1999). Interestingly, vMIP-II also binds CCR8 as an antagonist without signal
induction (Dairaghi et a!. 1999). In a chorioallantoic assay both viral chemokines
showed angiogenic characteristics and may therefore play a direct role in KS
pathogenesis (Boshoff et a!. 1997). Transcripts have been found in KS spindle
cells but only in a few lytically infected cells (Boshoff ci a!. 1997). In latently
infected PEL cells basal expression can be detected and can be further induced by
TPA (Moore ci a!. I 996a).
The third viral chemokine, encoded by ORF4.l, is related to MIP-1t3 and is a
macrophage chemoattractant (Neipel et a!. 1997b; Nicholas ci a!. 1997a). In
summary, the viral encoded chemokines may induce angiogenesis but may also be
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responsible for inflammatory infiltrates. Also the influence of these vMlPs in the
inhibition of HIV entry may influence disease progression in patients infected
with both HIV and KSHV. The viral and human chemokines may compete with
HIV-1 gpl2O for the binding to T cells. The survival of AIDS-KS patients has
been reported to be longer compared to AIDS patients without KS (Moore et al.,
1996a; Sand etal., 1999).
1.7 KSHV and Pathogenesis, a Hypothesis
KSHV is present in the vast majority of spindle cells in both early and late KS
lesions. Most cells are latently infected but a few spontaneously enter lytic
replication and produce viral particles. In EBV infection a similar scenario can be
observed. Here, latently infected cells express viral genes that are responsible for
genetic alterations leading to tumor growth. Perhaps this situation can be
transferred to KSHV pathogenesis.
Several genes within the KSHV genome encode proteins with sequence and more
importantly, functional homology to human oncogenes that have been implicated
in several forms of human cancers. Furthermore, viral proteins with transforming
potential have been identified. In Table 1.2 an overview of the KSHV genes
possibly involved in viral-associated diseases is given. KSHV targets the
checkpoint of progression through the Gl cell cycle encoding a functional
homolog to the cell cycle control protein v-cyc. This feature, of triggering cell
proliferation of the host cell despite a viral infection, has evolved in other DNA
viruses, such as HPV, adenoviruses and the polyomaviruses. These viruses all
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bind to the tumor suppresser proteins pRB or p53 and overcome growth arrest,
EBV also which induces cellular 01 cyclins. The KSHV cyclin is transcribed as a
latent protein and probably prevents replication to allow virus progeny production.
Most spindle cells in KS lesions are infected latently, suggesting a direct role for
KSHV in pathogenesis via latent growth-promoting viral proteins. Furthermore,
other proteins encoded by KSHV also maintain or restore proliferation
competence. The viral GPCR is able to transform NIH3T3 cells and induce
production of a potent angiogenic factor, the vascular endothelial growth factor
(Arvanitakis et a!. 1997; Bais et a!. 1998) and viral chemokines have been
identified that also induce angiogenesis. Other growth stimulating factors, like
vIL-6 may recruit uninfected cells as target for de novo infection. Cellular !L-6,
known as a B cell growth factor, has been shown to stimulate KS cells in vitro and
increased levels of IL-6 have been detected in Castleman's disease. In the
pathogenesis of KS, the autocrine and paracrine growth effects of cytokines,
growth factors and their receptors have been suggested to play an important role.
Therefore, KSHV, with its own chemokines and the chemokine receptor, may
satisfy this growth factor theory in itself and contribute to the development of KS.
KSHV may also enhance the growth of latently infected cells by creating a
favorable growth milieu resulting from the concerted activity of viral encoded
proteins secreted by adjacent cells undergoing lytic replication.
However, some of these potential oncogenes, such as vGPCR, vIRF and the
transforming gene KI, are unlikely to be transcribed during latency. Three latency
associated transcripts have been identified that encode LANA, kaposiri (possibly
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transforming), v-cyclin and the anti-apoptotic protein vFLIP. The latency
associated antigen LANA is thought to maintain the viral episome, vFLIP has
been demonstrated to prevent programmed cell death and could be active both in
maintaining proliferation and in blocking antiviral cytotoxic T cell-induced
apoptosis.
In summary, epidemiology, the consistent presence of KSHV DNA in tumor
tissue, the number of viral oncogenes and chemokines so far identified, and the
fact that KSHV sero conversion can predict tumor development, all favor this
virus as at least a major co-factor in tumor pathogenesis. Recently, a KSHV gene
with directly transforming properties, ORFKI, a homolog to EBV EBNA1 and
LMP2A, has been identified, which further support the hypothesis that KSHV is
an oncogenic virus.
In contrast, PEL cells are commonly co-infected with KSHV and EBV,
representing the first example of a consistent dual herpesviral infection. The latent
transcription pattern of EBV in PEL is restricted, with mainly EBNA I and no, or
very low, levels of major EBV growth transforming factors (Horenstein et al.
1997). Also the in vitro transformation of PBMCs with KSHV indicated the
importance of the presence of EBV for transformation (Kliche et a!. 1998). How
EBV and KSHV interact is hardly studied; but the presence of both viruses in
almost all cell lines derived from PEL indicates a possible link in tumorgenesis.
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1.8 Propagation of KSHV in vilro
1.8.1 B cell lines established from PEL patients
Attempts to cultivate KSHV in vitro have proven to be difficult. Cells derived
from KS lesions tend to lose the viral genome upon passage (Aluigi et al. 1996;
Ambroziak et a!. 1995). Several B cell lines derived from PEL have been
established, of which most are dually infected with KSHV and EBV. In PEL the
viral genome is maintained in the nucleus as a circular episome. Viral replication
can be subdivided into latent and lytic replication, during latency only a small
proportion of cells spontaneously undergo lytic replication and produce infectious
virions. The EBV expression pattern is restricted, with abundant levels of EBNA-
I and low LMP-1 and LMP-2A levels (Horenstein et a!. 1997). It has been
suggested that this combination of KSHV and EBNA-1 may have a similar
transformation potential to c-myc translocation and EBNA-1, as seen in Burkitts
lymphoma(Boshoffetal. 1998). Lytic gene expression of KSHV and EBV can be
individually enhanced by treatment with phorbol ester (EBV) or butyrate (KSHV)
(Miller et a!. 1996).
Some B cell lines are only infected with KSHV, such as BCBL-I and BCP-1,
which were established from the peripheral blood of a PEL patient (Renne et a!.
1996; Boshoff et a!. 1998). Both cells also exhibit similar growth properties in
SCID mice and immunoblastic lymphomas could be observed (Boshoff et a!.
1998; Picchio ci a!. 1997). However, since these B cell lines are already latently
infected in culture, studies on de novo viral entry and pathogenesis are difficult.
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1.8.2 Dc novo infection
KSHV has been passaged in primary B cells but few other primary cell lines,
some showing a productive infection. In general the genome is lost with
subsequent passage. Limited replication has been reported for the human
embryonic kidney cell line (293) with and without cytopathic effects (Foreman ci
a!. 1997; Vieira eta!. 1997; Renne et a!. 1998). Others have tested a diversity of
cell lines and demonstrated infectivity for BCBL-1 derived KSHV. Some of these
cell lines, including cells of fibroblastic, epithelial, endothelial or lymphoid origin
were susceptible to the virus but no CPE was produced and the level of infection
was low (Renne et a!. 1998). More successful viral transmission have been
reported for primary human endothelial cells, including both primary and
immortalized dermal microvascular endothelial cells (DMVEC). A distinct
biology of KSHV derived from KS lesions and from PEL cells have been
described in vitro culture systems (Friborg, Jr. ci a!. 1998). Using the EBV
negative Burkitt's lymphoma cell line, Loukes, transmission of KSHV from KS
lesions could be established and further induced with TPA to produce progeny
virions. Virus obtained from this infected cell line (named BKS-1) was able to
infect 293 cells and a CPE was detected, as was apoptosis. In contrast, virus
derived from TPA-induced BCBL-1 cells did not induce cell death in 293 cells
and viral DNA sequences were lost in culture (Friborg, Jr. eta!. 1998).
Human primary endothelial cells, in particular bone marrow microvascular
endothelial cells (BMVEC) and primary human umbilical vein endothelial cells
(HUVEC), were successfully infected with purified KSI-IV and supported lytic
replication. Initially some cells showed a CPE and died, whereas others could be
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maintained in culture. In the same experiments KSHV induced long term
proliferation compared to uninfected control cultures, where cells suffered
senescence. Using WA KSHV nuclear antigens were detected in 1-5% of the total
cell population, which led the authors to conclude a paracrine mechanism is
responsible for the survival of uninfected cells (Flore eta!. 1998).
Other researchers stably infected primary dermal microvascular endothelial cells
(DMVEC) by co culture with KS-I cells (Panyutich et a!. 1998). Recently, a
robust long term infection of HPV (E6 and E7) immortalized DMVECs has been
reported (Moses et a!. 1999). KSHV infection was monitored by PCR and lytic
replication detected by RT-PCR as well as IFA. The majority of cells could be
infected and maintained the viral genome indefinitely. While most of the cells
remained latent, a small number supported viral replication. Chemical treatment
also induced lytic gene expression. Interestingly, infected cells undergo
phenotypic changes including spindle cell morphOlogy and characteristics of a
transformed phenotype, precisely the features that resemble KS lesions (Moses et
a!. 1999).
B lymphocytes can also be persistently infected with KSHV under certain
conditions (Mesri et a!. 1996; Kliche et al. 1998). Studies showed that the
presence of EBV is necessary to immortalize PBMCs. Only PBMCs from EBV
positive individuals could be immortalized by supernatant derived from BCBL-1
cells (Kliche et a!. 1998). These immortalized cells possessed the phenotype of
activated B cells, similar to EBV positive lymphoblastoid cell lines (LCL). The
LCLs were persistently positive for both viruses, KSHV replication could be
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induced and KSHV could be serially passaged. Table 1.3 gives an overview of
currently established cell lines which supported a KSHV infection de novo.
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1.9 Herpesviral glycoprotein H and L
The envelopes of herpesviruses are relatively complex structures with large numbers
of viral glycoproteins. Some play a role in viral attachment to the host cells, others
mediate penetration into the host cell and some are involved in viral egress. Many
viral glycoproteins are expressed on the surface of infected cells and on the virion and
they constitute major antigenic determinants for the cellular and humoral immune
response of the host (Roizman, 1993; Spear, 1993).
Unsurprisingly, the entry process is complex and not fully understand. For the
alphaherpesvirus subfamily a number of entry mediators have been identified that
may also play a role in cell-to-cell fusion. The receptor(s) mediating EBV entry into B
lymphocytes have been determined, but productive infection of epithelial cells with
EBV in vitro remains a mystery. Each member of the herpesvirus family encodes a
diverse number of glycoproteins that enables them to establish its own niche. For the
herpes simplex virus 11 unique glycoproteins have been described, HCMV may
express even more (Spear, 1993; Spaete et a!. 1994). However, some glycoproteins
seem to be highly conserved among all herpesviruses. Glycoprotein H and
glycoprotein L are among the few viral glycoproteins which have functional
homologs in all three classes of herpesviruses. Studies have demonstrated that these
proteins form a complex with one another and are essential for virion infectivity as
well as virus-induced cell fusion in vitro and in animals (Babic et a!. 1996; Forrester
Forrester et a!. 1992; Farrell et a!. 1994; Fuller et a!. 1989; Haddad and Hutt Fletcher,
1989; Miller and Hutt Fletcher, 1988; Peeters eta!. 1992; Liu eta!. 1993b).
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1.9.1 Viral entry and cell to cell fusion
Herpesviral entry into cells is best studied in the alphaherpesvirus subfamily, in
particular for herpes simplex virus 1 (HSV-1). Viral entry into the host can be divided
into attachment of the virus to the cell surface and subsequent fusion of the viral
envelope with the plasma membrane (penetration). Both events are mediated by
several viral glycoproteins (Spear, 1993; WuDunn and Spear, 1989). Due to the fact
that so many glycoproteins are involved in attachment to the host cell it is unlikely
that only a single receptor will be responsible. These proteins presumably act in
concert and may use a number of different receptors (Handler et a!. 1996; Johnson et
al. 1990; Johnson and Ligas, 1988; Lee and Fuller, 1993). The initial interaction of
HSV with the cell membrane is mediated by glycoprotein C and/or B binding to
heperan sulfate proteoglycans on the cell surface in a relatively low affinity
interaction (Shieh et a!. 1992; Herold et a!. 1994). Subsequently, glycoprotein D
interacts with cellular receptor(s) and, together with glycoprotein B and the gH/gL
complex, triggers pH-independent fusion of the viral envelope with the host cell
plasma membrane (Whitbeck et a!. 1997; Cal et a!. 1988; Johnson et a!. 1990; Lee
and Fuller, 1993; Spear, 1993). A number of cellular proteins have been identified as
HSV-specific surface receptors based on this interactions with glycoprotein D. The
herpesvirus entry mediator, HVEM/HveA can mediate entry of HSV into a subset of
human cell types, including CHO cells and T lymphocytes and its interaction with gD
has been demonstrated (Montgomery et a!. 1996; Whitbeck et a!. 1997; Nicola et a!.
1997, Roller and Rauch, 1998).
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HveA is a member of the TNF/NGF receptor family that is associated with gene
regulation events and anti-apoptotic signaling. Its expression pattern suggests a role in
lymphoid development and immune responses (Gravestein and Borst, 1998).
Recently, other surface proteins allowing HSV entry into CHO cells, independent of
HveA have been detected (Geraghty et al. 1998). Originally identified as poliovirus
receptor related proteins, PRR1 and PRR2 have now been renamed HveC and HveB
(Lopez eta!. 1995; Eberle eta!. 1995; Geraghty eta!. 1998; Warner eta!. 1998). Both
molecules belong to the immunoglobulin superfamily and HveC has been
demonstrated to mediate entry of all alphaherpesviruses (Krummenacher eta!. 1998).
Herpesviruses also infect cells by cell-to-cell fusion, whereby an infected cell
membrane fuses with that of its non-infected neighbor. The mechanism by which
herpesviruses induce cell fusion is not clear (Spear, 1993). However, there is evidence
that cell to cell fusion is distinct from the membrane fusion event during viral entry
(Ejercito et a!. 1968). For example, certain cell lines are highly susceptible to
infection but resistant to I-ISV-induced cell fusion (Bzik and Person, 1981; Spear,
1993). Some viral glycoproteins are important for fusion but dispensable for entry,
e.g. gE, gI and gM (Davis Poynter et a!. 1994). In vitro studies using viral mutants
revealed that glycoproteins B, D and the gH-gL complex are essential for fusion of the
viral envelope with the plasma membrane (Cai et a!. 1988; Fuller and Lee, 1992);
Turner et a!. 1998). Also cell surface heparan sulphates are involved in HSV mediated
cell to cell fusion (Shieh and Spear, 1994). Furthermore, cells resistant to virus
induced cell fusion became susceptible when they expressed the herpesviral entry
mediator HveA (Terry Allison et al. 1998).
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In EBV, infection studies of viral entry are based on B lymphocyte cell culture
systems. Although epithelial cells are fully permissive for lytic infection in vivo, in
vitro EBV infections are inefficient. Several attempts to culture EBV have been made
with cell lines expressing the EBV receptor CD2I, but infections were abortive (Kieff,
1996; Sixbey eta!. 1983; Li eta!. 1992).
To enter B lymphocytes the EBV encoded glycoprotein gp340/220 binds to CD2 1 on
the cell surface, this interaction may lead to the activation of signal transduction
pathways (Kieff, 1996). The CD2I receptor is a member of the immunoglobulin
superfamily and naturally interacts with the C3d component of the complement
complex (Nemerow eta!. 1990; Tanner eta!. 1987). However, penetration of the virus
into B lymphocytes may require additional proteins, for example CD2 I accessory
proteins or other cellular proteins. EBV infection of epithelial cells transfected with
CD21 is inefficient indicating that other proteins may be required for effective EBV
infection (Kieff, 1996).
Following attachment EBV internalizes into cytoplasmic vesicles, subsequently the
viral membrane fuses with the vesicle membrane and the nucleocapsid is released into
the cytoplasm. In contrast, in Burkitt lymphoma cells the viral nucleocapsid is
released directly into the plasma membrane instead of being initially internalized
(Kieff, 1996). As described for alphaherpesviruses, gH and gL functional homologs
have been identified for EBV and are directly implicated in the fusion processes
(Miller and Hutt Fletcher, 1988; Yaswen eta!. 1993). In EBV a third protein has been
detected that associates with gH and gL and is important for B lymphocyte infection
(Li eta!. 1995; Spriggs eta!. 1996). An additional component of the gH gL complex
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has also been described for VZV and HCMV (Huber and Compton, 1997; Li et a!.
1997).
1.9.2 Glycoprotein H
Glycoprotein H is highly conserved among human and animal herpesviruses.
Homologs have been identified in representatives of all subgroups of herpesviruses
(Keller et a!. 1987; Heineman et a!. 1988; Cranage et a!. 1988; Gompels et a!. 1988;
Josephs eta!. 1991; Nicolson eta!. 1990; McGeoch and Davison, 1986; Pachl eta!.
1989; Klupp and Mettenleiter, 1991; Scott eta!. 1993; Pepper et a!. 1996). Primary
sequences are poorly conserved, with only a limited conservation being detected in
the C terminus (Gompels et a!. 1988). Identified gH proteins range in size from 706 to
743 amino acid residues for the beta- and gammaherpesviruses, to 838 to 841 for the
alphaherpesviruses. Overall, members of the gH family exhibit a conserved protein
structure. The hydrophobic N terminal region comprises an 'ER' signal sequence for
translation on membrane bound ribosomes, second hydrophobic region, adjacent to
the C terminus, may function as a membrane anchor. Greatest sequence similarity is
observed in the C-terminal halves of the protein including residues surrounding four
conserved cysteines, a conserved N-linked glycosylation site (NGTV) and a short
cytoplasmic domain (Gompels and Minson, 1986; Klupp and Mettenleiter, 1991;
McGeoch and Davison, 1986). Functionally, gH is an important factor in cell
penetration and cell-to-cell fusion. Monoclonal antibodies specific for gH allow
attachment of the virus but prevent entry; deletion mutants lacking gH have also been
shown to have this effect (Forrester et a!. 1992; Fuller and Lee, 1992; Keay and
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Baldwin, 1991). Recombinant gH is incompletely processed and accumulates in the
cytoplasm, in particular the pen nuclear membrane, and is most likely retained in the
endoplasmatic reticulum or cis Golgi (Gompels and Minson, 1989; Cranage ci a!.
1988; Heineman eta!. 1988; Forrester ci al. 1991; Foa Tomasi ci a!. 1991; Pulford ci
a!. 1994; Roberts et a!. 1991). Furthermore, some immunologically important
epitopes are not presented by the recombinant protein. When injected into mice, these
recombinant proteins only elucidate a weak immune response. Animals challenged
with virus showed no or little virus neutralisation (Roberts et a!. 1991; Ghiasi et a!.
1992).
Within the viral life cycle glycoprotein H is transcribed late in lytic infection
(McGeoch and Davison, 1986) and appears to be a relatively minor component of the
infected cell surface and virion envelope (Buckmaster ci al. 1984). Unsurprisingly, as
gH exhibits targets for virus-neutralising antibodies and intracellular over expression
would be disadvantageous for the virus (Miller and Hutt Fletcher, 1988; Montalvo and
Grose, 1986). Reports suggest that gH expression can be regulated by environmental
conditions, but the exact mechanisms have not been described. Similarly, interactions
between glycoprotein H and the host cell membrane could not be established and the
molecular mechanism of how gil contributes to viral fusion remains unknown. From
phylogenetic analysis of glycoprotein 1-I it is known that the NGTV motif has been
conserved over million of years (McGeoch ci a!. 1995). This may indicate an
important function within the viral life cycle. However, site directed mutagenesis of
the NGTV motif demonstrated no influence on HSV-1 mediated fusion events
(Galdiero eta!. 1997). In contrast, the C terminal tail of gH, which projects either into
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the cytoplasm or towards the virus capsid, has been shown to play an important role in
cell-to-cell spread (Browne et a!. 1996; Wilson et a!. 1994; Anderson and Gompels,
1999). HSV-1 recombinant viruses containing mutations within the serine-valine-
proline motif (SVP) of the cytoplasmic tail entered Vero cells less efficiently and
were unable to induce cell to cell fusion (Browne et a!. 1996). The domains involved
in entry processes remain to be characterised in detail. Within the external domain a
hydrophobic stretch of amino acids, preceding the transmembrane domain has been
associated with viral entry and polykaryon production (Galdiero et a!. 1997; Liu et a!.
1993a; Anderson and Gompels, 1999).
1.9.3 The association of glycoprotein 1-I and glycoprotein L
Glycoprotein L has been identified as a chaperone for gH processing and transport to
the cell surface in recombinant protein studies (Hutchinson et a!. 1992; Yaswen et a!.
1993; Pulford eta!. 1995; Duus eta!. 1995; Kaye eta!. 1992; Liu eta!. 1993b, Westra
et a!. 1997). Glycoprotein L homologs have been identified in all herpesvirus
subfamilies and association with gH has been consistently reported (Duus et a!. 1995;
Hutchinson eta!. 1992; Kaye eta!. 1992; Liu eta!. 1993b; Roop eta!. 1993; Yaswen
et al. 1993). Complex formation between gH and gL can be either non-covalent
(HSV-1, VZV, EBV) or via disulfide bonds (CMV, HHV6) (Hutchinson et a!. 1992);
Duus et a!. 1995; Kaye el a!. 1992). The authentic expression of gH in vitro is
dependent on this chaperone-like function of gL. A similar situation applies to gL
expression itself, glycoprotein L is dependent on gH for its own post-translational
modifications, since recombinant
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expression studies of gL alone show that this glycoprotein is processed incompletely
and either secreted into the culture medium (e.g. HSV) or retained within the cell (e.g.
EBV) (Hutchinson et a!. 1992; Roop et a!. 1993; Spaete et a!. 1993; Duus et a!.
1995). Furthermore, in HSV-1 gL is not independently anchored to plasma
membranes but is membrane associated only as a result of complex formation with gH
(Dubin and Jiang, 1995). The protein encodes a N terminal signal sequence targeting
the ER (Hutchinson et a!. 1992) but lacks a membrane spanning domain. Although the
family of gL proteins is divergent at the sequence level, a recent study showed that the
gammaherpesvirus EBV gL and the alphaherpesvirus VZV gL can substitute
functionally for each other in a transient transfection system (Li et a!. I 997a). A
similar observation has been reported for HHV6 and HCMV (Anderson et a!. 1996).
The way gH and gL interact is not yet clear. Within the N terminus of gH conserved
cysteines have been identified within all herpesviral subfamilies, that may be required
for binding (Duus et aL 1995; Anderson et a!. 1996). How glycoprotein H in
association with gL mediates membrane fusion is also not fully understood. Perhaps
gL is only a chaperone that has no effect on fusion itself (Duus and Grose, 1996), or
both gH and gL are co-localized at the surface and induce fusion in form of a complex
(Peng et a!. 1998b).
The gI-l/gL complex was also used in immunization studies of mice. Limited
protection against viral challenge has been reported for VZV gH/gL antisera, where
neutralizing, complement-independent, antibodies could be detected (Nemeckova et
a!. 1996). Also, using a secreted form of HSV-1 gH/gL where the transmembrane
domain of gH had been removed, the sera of immunized mice contained high titers of
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virus neutralizing antibodies (Peng et a!. I 998a). However, in comparison to the
highly protective glycoprotein D immunization, the immune response elicited by the
complex was relatively inefficient (Browne et a!. 1993).
Recently in some herpesviruses, including HCMV and EBV, a third viral glycoprotein
has been associated with the gH/gL complex (Huber and Compton, 1997; Li et a!.
1995). In EBV this third component, the protein gp42, plays a crucial role during viral
entry into of B cells (Li et a!. 1995). The existence of such a protein in KSHV has not
yet been established.
1.9.4 A third component of the gHlgL complex
In the human cytomegalovirus three protein complexes, designated gCI, gCIl and
gd!!, have been identified that consist of disulfide-linked glycoproteins (Britt, 1984;
Gretch et a!. 1988). Complex gCI is composed of gB homodimers, gd! is defined as
the gHIgL complex and gCIII is thought to contain gM (Britt, 1984; Cranage et a!.
1988; Gretch et al. 1988; Kari and Gehrz, 1993). Recently a third component of gCIll
has been identified, encoded by the HCMV UL74 ORF and designated as
glycoprotein 0 (Huber and Compton, 1997; Li et al. 1997; Huber and Compton,
1998). The intracellular formation and processing of this tripartite complex is under
investigation, but it has not been established how independent gH, gL and gO are for
their processing and targeting (Huber and Compton, 1999). The function of gO
remains to be analysed.
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The gammaherpesvirus EBV is associated with a number of lymphoproliferative
diseases. The virus is known to infect at least two different cell types in vivo, B
lymphocytes and epithelial cells. However, in vitro it has only been possible to
establish a productive EBV infection in B lymphocytes. Here, the virus attaches via
the viral gp350 glycoprotein to CD2I and, in association with gH and gL, enters the
host cell (Fingeroth et a!. 1984; Nemerow et a!. 1989; Haddad and Hutt Fletcher,
1989). Furthermore, a third protein gp42 associates non-covalently with the gl-lIgL
complex (Li et a!. 1995). This glycoprotein is encoded by the BZLF ORF and plays a
critical role in the infection of B lymphocytes (Li eta!. 1995). Monoclonal antibodies
binding to gp42 inhibit fusion of the virus with the B cell membrane but have no
effect on virus attachment to CD2I on B cells (Miller and Hutt Fletcher, 1988; Li et
a!. 1995; Wang and Hutt Fletcher, 1998). Reports have shown that gp42 binds to
human leukocyte antigen (HLA) class II molecules to facilitate viral penetration (Li et
al. 1997b; Spriggs eta! 1996). These class II molecules are found predominantly on
antigen-presenting cells, such as macrophages, dendritic cells and B cells. Hence,
glycoprotein gp42 probably represents an adaptation to infection of B lymphocytes, as
gp42 is not involved in viral entry processes into epithelial cells (Li et al. 1995).
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1.10 Project
The newly identified herpesvirus KSHV contains a large number of potential
oncogenes and cellular homologs that may play a complex role in the development of
this vascular sarcoma. However, a cell system to study viral entry as well as virus
pathogenesis of KSHV has not yet been identified. This PhD thesis can be divided
into three individual areas, each analysing a different feature of KSHV.
1.10.1 Characterization of 0RF22 and 0RF47, predicted to encode gH and gL
As described above, glycoprotein H is highly conserved within the family of
herpesviruses and it is a major target of the host immune response. Its involvement in
viral penetration into the host cell and the formation of syncytia is an interesting
feature in identifying potential target cells. Glycoprotein H and glycoprotein L have
been identified in KSHV as the gene products of 0RF22 and 0RF47 respectively.
Analysis of their amino acid compositions showed similar features to other
herpesviruses. Following mammalian expression of KSHV 0RF22 and 0RF47, either
individually or in co-transfection experiments, their localization within the epithelial
cell lines HEK293 and Cos-7 was determined. To facilitate the characterisation of the
glycoproteins it was attempted to establish constitutively expressing cell lines. In
summary, levels of expressed proteins were low in both cell lines and an in depth
characterization was not possible because of the lack of glycoprotein-specific
antibodies. However, the intracellular distribution of KSHV gL has been analysed and
similar features to other herpesviruses demonstrated. Surprisingly, cell-to-cell fusion
has also been detected when both cell lines, Cos-7 and 293, were transfected with gL
alone.
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1.10.2 A hepatoma cell line as a target for KSHV
The propagating of KSHV in vitro has been rather unsuccessful. B cell lines have
been established from PEL patients and maintained in culture. However, these cell
lines are already infected with KSHV, making them inadequate for de novo infections.
The lack of such in vitro systems makes viral pathogenesis studies as well as the
search for possible receptors used by KSHV complicated. Only recently, several
research groups have identified cell lines that seem susceptible to KSHV infection and
to support viral replication over an extended period of time.
During our research we identified the hepatoma cell line HepG2 to be able to support
the growth of the KSHV positive B cell line BCP-1. Subsequent experiments showed
that this cell line can be infected with KSHV under certain conditions. The presence
of EBV in the inoculum was demonstrated to be necessary for KSHV to enter HepG2
cells successfully. In contrast, KSHV DNA could not be detected within HepG2 cells
when incubated in the presence of cell-free supernatant from the KSHV singly
infected BCP-1 cells. These results confirm an observation made by others, that EBV
might be a supportive co factor in viral entry/growth under certain conditions (Kliche
eta!., 1998).
1.10.3 Quantification of KSHV in plasma samples
Recently, the demand for quantification of pathogens, including viruses, bacteria, or
fungus during disease progression has increased. Several assays have been developed
that not only detect the infectious agent but also allow its quantification. This has the
advantage that disease progression can be directly monitored and may help to assess
the activity ofantiviral drugs. Furthermore, these assays can be useful in
93
burden. KSHV infection of an individual can currently be demonstrated by the
presence of antibodies using either serological assays or by PCR. As for KSHV and
other herpesvirus, the viral life cycle can be divided into a latent and lytic stages. For
research as well as for diagnostic purposes a quantitative assay may help to establish a
correlation between the latent/lytic replication and disease progression by monitoring
viral load.
The third part of this project describes the development of such a quantitative assay
and testing of serum and plasma samples. Based on other viral load assays developed
in the Department of Virology, a KSHV specific 96 well quantification assay was
developed. Briefly, total DNA is extracted from patient serum samples or plasma
samples, a specific sequence amplified by PCR, amplicons coated onto 96 well plates
and, following hybridisation with a KSH V-specific probe, analysed by
chemiluminescence. Several serum and plasma samples were tested and the data
demonstrated (a) the assay is able to detect KSHV quantitatively and (b) that the virus
is most prominently detectable in plasma, whereas serum shows a more than lOfold
decrease in viral load.
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2. Material and Methods
2.1 Material
All chemicals used throughout this thesis were obtained from Sigma or BDH
unless otherwise stated. All solutions used are listed in Appendix I. Appendix II
illustrates plasmid maps of all vectors used and Appendix III gives details about
the manufacturers' addresses.
2.1.1 Plasmid Vectors
Original plasmids were resuspended in 1mM Tris-EDTA (pH 7.5) and stored at
-20°C.
Plasmids were also transformed into E.coli on receipt and stored as glycerol stocks
at -20°C.
pcDNA3:	 The vector pcDNA3 (Invitrogen) is designed
for mammalian protein expression. It contains the cytomegalovirus (CMV)
immediate early promoter for recombinant expression in eukaryotic cells as well
as a T7 promoter/priming site, allowing the expression of the same protein in
prokaryotic systems. For the establishment of a stable cell line the vector has a
neomycin gene, enabling the transfected cells to grow in the presence of the
antibiotic geneticin. Cloning procedures can be performed in E. coIl as the vector
carries a prokaryotic origin of replication (ColEl) and the ampicillin resistance
gene. For a schematic map of the vector see Appendix II.
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pcDNA3.3p6:	 This vector is a modified version of the
plasmid pcDNA3. The CMV immediate early promoter as well as the T7
promoter/priming site were removed and replaced by the stronger CMV major
immediate early enhancer-promoter sequence derived from the plasniid P2 (see
below). Thus, this vector can offer advantages in the establishment of stable cell
lines as the level of expression is increased. To further increase the efficiency of
synthesis of mature recombinant glycoprotein, a 'leader sequence' encoding the
first 21 amino acids of the tissue plasminogen activator (tPA) has been inserted
downstream of the promoter. This allows cloning of DNA fragments immediately
downstream of the leader sequence. The replacement of the natural signal
sequence can result in more efficient post translational processing. Both, CMV
promoter and tPA leader sequences were derived from the plasmid pEEI4.gpI2O
(P2). The design and construction of pcDNA3.3p6 was carried out by Dr P Balfe
and DrJ May.
P2 (pEE14.IPA-gpl2O)	 DNA sequences encoding HIV-I BHIO gpl2O
in frame with the signal sequence of the tissue plasm inogen activator (tPA) have
been inserted into the HindIll site of the multiple cloning side of pEE 14.neo
(Rhodes et a!. 1994). The promoter is derived from the major immediate-early
(MIE) gene enhancer-promoter of the human cytomegalovirus (hCMV). It
contains the 5' untranslated sequence (intron) of the MIE gene (Accession number
M21295; Akrigg et a!. 1985). The mammalian expression vector pEEI4.neo was
supplied by Celitech Research (kind gift by Dr Paul Stevens).
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pcDNA3.1	 This mammalian expression vector is an
updated version of pcDNA3. It contains all features described for pcDNA3 to
allow efficient protein expression, including CMV immediate early promoter, T7
promoter/priming site, origin of replication (CoIEI), ampicillin resistance gene,
etc.. To allow selection of positive transfectants the vector encodes the zeocin
resistance protein (Sh ble gene).
The protein binds to zeocin and inhibits the antibotics DNA strand cleavage
activity, hence allowing cellular growth in the presence of zeocin. The multiple
cloning site of pcDNA3 was extended and slightly modified to disrupt a formation
of an mRNA hairpin structure which has been demonstrated to affect recombinant
expression of genes cloned downstream of the restriction site Not! (Invitrogen,
personal communication).
pcDNA3.1-fl— Gal-His	 This mammalian expression vector was
kindly provided by Invitrogen (Leiden, The Netherlands) and encodes a histidine
tagged 3-gaiactosidase. The vector is used in optimization studies of transfection
and western blot procedures.
2.1.2 Prokaryotic cells
Bacterial strains were grown aerobically at 37°C in an orbital shaker. For plasmid
purification purposes 3ml (Miniprep) to 25m1 (Midiprep) of Luria Bertani (LB)
medium supplemented with 1OOtg/mi ampicillin were inoculated with a fresh
over-night culture. E. coil SCS-1 and XL 1-blue were obtained from Stratagene as
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bacterial stabs. Full genotypes of these strains are given in the company's
catalogue.
E coli SCS-1 This bacterial strain is recA deficient to ensure insert stability and
has been shown to reliably yield good competent cells. Competent bacteria are
used in DNA cloning procedures. Prior to transformation cells were treated with
calcium chloride to allow subsequent uptake of plasmid DNA.
XL-1 blue	 This bacterial strain contains an antibiotic (Tetracyclin) resistant F'
episome. For high quality plasmid DNA it has a mutation in the endAl gene. E.
coil XLI-blue is used in DNA cloning procedures as described for the SCS-1
strain.
2.1.3 Mammalian cell lines
All mammalian cell lines were maintained in T75 or T25 sterile tissue culture
flasks and grown at 37°C in a 5% CO2 humid atmosphere.
293 cells:	 The HEK 293 cell line is derived from human embryonal kidneys
and is used in the recombinant expression of glycoproteins. 293 cells were
transformed to continuous growth using adenovirus Ad5 DNA.
Morphology: Epithelial
Media:	 Dulbecco's Modified Eagles Medium (DMEM)
(ICN) supplemented with 10% (v/v) Foetel Calf serum (FCS),
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2mM L-glutamine, 50 lU/mI penicillin, 50mg/mi streptomycin and
0.075% sodium bicarbonate.
COS-7:	 Cos-7 cells are derived from african green monkey kidneys. Cells
were transformed with an SV4O mutant, which encodes for the large T-Antigen.
Cos-7 cells are used in combination with the mammalian expression vector
pcDNA3.1. The vector encodes for SV4O origin of replication and therefore is
capable of episomal replication in this cell line.
Morphology: Fibroblasts
Media:	 RPMI with Glutamaxil (Life Technologies),
supplemented with 10% (v/v) Foetel Calf serum (FCS), 50 lU/mI
penicillin, 50mg/mI streptomycin and 0.075% sodium bicarbonate
HepG2 cells HepG2 cells are a well differentiated liver cell line, exhibiting
biosynthetic capabilities of normal liver parenchymal cells. Originally established
from a 15 year old male Caucasian, this hepatoma cell line was used in infection
studies of KSHV.
Morphology: Epithelial
Media:	 RPMI with Glutamaxil (Life Technologies),
supplemented with 10% (v/v) Foetel Calf serum (FCS), 50 lU/mI
penicillin, 50mg/mi streptomycin and 0.075% sodium bicarbonate
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BCP-1 cells: BCP-I cells are derived from the peripheral blood of a patient with
body cavity based lymphoma. Cells are singly infected with HHV8 and lack c-myc
rearrangements (Boshoff et a!. 1998). Following several experiments BCP-1 cells
were maintained when co-cultivated with human embryonic lung (HEL) cells as
feeder cell monolayer. BCP-1 cells were obtained from the Institute of Cancer
Reasearch, London, UK.
Morphology: B cell lineage
Media:	 RPM! with Glutamaxil (Life Technologies),
supplemented with 10% (v/v) Foetel Calf serum (FCS), 50 LU/mI
penicillin, 50mg/mi streptomycin and 0.075% Sodium bicarbonate
SYcells	 SY cells are derived from primary effusion lymphoma and the cell
line was established in the Virology Department, Windeyer Building, RFUCMS,
UCL, London, UK. Cells are dually infected with KSHV and EBV (Ursula
Ayliffe, personal communication). SY cells are maintained in the presence of a
feeder layer of human embryonic lung (HEL) cells.
Morphology: B cell lineage
Media:	 RPMI with Glutamaxil (Life Technologies),
supplemented with 10% (v/v) Foetel Calf serum (FCS), 50 lU/mi
penicillin, 50mg/mi streptomycin and 0.075% sodium bicarbonate
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2.1.4 Antibodies
a-His-IgGl Monoclonal Antibodies
Mouse Monoclonal antibodies detecting proteins with a histidine tag were
obtained from Qiagen. The Penta-Histidine monoclonal antibody recognizes five
consecutive histidine residues, whereas the Tetra-histidine monoclonal antibody is
highly specific for four consecutive histidine residues.
a-c-myc-Monoclonal Antibody
A hybridoma cell line producing the monoclonal antibody 9E10 was kindly
provided by the Imperial Cancer Research Fund. The antibody is used in the
detection of recombinant proteins containing the c-myc epitope.
Epitope:	 EQKLISQQDL
Goat a-mouse IgG Horse Radish Peroxidase conjugate
This antibody is used as a secondary antibody, in Western Blot procedures and
was supplied by Harlan Sera-Labs.
Goat a-mouse IgG FITC conjugate
This antibody is used as a secondary antibody in indirect immunofluorescence
studies and FACScan analysis (supplied by Dako).
Goat a-mouse JgG /3-Galaciosidase conjugate
This antibody is used as secondary antibody in histochemical staining procedures
and was supplied by Harlan Sera-Labs.
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2.1.5 Chemicals used in staining of Golgi organelles
The chemical probe BODIPY-TR were obtained from Molecular Probes (Leiden,
The Netherlands) and used as indicated in the manufacturer's instructions.
2.1.6 Enzymes
All reactions requiring enzymes were performed following the manufacturers
guidelines.
Enzymes	 Manufacturer
Restriction endonucleases	 Roche	 Diagnostics	 (Boehringer
________________________________________ Mannheim)
T4 DNA Ligase	 Promega
TaqGold DNA polymerase 	 Perkin Elmer
Taq DNA Polymerase 	 Promega
Expand Long Template DNA Polymerase Roche 	 Diagnostics	 (Boehringer
______________________________________ Mannheim)
Uracil DNA Glycosylase	 Roche	 Diagnostics	 (Boehringer
________________________________________ Mannheim)
Shrimp Alkaline Phosphatase	 Amersham (USB)
2.1.7 Oligonucleotides
The design of oligonucleotides is described for each polymerase chain reaction
individually. All primers were obtained from Oswel DNA Service, Southampton,
UK.
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2.2 Methods
2.2.1 Patient samples
Patient samples were obtained from the UCH Diagnostic Virology Service as serum
and plasma. Samples were stored at -20°C and for DNA extraction thawed quickly in
a 37°C water bath. These were residual samples remaining after diagnostic testing.
Consent was obtained from the chairman of the UCLI-I tEthics Committee for use of
these samples (see attached letter, Appendix IV). All samples were tested
anonymously.
2.2. 1.1 Sample preparation
EDTA blood was centrifuged for 5mm at 1800rpm and imi of plasma transferred to a
I .5m1 screw top eppendorf tube. An equal volume of PB S was added to the remaining
blood, the tube inverted and 1 ml of reconstituted blood collected and stored in 1 .5m1
screw top eppendorf tubes. Serum, plasma and whole hlood were stored at -20°C in
accordance with the standard laboratory practice in the Diagnostic Virology
laboratory at UCLH.
A variety of clinical samples, as well as cell culture material were used as DNA
templates for the amplification of specific viral sequences. Total genomic DNA was
prepared using a blood extraction kit, obtained from Qiagen, in accordance with the
manufacturers instructions.
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2.2.1.2 QIAamp blood Mini kit total DNA extraction
Total DNA purification from cell culture material and patient blood or plasma was
performed according to the instructions supplied with the QIAamp blood Mini kit
(Qiagen). Briefly, 200p1 of the sample were mixed with 200iil of lysis buffer,
containing Proteinase K (10.tlIml). After 10 mm incubation at 56°C, 200.il absolute
ethanol was added, tubes vortexed for 15 sec and the mixture applied to a spin
colunm. Following three spin-wash steps the DNA was eluted in 50p.l of elution
buffer and the extracted DNA stored at -20°C.
2.2.1.3 DNA from cell culture supernatant containing infectious viral particles
KSHV DNA was prepared from BCP- 1 and SY cell culture supernatants. Supematant
was collected in 1 .5ml screw top eppendorf tubes and centrifuged for 5mm at
5000rpm to remove any remaining cells. After 5 mm boiling eppendorf tubes were
wiped down with ethanol and removed from the category 3 laboratory. Total DNA
was then extracted using the Qiagen Blood Mini Kit and the viral copy number
determined by Poisson limited dilution PCR. Twenty microliter aliquots were stored
at -20°C.
2.2.2 Polymerase Chain Reaction (PCR)
The polymerase chain reaction was applied at several stages of this thesis. Firstly for
the amplification of viral DNA sequences encoding glycoprotein H and glycoprotein
L (Cloning PCR), secondly to test for the presence of KSHV DNA in the hepatoma
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cell line HepG2 (Infection PCR) and finally for the quantification of KSHV in patient
blood samples (ELONA-PCR).
2.2.2.1 Sequences and Primer design
A complete list of all oligonucleotide sequences used in this thesis is given on the
following pages (table 2.1 to 2.3). In addition schematic pictures illustrate their
localization within the viral open reading frames.
2.2.2. la Cloning PCR
The DNA sequences as well as the amino acid sequences encoding the viral
glycoproteins were obtained from GenBank (Accesion number: U75698). Analyses to
determine the immunoreactivity of each protein were performed using the PREDICT
program of the G-C-G package. Signal sequence cleavage sites were predicted for
each protein using the SignalP V1.1 World Wide Web Server (Nielsen eta!. 1997).
The KSHV open reading frames 22 and 47 were amplified by nested polymerase
chain reaction and inserted into mammalian expression vectors. Synthetic
oligonucleotide primers were designed depending on the vector of choice.
Primers for the amp! j/I cation of truncated protein
The vector pcDNA3.3p6 encodes the signal sequence, amino acid Ito amino acid 21,
of the tissue plasminogen activator (tPA). Viral glycoproteins were therefore
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1.
amplified without their own signal sequence in order to be expressed in frame with
the tPA leader sequence. The sense primers used in the first round of PCR are located
at the 5'end of the coding sequence whereas the 3' oligonucleotides are
complementary to sequences outside the coding region. To increase cloning
efficiency the set of inner primers were designed with uracilated tails as described in
the Clone AmpTM pAmpi rapid Cloning system by Life Technologies. These cloning
'tails' were complementary to sequences annealed to the linearised pcDNA3.3p6
vector, allowing cloning in the presence of the enzyme Uracil DNA glycosylase (J
May Ph.D. thesis, 1998).
In addition second round primers encoded the restriction sites EcoRI (sense primer)
and NotI (anti-sense primer) to facilitate possible subcloning. For protein detection
purposes the anti-sense inner primer encoded either a C-terminal c-myc motif, for
glycoprotein L constructs, or in case of glycoprotein H, six histidine residues,
together with a stop codon for proper termination.
Primers for the amplification of the entire coding sequence
For the amplification of fill-length sequences encoding the viral glycoproteins, a
separate set of primers was designed. Sense and anti-sense primers used in the first
round of PCR were both localized outside the coding region. Inner primers were
designed to anneal to the 3' and 5' ends of the protein coding region. As described
above inner primers also encoded restriction sites, Hindu! and Not!, as well as C
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terminal protein tags. Amplicons were inserted into pcDNA3.1 by 1-lindlil/Noti
restriction digest followed by ligation.
2.2.2.lb Infection PCR andELONA-PCR
Infection and ELONA PCR are based on oligonucleotide primers specific for KSHV
0RF26. Patient samples and tissue culture material were tested for the presence of
KSHV by nested PCR. However, to quantify samples a single round PCR was
applied.
Primers were kindly provided by Dr. M Howard. The primers were specific for
sequences within the KSHV 0RF26. The first round primer set has been published in
1994 by Chang and colleagues and were used in the initial identification of KSHV.
For nested PCR an inner primer pair has been designed as detailed in Dr. M Howards'
Ph.D. thesis (1999). For the enzyme linked oligonucleotide assay (ELONA) an anti-
sense oligonucleotide has been designed which is complementary to sequences within
the second round PCR product. This probe is 5' alkaline phosphatase conjugated and
used for the quantification of KSHV in patient samples.
For optimal primer design sequence variability between different KSHV isolates
sequences was analysed by alignments of all known viral 0RF26 sequences using
Clustal.W. Sequences were obtained from GenBank.
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2.2.2.2 PCR parameters
The polymerase chain reaction conditions for the amplification of each DNA
sequence was optimized individually. Different parameters, such as annealing
temperature, oligonucleotide primer concentrations, amount of template as well as the
quantity of DNA polymerase were assessed for each DNA template. Prior to
amplification all PCR reactions were overlaid with 5Ojil paraffin to prevent
evaporation.
2.2.2. 2a Cloning PCR
Using a RoboCycler thermal cycler (Stratagene) optimal annealing temperature,
oligonucleotide primer concentration and cycle count for the amplification reaction of
KSHV 0RF22 and 0RF47 were assessed. Once an optimal amplification was
achieved subsequent reactions were carried out using Perkin Elmer TC- 1 thermal
cyclers.
To avoid possible misincorporation during the amplification reaction the Expand
Long Template DNA Polymerase was used. This mixture of proof reading (Pwo DNA
polymerase) and non-proof reading (Taq DNA polymerase) DNA polymerases allows
the efficient amplification of long DNA templates with high fidelity.
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Amplification of 0RF22, encoding glycoprotein H
For the amplification of KSHV glycoprotein H DNA samples were applied to two
round-nested PCR, each round comprising 30 cycles, followed by a 7mm extension at
72°C.
The first round reaction was performed using a 50p1 reaction mixture containing
ixExpand PCR reaction buffer 3, 40OM dNTPs, 1U Expand DNA polymerase and
the oligonucleotide primer pair KS22.O.dir (or KS22H.O.dir) and KS22.O.RC at a
final concentration of 200pM. Two microliters of this first round product was used as
the DNA template in the second round of the nested PCR. Amplification was
achieved using ixExpand PCR reaction buffer, 400pM dNTPs, 1U Expand DNA
polymerase and the oligonucleotide primer pair KS22.I.dir (or KS22H.I.dir) and
KS22.LRC (or KS22N.I.RC) at a final concentration of 100pM. Cycling conditions
for both rounds are as follows: Initial denaturing for 4 mm at 94°C, 30 cycles of 45
sec at 94°C, 45 sec at 54°C and 3 mm 30 sec at 68°C.
AmplfIcation of 0RF47, encoding glycoprotein L
KSHV 0RF47 was amplified using the primer set KS47.O.dirIKS47H.O.dir and
KS47.O.RC during the first round, and primer set KS47.I.dir/KS47H.I.dir and
KS47.I.RC/KS47N.I.RC in the second round. DNA was amplified using the same
reaction conditions as described above for 0RF22, except primers were used at a final
concentration of 1 00tM, respectively.
112
2.2.2. 2b Infection PCR
Reaction conditions were initially developed by Dr. Mark Howard but optimised in
this thesis.
Total DNA from tissue culture material was purified using the Qiagen Mini Blood kit.
One to ten microliters of extracted DNA were transferred to a 50t1 PCR mix,
containing lxTaq reaction buffer, 1.5mM MgC1 2, 1mM dNTPs, 1.5U Taq DNA
polymerase and the outer primers MCP.O.dir and MCP.O.rev at a final concentration
of 200i.LM. The mixture was subjected to an initial denaturing step at 95°C for 4 mm
followed by 35 cycles (94°C, 1 mm; 50°C, 1 mm; 72°C, 1 mm) of amplification and a
final extension at 72°C for 7 mm.
One microliter was transferred to 25.tl of a second round PCR mix. Amplification
was achieved using 1 xTaq reaction buffer, 1mM dNTPs, 1 U Taq DNA Polymerase
and the primers MCP.I.dir and MCP.I.rev at a final concentration of 5001.iM and the
cycling conditions 4 mm at 94°C, followed by 25 cycles of 1 mm at 94°C, 1 mm at
50°C, 1 mm at 72°C and finally 7 mm at 72°C. Ten microliters of PCR product were
visualized by electrophoresis on a 1% agarose gel.
2.2.2.3 Limit Dilution Polymerase Chain Reaction
If the PCR used is "limit sensitive", i.e. capable of detecting a single molecule of
DNA, the number of viral DNA molecules within a DNA sample can be assessed by a
limit dilution polymerase chain reaction. The DNA amplification performed as
detailed for the infection PCR was shown to be limit sensitive.
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In general the limit dilution PCR was performed in sets of ten tubes. Each member of
the set containing the same dilution of the sample. Ten microliters of the neat or
diluted sample were used in the nested PCR described above. Following the reaction
ten microliters of each sample were analysed by gel electrophoresis and the number of
viral DNA molecules within the tested sample was calculated as follows: the number
of negative or 'zero' (f0) amplification products in each set of 10 tubes was counted.
According to the zero term of the Poisson probability distribution the average number
of DNA molecules per tube (j.) can be assessed by inserting the frequency of non-
amplifications per set into the following equation:
= - ln (f0)
Taking the dilution factor into account the number of DNA molecules per sample can
then be determined. For example if 5/10 reactions were negative f0 = 0.5 and t 0.69,
taking the dilution factor into account the copy number can be determined by simple
multiplication.
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2.2.3 Enzyme linked oligonucleotide assay (ELONA)
2.2.3.1 ELONA-PCR
To determine the number of KSHV copies within DNA samples from patients, a
single round PCR was performed. The 0RF26 has been analysed for sequence
variation between viral isolates (Zong et al. 1997). The second round primer set was
chosen for the ELONA-PCR because more sequence data was available, indicating a
high level of sequence conservation.
One and 10 microliters of Qiagen extracted DNA from patient blood samples was
subjected to the second round of the above described nested PCR (infection PCR).
The volume of reaction was increased to 50jil per tube and 38 cycles of PCR
performed. Optimization experiments showed this number of cycles to give the best
result (see chapter six). Following the reaction 5p1 of the PCR product was analysed
by an enzyme linked oligonucleotide assay.
2.2.3.2 ELONA
Whitby and Garson originally described this assay in 1995. Briefly, a biotinylated
PCR product is captured onto a blocked streptavidin coated plate, the dsDNA
denatured using NaOH and an alkaline phosphatase conjugated oligonucleotide
robe) added. An enzymatic reaction with a luminescent phosphatase substrate
(Lumiphos) can be measured by a luminometer in relative light units (RLU). Black 96
well streptavidin coated plates were purchased from Advanced Biotechnologies (see
Appendix III). Single round PCR products were diluted one in twenty in sample
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diluent (see Appendix I) and 1 00tl per well added. After 45mm incubation at 45°C
unbound PCR product was washed away using a plate washer, washing each well
with 1xTTA (see Appendix 1)10 times followed by a 1mm soak. To denature the
dsDNA each well was incubated with 1 00tl of 0.1 5M NaOH for 5mm. After another
wash step, 1 00.tl of alkaline phosphatase conjugated internal probe, diluted 1 in 1800
(2.7nM f.c.) in probe diluent (see Appendix I) was added to each well. The probe was
left to anneal for 30mm at 45°C. The plate was then washed three times as described
above, leaving it to soak for 1mm after each wash. Subsequently Lumiphos
(100il/well) was added, the plate sealed and incubated for lh in the dark to avoid
photobleaching. After one hour incubation light emission reaches a plateau level and
measurements can be performed.
The emitted photons were measured using a TopCount 480 luminometer (Packard).
Data was analysed using Genesis Version 2.20 software.
2.2.4 DNA analysis and manipulation
2.2.4.1 DNA electrophoresis
DNA electrophoresis was performed using agarose as a matrix, generally at a
concentration of 1% (w/v) dissolved in 1xTAE. The DNA fragments were directly
visualized by ethidium bromide added to the agarose gel (0.2ig/ml). Samples were
diluted in loading dye and I 2p.l per well loaded. To estimate the size of the DNA
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fragments a 1kb DNA ladder (Life Technologies) was also loaded in each gel. The gel
run was generally performed at 1 OOV and 8OmA for 45mm.
2.2.4.2 Pur/ication of DNA fragments from agarose gels using the
Genecleanli Kit (BlO 101 mc).
DNA was separated on 1% agarose gel and the desired band excised using a sterile
scalpel blade. The gel block was transferred to a plastic 1 .5m1 eppendorl tube and the
DNA purified following the instructions of the manufacturer. The extraction kit is
based on a specially formulated silica matrix (glassmilk) which binds the DNA.
Following three washes of the DNA-glassmilk complex the DNA was eluted in 20p.l
TE by incubating the tube at 50°C for 3 mm.
2.2.4.3 Restriction Endonuclease Digest
Restriction digest procedures were used in cloning procedures and to confirm the
cloned insert. Restriction enzymes were used in combination with the reaction buffer
recommended by the manufacturer. For Noti/Hindill restriction digests buffer H was
used (Roche) (see Appendix), for EcoRIIXhoI digests the reaction was performed in
1 xUniversal buffer (Stratagene) (see Appendix I).
In general 250 to 400ng of purified plasmid DNA were mixed with 10-16U of
restriction enzyme, lxReaction Buffer, and water to a final volume of 20 to 30 1ii.
The reaction mixture was incubated for 37°C for 2h. To inactivate enzyme activity an
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incubation of 15 mm at 65°C was performed. The resulting DNA fragments were
analysed on a 1% agarose gel.
2.2.4.4 Dephosphorylation of linearised vector
For cloning procedures the linearised expression vector was gel purified and
dephosphorylated to prevent self-ligation. One unit of Shrimp alkaline phosphatase
and lxReaction buffer were added to the purified and digested DNA. Following a 20
mm incubation at 37°C, the phosphatase was inactivated for 15mm at 65°C.
2.2.4.5 Ligation and Annealing reaction
2.2.4. 5a Ligation
During the ligation reaction the linearised vector and the insert of interest are mixed
together and ligated by the action of the enzyme T4 DNA ligase. The plasmids
pcDNA3 and pcDNA3.l were digested with the restriction enzymes HindlIl and Noti.
The insert, encoding the desired protein, was prepared with the same restriction
enzymes as the target vector. The PCR products were purified by agarose gel
electrophoresis and restriction digested. To eliminate the restriction enzymes 5.il of
Strataclean resin was added and, after a five minute incubation at room temperature,
pelleted at 13000rpm for one minute. 200-250ng of the pre-treated linearised vector
was used per ligation reaction. The amount of insert was calculated individually. For
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the cloning of glycoprotein H a vector:insert ratio of 1:2 was successful, as was a 1:8
ratio for glycoprotein L.
The entire 20p1 ligation mix contained the above mentioned components as well as
I xLigase Buffer and 3U of T4 DNA ligase. Digested vector without insert served as a
negative control. Ligations were performed over night at 12°C.
2.2.4.5b Cloning into pcDNA3.3p6
The Clone Amp rapid cloning system by Life Technologies was modified for the
pcDNA3.3p6 vector. Double stranded tails that consisted of an uracilated strand and a
complementary dTMP strand were ligated to the linearised vectors. As described
earlier the insert was amplified with primers encoding complementary uracil-
containing extensions. In the presence of the enzyme Uracil DNA Glycosylase these
uracilated bases will be removed, producing sticky ends. Vector and insert will then
anneal, resulting in a circulised form of the vector, which can be transformed into
competent bacteria (J May PhD thesis, 1998). The vector pcDNA3.3p6 was kindly
provided in linearised and tailed form by Dr J May.
Tails were designed to create an EcoRI and Not I restriction site at the 3' and 5' end
of the insert, allowing future subcloning of the insert. PCR products were purified by
agarose gel electrophoresis and 7-lOpi (lOO-l5Ong) added to a 20j.il reaction mix
containing IxAnnealing Buffer, 25ng of the vector and IU UDG. The annealing
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reaction took place at 37°C for 1 h and 1 Oj.ii of the mixture were transformed into
calcium competent E.coli SCS-1.
2.2.4.6 Transformation
2.2.4. 6a Competent Bacteria
A 250m1 vented Erhlenmeyer flask containing 50m1 LB growth medium was
inoculated with 500p.l of an E. coli SCS-1 or E coli XL-lblue over night culture and
incubated at 37°C in an orbital shaker. Flasks were grown to mid log phase and
subsequently placed on ice for 1 5mm. Following a five minute spin at 3000rpm in a
pre cooled (4°C) centrifuge the supernatant was removed and the pellet resuspended
in 100mM ice-cold calcium chloride (25m1). After a further 1 .30h incubation on ice,
bacteria were centrifuged as before and again resuspended in 100mM calcium
chloride (5ml). All steps were performed on ice to maintain cell viability.
2.2.4. 6b Transformation
1 O0-200j.tl of competent E. coil were transferred to round bottom transformation tubes
(Falcon 2059) and placed on ice. Five to eight microliters of the ligation mix (10tl of
the annealing reaction) or 250ng of purified plasmid DNA was added. A 30-40 mm
incubation on ice allowed the adsorption of the plasmid to the bacterial surface.
Subsequent transfer to a 42°C preheated water bath for 90sec resulted in the uptake of
DNA by the competent bacteria. After a short recovery on ice, the bacteria were
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spread on LB/ampicillin (f.c. 10Oig/d) plates and the dishes incubated overnight at
3 7°C. Colonies were screened by PCR to verify the presence of inserts.
2.2.4.7 Screening of bacterial transformants by PCR
Colonies obtained were screened by a single round PCR for the presence of gH and
gL. To facilitate the amplification 'screening' primers (KS22.SR and KS47.SR) were
designed, which produce small DNA subfragments of the insert.
Using a flamed loop single colonies were transferred to a numbered grid on an
ampicillin agar plate as well as added to a prepared 20p.l PCR mixture containing 1 U
Taq DNA polymerase, 1 xTaq reaction buffer, 1.5mM MgCl2, 1 00pM of each dNTP
and the appropriate synthetic oligonucleotide pairs at a final concentration of 1 OOnM
each (KS22.I.dir/KS22.SR or KS47J.dir/KS47.SR).
Targets were amplified in a 25 cycle PCR (94°C, 35sec, 35sec, 50°C, 2mm 30sec,
72°C) followed by an extension of 7mm at 72° C. Ten microliters of the reaction were
analyzed by agarose gel electrophoresis.
2.2.4.8 Small Scale Plasmid preparation provided by QlAprep Plasmid Kit
PCR positive colonies were grown aerobically overnight in 3ml LB-Medium,
containing 1 001g per ml ampicillin for selection. The following morning plasmids
were purified according to the manufacturers instructions (Qiagen). The QlAprep Kit
uses solid-phase anion exchange separation method.
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Cells were pelleted and an alkaline lysis performed. Proteins, cell debris and
chromosomal DNA were precipitated with SDS and high salt, whereas the
supercoiled plasmid DNA renatured and remained in solution. Subsequent
centrifugation for I 0mm at 16000rpm separated the two fractions and the supernatant
was bound onto a Qiagen gravity flow column. After two wash steps the DNA was
eluted with Elution Buffer, supplied with the Kit. Following isopropanol precipitation
the DNA was washed in 70% ethanol and finally dissolved in 1 OOp.l TE. The average
yield was between 1 50-200ng per microliter. The purified plasmids were analyzed by
restriction digest to verify the cloning procedure. Bacterial clones containing the
plasmid of interest were grown over night in 3ml LB/ampicillin and an aliquot stored
as a glycerol stock (500 j.tl bacterial culture mixed with 500t1 of 98% glycerol) at -
20°C. Bacteria grown from glycerol stocks were streaked onto LB agar plates
supplemented with lOOjtg!ml ampicillin and incubated over night at 37°C. The
following morning a single colony was transferred to 3ml of selective growth media
and incubated for 8h at 37°C. This starter culture was then diluted 1 in 800 and grown
over night for further plasmid purification.
2.2.4.9 Midi DNA plasmidpurflcation
For high yield plasmid purification, the Qiagen Midi Kit, providing gravity flow
columns with a higher DNA binding capacity, was used. A single colony was
transferred to selective LB medium and cultured for 8h at 37°C, Following a 1 in 800
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dilution bacteria were incubated for an additional 16 to 1 8h in 25m1 LB-Medium,
containing lOOtg per ml ampicillin for selection. The DNA purification was
performed according to the manufacturers protocol. The pellet in the final step was
eluted in 3OOtl TE, the average yield was approximately 350-700ng per microliter.
2.2.5 Automated Sequencing
Plasmids were sequenced using the Thermo Sequenase pre-mixed cycle sequencing
kit (RPN 2444) and the Vistra DNA Sequencer 725 by Amersham.
The sequencing protocol is based on repeated cycles of thermal denaturing, annealing
and extension/termination. DNA strand synthesis starts at a specific site, as
determined by the Texas Red labelled primer, and ends with the incorporation of a
chain terminating dideoxynucleoside triphosphate.
DNA samples were sequenced using the sense primer pCMV and the antisense primer
p3rev. Oligonucleotide sequences are given in table 2.4.
Oligonucleotide primer	 Sequence (5 '-3')	 Localization
(OsweIl code numbers)
pCMV	 CGCAAATGGGCGGTAGGCGTG	 CMV promoter
p3rev	 TAGAAGGCACAGTCGAGG	 BGH polyadenylation signal
Table 2.4: Oligonucleotide primers used in sequencing of plasmids. Localization is
given with respect to the DNA sequences published by Invitrogen.
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Cycle sequencing protocol
Plasmids were prepared using the Qiagen Plasmid Mini Kit. A 25tl master mix was
prepared containing 2pmol Texas Red primer and 900ng of plasmid DNA. Six
microliter of this template/primer mixture was transferred into four eppendorf tubes,
already containing 2tl of either A, C, 0 or T reagents. Prior to PCR the reactions
were overlayed with 20t1 of paraffin. Tubes were placed into a Perkin Elmer Thermal
Cycler and received an initial 4 mm denaturing step at 94°C, followed by 25 cycles of
94°C for 15 see, 50°C for 15 sec and 72°C for 30 sec.
Following amplification samples were transferred to a 96 well microtitre plate and
mixed with 3tl of loading dye. The plate was then placed in a vacuum desiccator on a
hot (80°C) aluminium block and left to evaporate for approximately 10 to 1 5mm to
reduce the volume to 31.tl. Samples were loaded on the Vistra 750 sequencer. A
mixture of loading dye, salt solution and water (2:1:1) was loaded into all empty lanes
to avoid thermal artifacts.
Sequencing gels contained hg urea diluted in 3mIs 1OxTBE, 3mls 2%BIS/40%
Acrylamide (Sigma), 1 ml 40% Acrylamide and 1 Sml of water. For polymerization
200p1 of APS and 20j.1 of TEMED were added. Generally sequencing gels were run
for 9h at 1400V
Computer analysis
Sequences were analysed using Sequencher 3.1. (Gene Codes Corp.).
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2.2.6 Mammalian Cell culture
2.2. 6.1 Maintenance of mammalian cell lines
In general all cell lines were maintained in T75 tissue culture flasks and passaged
twice a week in a one to eight ratio. Culture media was removed and cells washed
once in 4ml PBS to remove residual media. Cells were then covered with 2ml of
TrypsinIEDTA. Following a 5mm incubation at 37°C the flask was shaken until the
cells were in suspension. An appropriate volume of cells was then transferred to a
new T75 tissue culture flask, already containing 1 5ml of complete growth medium
(see Appendix I).
Established stable cell lines were maintained in complete media supplemented with
the appropriate drug and maintained as described above (see Appendix I).
2.2.6.2 Cryogenic preservation of mammalian cell lines
Transfected cells acquiring resistance to neomycin or zeocin were selected. Prior to
single cell cloning, nitrogen stocks were prepared. A 90% confluent T75 flask was
harvested using TrypsinIEDTA and cells were pelleted at 1500rpm for five minutes.
Supernatant was removed and the cells were resuspended in 4m1 of freezing media
(see Appendix I). This mixture was transferred to four pre-cooled Nunc Cryovials and
cooled slowly over night to -80°C before storage in a liquid nitrogen container.
To recover cells from nitrogen stocks, vials were rapidly thawed in a 37°C waterbath,
diluted into l0mls complete media, and subsequently centrifuged for 5mm at
1500rpm. Supernatant was removed and cells resuspended in 15m1 of pre-warmed
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complete or selective growth media. The resuspended cells were then transferred to
T75 tissue culture flasks. Media was replaced the following day.
2.2.6.3 Transfection
Different methods of transfecting mammalian cells have been tested. The efficiency
of transfection was assessed using the plasmid pcDNA3.1-betaGal-His (see Appendix
II for plasmid map).
2.2.6. 3a LipofectAMINE TM Transfection
The plasmid pcDNA3.3p6 was transfected into 293 cells using lipofectamine (Life
Technologies). Two to ten pg DNA were complexed to liposomes according to the
manufacturer's instructions and transferred to a tissue cell culture dish. Transfections
were performed in tissue culture dishes (60nmi) or multi-well plates. The amount of
DNA as well as the number of cells seeded are illustrated in table 2.5. Cells were
prepared one or two days prior to transfection and incubated at 37°C until they
reached 60-80% confluence. Supernatant was removed and cells washed twice with
lml PBS. Subsequently cells were covered with fresh serum free DMEM and
incubated for 2h at 37°C. In the meantime the transfection mixture A and B were
prepared. Mix A contained the diluted lipofectamine (e.g. for a 6 well dish: 6p.1 in 94
serum free DMEM) and mix B the plasmid, also diluted in serum free DMEM.
Prior to transfection both solutions were mixed and left for 1 5-30mm at room
temperature to allow complex formation. The transfection mixture was then added
126
dropwise to the cell monolayer and plates returned to 3 7°C. The following morning
cell supernatant was removed and freshly prepared complete growth medium added.
Forty eight to seventy two hours post-transfection supernatant was collected,
transfected cells washed twice with PBS and prepared for further applications
according to the appropriate protocol.
Dishes	 Number of 293 cells 	 Amount of	 Amount of
lipofectamine/final 	 DNA/final volume
volume
60mm dish	 8x105 per well	 10tl per dishI25OpJ 	 8tg per dish1250tl
6well dish	 3x105 per well	 6.il per we1l/1OOtl	 5tg per well/lOOp 1
l2well dish	 2x105 per well 	 3jt1 per well/5Otl 	 2.tg per well/50pJ
Table 2.5: Number of cells seeded, amount of plasmid DNA and transfection reagent
used for transfection of mammalian cells using Lipofectamine.
2.2.6.3b EffecteneTM Transfection
Effectene transfection is based on a DNA lipid complex formation. DNA is condensed
by a so called 'enhancer' and subsequently the Effectene reagent coats this complex
with cationic lipids.
The transfection method was optimized following the guidelines provided in the
manufacturer's instructions. The optimal ratio of DNA to transfection reagent was
determined for each cell line as well as for each plasmid and culture vessel.
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In general, a 'mastermix', containing diluted DNA and enhancer was prepared and
incubated for 5 minutes at room temperature. Aliquots were then transferred to 1 .5m1
eppendorf tubes or plastic bijoux already containing the Effectene transfection
reagent. Tubes were briefly vortexed and incubated for an additional 1 0mm. While
complex formation was taking place, cells were washed twice in PBS and overlaid
with fresh culture medium. Finally, the DNA complex was diluted in culture medium
and applied dropwise to the cells.
Cells were returned to the incubator and harvested 48 to 72 h post transfection.
However, if cytotoxicity was observed, the transfection complex was removed, the
cell monolayer washed once with PBS and fresh media added.
2.2.6. 3c Sodium butyrate induction of transiently tran.sfected cells
To increase recombinant protein expression n-butyrate was added to transfected cells
24h post transfection. Culture medium was removed and replaced by fresh medium
containing 2-10mM sodium butyrate. Following another 24h incubation, cells were
harvested for recombinant protein detection.
2.2. 6.4 Stable Protein Expression
For the establishment of a cell line expressing viral glycoproteins constitutively,
plasmids were transfected as detailed for transient transfection. Two days post
transfection cells were split in a 1:10 ratio and transferred to a T25 culture flask
containing selective media. Media was subsequently changed every five days. After
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one to two weeks colonies could be observed. Further cultivation of those selected
colonies was performed as described for maintaining mammalian cells. As soon as a
sufficient number of cells were available, cells were divided into two T25 tissue
culture flasks, grown until they reached 80-90% confluence and subsequently cloned
using a 96we11 dish as well as being stored as nitrogen stocks.
2.2.6.5 Single cell cloning
A confluent T25 flask was harvested using 1 ml of trypsin. To achieve a single cell in
suspension the flask was shaken vigorously for 30 seconds. Cells were then
transferred to a sterile bijoux and counted using a KOVA glasstic slide. One hundred
microliters of trypsinised cells were mixed with an equal volume of trypan blue and
1 Op.l were transferred into a chamber of the slide. The number of viable cells in 10
small grids was determined. To obtain cells per microliter the average number of cells
per small grid was multiplied by 180.
To obtain a single cell per well, a dilution series was prepared, starting with 100 cells
diluted in lOml selective media. Five millilitres of this cell suspension were
transferred to 48 wells, adding approximately 200 jtl per well by using a 5ml pipette.
Subsequently another 100 cells were added to the remaining 5m1 of the cell
suspension and 2.5m1 transferred to 24 wells. Finally, a further 100 cells were mixed
with the 2.5m1 left in the Universal tube and added to the remaining empty wells.
129
The plates were incubated until single cells started to divide and colonies had formed.
The culture medium was removed and cells were trypsinised as described before.
Detached cells were then expanded and tested for recombinant protein expression by
various assays.
2.2.6.6 Sodium butyrate induction of stable cell lines
Selected 293 or COS-7 cells were seeded in 60mm 2 dishes or cover slips. Cells were
grown until they reached 60-70% confluence. Culture media was removed and cells
washed once with 5001.d (cover slip) to 2ml (dish) of PBS. Subsequently fresh media
supplemented with 2-10mM n-butyrate was added and cells incubated over night at
37°C. The following morning cells were tested for recombinant protein expression by
various assays.
2.2.6.7 Detection of cloned insert within mammalian cells by using the
Polymerase Chain Reaction
Genomic DNA was isolated using a Genomic DNA Isolation Kit (Promega).
Approximately 5x106 mammalian cells were harvested and transferred to a 1 .5ml
eppendorf tube. Following centrifugation for 20sec at 16000 x g cells were lysed in
600p.l Nuclei Lysis Solution (supplied by the manufacturer). Subsequently 3tl of
RNase solution was added to the nuclear lysate and mixed by inverting the tube 25
times. Further steps, including protein precipitation and DNA precipitation using
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Isopropanol were performed as detailed in the manufacturers manual. The pellet,
containing the total genomic DNA was resuspended in 50 p1 of nuclease free water,
supplied by the manufacturer. The extracted DNA was subjected to a standard PCR,
amplifying a subfragment of the insert of interest. Oligonucleotide primers and PCR
conditions are identical with the previously described colony screen PCR (see above).
2.2.6.8 HepG2 infection
Prior to inoculation supernatant derived from BCP-1 and SY cells was collected in
two separate SOml falcon tube and cleared by 30mm centrifugation at 5000rpm. The
infectious supernatant was transferred to a fresh 50m1 falcon tube and stored at 4°C.
Aliquots were collected in I .5m1 screw top eppendorf tubes and stored for PCR
testing.
A 90% confluent HepG2 culture was split in 2m1 trypsin as described before and
500t1 aliquots transferred to four T25 culture vessels. Cells were incubated for 2 days
at 37°C (60% confluence). HepG2 cells were washed twice in lml PBS and aliquots
of supernatant stored at 4°C for PCR testing. The cell monolayer was then overlaid
with pre-cleared infectious supematant either neat or diluted in fresh complete RPMI
(dilutions are detailed in the results section). Immediately after inoculation, aliquots
of the cell supernatant were removed from each flask and stored for PCR. The
following day further aliquots were collected.
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Five days post infection supernatant was removed, cell monolayers washed three
times with 2.5m1 PBS and cells covered in lml trypsin. After a 5mm incubation at
37°C cells detached and 500pi were transferred to a new T25 culture vessel. Aliquots
of supernatant, third wash and detached cells were harvested and stored for further
testing. Supernatant and third wash were also centrifuged for 5mm at 5000rpm to
remove any cells. Two hundred microliter aliquots of both supematant and wash were
then transferred to 1.5 ml eppendorfs. In cases, where a considerable number of
detached cells were present in the supematant the pellet was resuspended in 200p.1 of
PBS and analysed by PCR.
HepG2 cells were split every week and samples taken as detailed above. As this
experiment was performed in a category 3 laboratory, the samples were boiled for
5mm and tubes wiped down with ethanol prior to transfer.
DNA from cell culture samples was extracted using the Qiagen Mini Blood Kit and
tested by nested PCR as detailed above.
2.2.6.9 Sodium butyrate induction of HepG2 cells
It has been shown that sodium butyrate can induce lytic cycle replication of KSHV in
PEL cells (Miller et al. 1996). HepG2 cells containing KSHV DNA, as indicated by
PCR, were split as described above. One culture flask was then incubated with
complete RPMI, supplemented with 3mM n-butyrate, whereas the second flask only
contained complete RPMI. Two hundred microliters of culture supernatant were
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collected 24h after induction. Following another 24h incubation aliquots of culture
supernatant, third wash and HepG2 cells were collected and analysed as described
earlier.
2.2.7 Detection of recombinant protein expression
2.2.7.1 Preparation of a cell lysate
Transiently transfected cells as well as stably selected cells were lysed prior to
recombinant protein detection using several different lysis buffers, described in the
literature (Westra et al. 1997; Pulford et al. 1995).
Supernatant was collected and stored for testing at -20°C. Cell monolayers were
washed twice with lml ice-cold PBS and detached in imi of PBSIEDTA (see
Appendix I). The detached cells were transferred to a I .5m1 eppendorf and pelleted at
5000rpm for 5 mm. Supernatant was discarded and the cells lysed in 50-lOOpi of
Triton-X-100 lysis buffer (see Appendix I). The lysis was performed on ice for 30mm
and the extracts subsequently centrifuged for 5 mm atl4000rpm. The soluble fraction
was transferred to a fresh I .5m1 eppendorf tube and the pellet (insoluble fraction)
dissolved in 50.tl SDS-lysis buffer (see Appendix I). Insoluble protein fractions were
sonicated three times for 10 sec at 30 Watts on ice using an ultrasonic probe.
Both protein fractions were stored at -20°C for further applications.
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2.2.7.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE)
To detect recombinant protein expression cellular proteins were separated by standard
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using a MiniProtean II system
(Bio Rad).
Depending on the size of the protein either 7% or 12% polyacrylamide gels were
prepared on the day of use (see table 2.6). Prior to loading, samples were mixed with
an equal volume of Loading buffer (see Appendix I), and 20 to 30 tl of cell
supernatant or cell lysate loaded per well. Protein gels were run at 120 V, 30 mA for
1h30 in ixPage buffer (see Appendix I) and electroblotted onto PVDF membrane
(Amersham) for further detection assays.
To estimate the molecular weight a Rainbow molecular weight marker (Amersham)
was used routinely.
Stacking gel	 Separation gel 	 Separation gel
__________________________ _____________ 	 7%	 12%
30%Acrylamide/2%Bis	 500.tl	 3ml	 4.4m1
Acrylamide_____________ ______________ ______________
1M Tris-Ci pH	 600t1	 4.5m1	 4.lml
10% SDS	 25tl	 90.tl	 100
Water	 3.5m1	 4.3m1	 2.2m1
10% APS	 80p.l	 60.il	 100
TEMED	 5p.l	 12p.l	 5il
Table 2.6: Composition of the denaturing polyacylamide gels used for protein
analyses.
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2.2. 7.3 Enzyme linked immunosorbent assays (EJA)
For the detection of recombinant glycoprotein expression indirect enzyme linked
immunosorbent assays were performed, coating the cell lysate onto plates via
Galanthus nivalis (GNA) lectin (Roche). Assays were performed in 96 well Nunc
Maxisorp plates and lOOp.l per well were used throughout the assay.
Plates were coated over night at 4°C with 1 tg GNA lectin per well in 0.1 M NaHCO2.
The following morning plates were washed three times with ixTris-Saline (TS, see
Appendix I) and non-specific binding blocked by coating the plates with Blocking
buffer (see Appendix I) for 2h at room temperature. Following three further wash
steps undiluted cellular lysate or cell supematant were added to the well and
incubated for 2h at room temperature. Wells were washed three times with I xTS and
bound antigen detected using monoclonal antibodies (mAbs) specific for this C-
terminal protein tags. The mAbs were diluted in TBS buffer (see Appendix I)
supplemented with 3% BSA. To further block cross reactivity, lysed 293 cells were
added to the mAbs/TBS mixture and incubated at room temperature for 10 mm prior
to reaction in the well. Following an lh incubation at room temperature the washing
procedure was repeated and a secondary anti-species goat polyclonal serum,
conjugated to horseradish peroxidase and diluted I in 1000 in TMTGS (see Appendix
I), added. After another 1 h incubation plates were finally washed five times with
1xTS, soaking the wells for one minute between each wash. Bound HRP-conjugated
antiserum was reacted with TMB substrate to give a coloured product (Murex). TMB
substrate and substrate diluent were mixed at equal volumes according to the
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manufacturer's directions. One hundred microliters were added per well and the plate
incubated for 20-30mm at 37°C. Following the observation of blue coloured wells,
1OOtl of O.5M HC1 was used to stop the oxidisation reaction. The absorbency of each
well at 450nm was then determined using a TitreTek MCC multiskan MP (???).
Supernatant and cell lysate from mock transfected cells were used as negative
controls in all assays.
2.2.7.4 Western Blot
A western blot comprises SDS-polyacrylamide gel electrophoresis, transfer of the
proteins to a membrane, antibody incubation and finally the demonstration of the
presence of an antibody-protein complex using an antibody probe. In the following
procedure different primary antibodies were used. Glycoprotein H, encoding a
6xhistidine tag was incubated with monoclonal antibodies specific for either four or
five histidine residues (Qiagen), the monoclonal antibody 9E10, raised against the c-
myc motif, was used to detect recombinant glycoprotein L. Visualization was
performed using the ECL Western Blot System which is based on chemiluminescence
(Amersham).
Cell supernatant and protein samples from total cell lysates were resolved by SDS-gel
electrophoresis and electrotransferred to PVDF membrane (Amersham) by use of a
semi dry blotting apparatus.
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Whatman filters were rinsed in the Towbin transfer buffer (see Appendix I) for 15-20
minutes and arranged as illustrated in figure 2.1. Blotting conditions were 10-20 V,
220 mA for 45mm and resulted in the transfer of most proteins. To transfer larger
proteins the transfer sandwich was left overnight at 60 mA. Prior to protein detection
the membrane was pre-wetted with methanol and rinsed with distilled water.
I
I Cathode
PVDF-membrane	
-	 L SDS-GeI
	I 	 I Anode II
Anode I
Figure 2.1: Arrangement of SDS-PAGE transfer blot
The membrane was transferred to a sandwich box containing I OOml Tris-Marvel (see
Appendix I) and blocked for 90 minutes at room temperature on an orbital shaker.
When probing the membrane with anti-his monoclonal antibody, the membrane was
blocked in 1% casein instead of milk powder. After being washed three times for 10
mm in TBSTT (see Appendix I) the membrane was incubated with primary antibody,
diluted in Tris-BSA (9E10) or in Tris-casein (anti-His) (see Appendix I) for 2-3h at
room temperature. The anti-His monoclonal antibody was diluted 1 in 2000, 9E 10
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was used at a 1 in 700 dilution. After three further washes, the anti-mouse HRP
conjugated antibody (Harlan Sero Labs), diluted according to the supplier's manual
(1:20000) in Tris-NGS (see Appendix I), was incubated with the membrane for 1 h.
The membrane was then extensively washed (four times for 1 0mm each time) and
developed with the ECL Plus Kit. Hyperfilm ECL film sheets (Amersham) were
developed using an automated developer.
2.2.7.5 Blue CellAssay (Clapham eta!. 1992)
The blue cell assay is an in situ indirect enzyme linked detection assay. Instead of
capturing the soluble antigen in a solid phase EIA, transfected cells are tested in situ
for antigen expression. The primary antibody is specific for the recombinant protein
tag and is detected by a species-specific antibody which is -galactosidase
conjugated. The assay is used to assess the frequency of recombinant protein
expression after transient transfections as well as to assay stably transfected cell lines.
Transfections were performed in 12 or 24 well dishes. Cell supernatant was removed
and cell monolayers washed twice with imi PBS. Ice-cold methanol acetone was
added until cells were covered and dishes left for 30mm at -20°C. Following three
washes using DMEM supplemented with 2% FCS, recombinant antigen expression
was detected using anti-myc monoclonal antibodies 1 in 100 diluted in washing
buffer. Dishes were placed on a slow orbital shaker and incubated for 2h at room
temperature. Subsequently cells were washed three times and incubated with the
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second antibody, a goat anti-mouse -galactosidase conjugate (diluted 1:600) (Harlan
Sero Labs), for lh. Washing steps were repeated and cells were finally washed twice
with PBS to remove any residual DMEM. The substrate X-Gal (Roche Diagnostics)
was diluted 1 in 100 (f.c.0.5mg/ml) in staining solution (see Appendix I). Blue
coloured cells were visible after two hours. To preserve the colour reaction, plates
were incubated in the dark.
2.2. 7.6 Indirect immunofluorescence confocal microscopy
The intracellular localisation of the recombinant proteins was analysed by indirect
immunofluorescence using a Bio Rad MRC 1024 Confocal System. Images were
overlaid using NIH Image 1.61 software.
Cells were either directly transfected in coverslips or seeded onto coverslips (Life
technologies) after the selection process.
2.2.7. 6a Staining offIxed cells
The culture media was removed and cells washed twice with 1 ml of ice cold PBS.
Subsequently cells were covered with ice-cold methanol/acetone and left at -20°C for
30mm. After three washes with DMEM, supplemented with 2%FCS, non-specific
binding sites were blocked in DMEM containing 5% normal goat serum (NGS) for
30mm at room temperature. The wash steps were repeated and the antibody, diluted 1
in 20 in washing buffer, added. Following a 1 hour incubation at 37°C cells were
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washed again and further incubated with a goat a-mouse FITC conjugated antibody
(1:20 diluted) (Dako) for 60 mm. The dilution buffer was supplemented with 2%
normal goat serum. Finally cells were washed thoroughly 3 times with washing buffer
and 2 times with PBS. Slides were air dried and covered with a glass coverslip using
mounting fluid (Dako). All incubation steps were performed on an orbital shaker. For
counterstaining of DNA cells were mounted using VECTASHIELD mounting
medium containing 1.5j.tg/ml propidium iodide (P1) (Vector Labs). In addition to
methanol/acetone fixation some cells were incubated for 1 5mm with 2%
paraformaldehyde in PBS. After three wash steps, cells were permeabilized for
another 15mm in 0.1% Triton-X-100 in PBS or in acetone for 5 minutes. Subsequent
staining was performed as detailed above.
2.2. 7.6b Staining of viable cells
To detect possible surface expression cells were stained on ice prior to fixation. Cells
were harvested and labelled as described above. Following the last wash step cells
were fixed in methanollacetone and prepared for confocal microscopy as detailed in
section 2.2.7.6a.
2.2.7. 6c Staining of Golgi organelles
For experiments in which cells were double labelled for recombinant glycoprotein L
and for Golgi organelles, BODIPY TR ceramide (Molecular Probes), a golgi marker,
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was added at a final concentration of 0.5 to 1 .iM during incubation with secondary
antibody. BODIPY TR ceramide has spectral properties similar to those of Texas
Red.
2.2.7.7 Flow-cytometric analysis
Stable cell lines and transiently transfected cells were analysed by Flow cytometry
(FACS) for recombinant protein expression.
Harvesting
For transient transfections mammalian cells were transfected in 60mm dishes as
described above. At 48h post transfection, tissue culture supernatant was removed and
the cells washed twice with 2ml PBS. Cells were then harvested using imi of trypsin
and transferred to 3 ml polystyrene round bottom tubes (Falcon 1260). Viable cell
counts were determined (trypan blue exclusion) and cells pelleted (5mm at 2000rpm).
Cells were resuspended in PFA (see Appendix I) at 106 cells per ml.
Stably transfected cells were harvested using 1 ml of trypsin and transferred to falcon
tubes as described above.
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Staining
A total of lO5cells were incubated with lOOpi of primary antibody (mAbs diluted 1 in
50 in PFA) for lh at room temperature. To fix cells, 4Opl of PennaFix (ORTHO
Diagnostics) was added to each tube.
Cells were washed by adding 5m1 of PFA followed by centrifugation at 2000rpm for
5mm. Cells were resuspended in lOOp 1 of PFA, supplemented with 2% normal goat
serum, containing goat anti-mouse FITC conjugated antibody (Dako) at a 1 in 30
dilution. After incubation for lh at room temperature, the cells were washed twice
with 5 ml PFA and finally resuspended in I OOpi of PFA. 10000 cells were analysed
using a FACScan apparatus (Becton Dickinson). Data obtained was analysed with the
software Win MDI Version 2.8.
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3. Expression of the KSHV glycoprotein H and glycoprotein L
3.1 Introduction
KSHV is implicated in the pathogenesis of Kaposi's sarcoma (KS). The viral
genome has also been identified in other lymphoproliferative diseases such as
primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD).
Herpesviruses encode a large number of glycoproteins which are involved in viral
attachment and viral penetration into the host cell. The herpesviral glycoprotein H
is highly conserved throughout the herpesvirus family and studies demonstrate its
importance in viral fusion processes. Recombinant expression of authentic
herpesviral glycoprotein H and its transport to the cell surface has been
demonstrated to depend on the presence of a second viral glycoprotein,
glycoprotein L. Sequence homology searches have identified gH and gL homologs
within the genome of KSHV. Using nested PCR KSHV ORF 22 (gH) and ORF 47
(gL) were amplified and cloned into the mammalian expression vector
pcDNA3.3p6. Oligonucleotide primers were designed to encode different C
terminal protein tags for each protein to facilitate detection when co expressed.
The generated clones, named pcDNA3.3p6.22, and pcDNA3.3p6.47 were co- or
separately transfected into HEK293 cells and subsequent protein expression
analyzed. In addition, successfully transfected cells were selected and tested for
protein expression.
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3.2 Expression systems for the production of viral glycoproteins
Several protein expression systems have been developed, all having their
advantages and disadvantages. To study the function of viral glycoproteins their
glycosylation pattern has to be as authentic as possible to maintain confirmation
and possible epitopes that are important in immunological recognition. The
synthetic production of eukaryotic proteins frequently requires post-translational
phosphorylation, oligomerization, or specific proteolytic cleavage processes that
are not performed by bacterial cells. As demonstrated for the expression of the
HIV-1 gpI2O glycoproteins E. coli and yeast produce a recombinant protein that is
neither glycosylated nor correctly folded (Sohn et al. 1996). To synthesize
recombinant glycoprotein that most closely reflects the wild type glycosylation
pattern of the protein, expression systems based on mammalian cells are
recommended. However, some cell lines are more productive than others and the
choice of an expression vector is crucial in optimizing expression levels.
3.2.1 Choice of mammalian cell line
Several mammalian cell lines are widely used for expression studies, including
CHO, Cos7 and HEK293 cells. However, each cell line shows a different
glycosylation pattern (Mizuochi et a!. 1990). As mentioned before, viral
glycoproteins play an important role in immune response of the host cell and
antibody recognition may depend on oligosaccharide structures (McKeating et a!.
1992). Thus a mammalian expression system should be selected which allows
optimal glycosylation as well as a high yield of recombinant protein. The human
embryonic kidney cell line (293HEK) has been extensively used in transient and
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stable protein expression for a variety of proteins (Fao-Tomasi et al, 1991;
Brightwell et al. 1997). The cell line is adherent and shows a high transfection
efficiency.
3.2.2 Choice of mammalian expression vector
Several aspects have to be considered when selecting an expression vector. For the
establishment of a stable cell line the vector has to encode a selectable marker
which confers resistance to an antibiotic or other drug. Secondly, the promoter
should provide a strong 'drive' for protein expression. The vector pcDNA3.3p6
has been designed and generated in the Department of Virology, UCL (J. May,
PhD thesis, 1998) and contains the neomycin gene, enabling transfected cells to
grow in the presence of geneticin to select positive transfectants. Furthermore, the
original hCMV promoter has been replaced by the major immediate-early (MIE)
gene enhancer-promoter of human cytomegalovirus (hCMV) that contains the 5'
untranslated sequence (Intron) of the MIE gene (Accession number M21295;
Akrigg et a!. 1985). Studies have showed that the additional intron increases
expression levels in stable as well as transient transfections (Boshart eta!. 1985;
Stephens and Cockett, 1989)
However, newly synthesized proteins must also be targeted to their functional
compartment within the cell. A signal sequence located at the N terminus of the
protein translocates the pre-protein into or across the endoplasmatic reticulum and
Golgi for post translational modifications (Wilkinson et a!. 1997). Signal
sequences contain a hydrophobic core but show great variation both in overall
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length and amino acid sequence. Some signal sequences are less efficient than
others and the yield of expressed protein is decreased (Li et a!. 1994). The
replacement of the natural signal sequence by an artificial sequence has been
shown to increase the level of protein produced (Li et a!. 1994). In particular the
signal sequence from the tissue plasminogen activator (tPA) has been used
successfully (Golden et a!. 1998; Rhodes et a!. 1994). The vector, pcDNA3.3p6,
used for the expression of gH and gL encodes the tPA leader sequence (between
HindIII/BamHI restrictions sites of the polylinker) upstream of the inserted open
reading frame. The design and generation of this vector are described in detail in
the PhD thesis of J. May (1998). A plasmid map is given in Appendix II.
3.2.3 Cloning of KSHV 0RF22/gH and 0RF47/gL
Prior to amplification of the two viral open reading frames, their amino acid
sequences were analysed for the presence of a signal sequence and possible
transmembrane domains. The sequences predicted to encode gH and gL were
obtained from GenBank (Accession number: U75698). The region spanning
nucleotide 37113 to 39305 (0RF22) is predicted to encode gH, and nucleotides
69412 to 69915 (0RF47) are considered to encode the gL homolog. Following
prediction of the signal sequences oligonucleotide primers were designed and the
PCR conditions optimized. Once amplicons were obtained the DNA fragments
were cloned into the mammalian expression vector pcDNA3.3p6.
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3.2.3.1 Computer-assisted characterization of KSHV 0RF22/gH and
ORF4 7/gL
Computer analysis of the amino acid sequences corresponding to KSHV
0RF22/gH revealed characteristics of a membrane spanning glycoprotein;
including an N terminal hydrophobic signal, a transmembrane sequence, a putative
cytoplasmic tail and the presence of N-linked glycosylation sites (Schlesinger and
Schlesinger, 1987). In figure 3.1 a hydrophilicity plot of the KSI-IV 0RF22/gH
along with the predicted glycosylation sites, indicates two regions that may be
membrane transversing. If the average hydrophobicity of a region of 19 amino
acids is greater than 1.6, a high membrane spanning probability may be predicted
(Kyte and Doolittle, 1982). In fact, 0RF22/gH encodes two such regions, one at
the N terminus and one towards the carboxy terminus (Fig 3.IA, underlined). The
first 17 amino acid residues at the N-terminus could serve as a signal sequence for
co-translational translocation of the protein across the endoplasmatic reticulum.
This sequence is similar in length and composition to other known eukaryotic
signal sequences (McGeoch, 1985; von Heijne, 1986) A signal cleavage site may
be predicted after amino acid 17, using evaluations of amino acid counts in each
position of known eukaryotic signal sequences. Cleavage at this site would result
in a protein of 713 residues with a predicted molecular weight (M r) of 79kDa. The
protein sequence also contains 15 potential N-glycosylation sites (as indicated by
peaks). Furthermore, the highly conserved glycosylation site NGTV could be
identified at position 688 to 691 (sequence not shown). This motif for N-linked
glycosylation has been described for all glycoprotein 1-1 homologs.
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Analysis of 0RF47/gL, presumed to encode the homolog to the herpesviral
glycoprotein L, also showed evidence of a hydrophobic domain at the amino
terminus, suggesting that this region also encodes a signal sequence (figure 3.IB).
The cleavage site is most likely after amino acid 20, leaving a 147 amino acid
polypeptide of M1 l6kDa, containing 2 potential N-glycosylation sites. As
indicated in the hydrophilicity plot, no evidence for a membrane spanning region
could be detected, despite the theoretical signal sequence.
3.2.3.2 Choice of DNA samples
KSHV has been identified in KS, primary effusion lymphoma and multicentric
Castleman's disease. The overall variability between different viral isolates is
suggested to be low, approximately 1-1.5% (Zong et al. 1997). Glycoprotein H is
highly conserved throughout the herpesvirus family. A recent study examining
KSHV transmission between individuals from different geographic regions
confirmed that KSHV gil also shows low sequence variability, less than 0.6%
respectively (Meng et a!. 1999). Therefore, only two different isolates were
selected for initial expression studies. Total DNA was purified from BCP-1
supernatant, representing cell culture adapted virus, and from blood of a classic
KS patient. Sequences derived from BCP-1 supernatant are referred to as ORF22S
for gH and ORF47S for gL, while ORF22C and ORF47C indicate the 'classic' KS
origin.
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3.2.3.3 Ampi/Ication of KSHV 0RF22/gH and 0RF47/gL
The number of viral DNA molecules in each sample was assessed using limiting
dilution PCR (see section 2.2.2.1). For the amplification approximately IO DNA
molecules were added to a 5Ot1 PCR reaction mixture. The amplification of
KSHV 0RF22/gH was optimized by testing a range of annealing temperatures and
primer concentrations. An optimal result was achieved by changing both
parameters (see section 2.2.2.2a for a detailed description). The combination of a
54°C as annealing temperature and a higher concentration of primers resulted in
the amplification of an approximately 2IOObp DNA fragment as illustrated in
figure 3.2A. The polymerase chain reaction amplifying glycoprotein L was
performed using the reaction conditions as described for gH. The separated 480bp
DNA fragments are shown in figure 3.2B. The oligonucleotide primers used in
these reactions are described in chapter 2.
3.2.3.4 Cloning of the desiredfragments
The amplified DNA fragments, encoding KSI-IV 0RF22/gH and 0RF47/gL were
recovered from agarose gel electrophoresis and cloned into pcDNA3.3p6 using the
Clone Amp reaction originally described by Life Technologies (May J., PhD
thesis, 1998). Following transformation into E. coil SCS-1, plasmids were purified
and digested with the restriction enzymes EcoR! and XhoI. To avoid possible
PCR-derived point mutations two to three clones were selected and analysed. As
0RF22/gH exhibits restriction sites for these enzymes, positive digests resulted in
three fragments with sizes of approximately I3Obp (EcoRl/EcoRl), 690bp
(EcoRl/XhoI) and l400bp (XhoI/Xhol) respectively (figure 3.3A, lanes 5-8).
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Figure 3.2: Agarose gel (1%) analysis of the PCR amplification products. Total DNA
was extracted and 1.tl was subjected to nested PCR as detailed in the text.
(A) KSHV 0RF22 (gH); M: 1kb DNA ladder (Life Technologies); lane 1: 0RF22
from classic KS patient; lane 2: 0RF22 from BCP-1 supernatant
(B) KSHV 0RF47 (gL) M: 1kb DNA ladder (Life Technologies); lane 1: 0RF47
from classic KS patient; lane 2: 0RF47 from BCP-1 supernatant
Numbers on the left hand side of each picture indicate the molecular marker.
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Figure 3.3: (A) Agarose gel analysis (1%) of the DNA fragment pattern
after EcoRI/XhoI restriction digest. Plasmids were purified and digested
with the restriction enzymes EcoRI and XhoI. Lane 1: pcDNA3.3p6.47S.2;
lane 2: clone 8; lane 3: pcDNA3.3p6.47C.9; lane 4: clone 4;
lane 5: pcDNA3.3p6.22S.4; lane 6: clone 10; lane 7: pcDNA3.3p6.22C.16;
lane 8: clone 20; M: 1kb DNA marker (Life Technologies). (B) Schematic picture
of the HindHIIXhoI fragment encoding KSHV 0RF22/gH and 0RF47/gL that
were inserted in pcDNA3.3p6. Blue: tPA leader sequence; red: KSHV ORF,
green: protein tags. EcoRL'XhoI cut site coordinates shown in brackets.
152
However, a faint 2300bp fragment could also be detected, suggesting a possible
partial digest (EcoRI-Xhol-XhoI). In contrast, for plasmids encoding 0RF47/gL,
the enzymes EcoRJ and XhoI release the insert, resulting in a 5IObp DNA
fragment (lanes 1-4). Positive clones were named either pcDNA3.3p6.22S or
pcDNA3.3p6.47S followed by the clone number, for sequences derived from
BCP-1 supernatant or pcDNA3.3p6.22C and pcDNA3.3p6.47C for sequences
derived from an individual with classic KS. In theory these constructed plasmids
should be able to express the KSHV homolog glycoproteins with a) a N terminal
tPA leader sequence for efficient post-translational modification and b) a C
terminal protein tag to facilitate the detection of recombinant protein expression.
For detection of each glycoprotein in co-expression studies glycoprotein H
encoded six histidine residues, while glycoprotein L contained the c-myc epitope.
A schematic diagram of the HindllI/XhoI DNA fragments encoding gH and gL as
cloned into the expression vector is given in figure 3.3B. Numbers indicated the
restriction sites within the fragment; number one is defined at the HindIlI site.
3.2.4 Transient transfection experiments
Transient transfections allow a rapid analysis of recombinant protein expression.
All plasmids were initially tested in transient transfections to establish the level of
protein expression. Transfection procedures were optimized using the control
plasmid pcDNA3.1-his--Gal (see Appendix II for plasmid map), expressing the
3-galactosidase with six N terminal histidine residues. Transfection efficiency was
scored by counting the number of blue cells detected per well. HEK293 cells were
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transfected at 60-70% confluence using lipofectamine (Life Technologies). Two
days post-transfection cells were fixed in a 1:1 methanol/acetone solution and the
substrate X-Gal added. Following a one hour incubation blue cells were counted
by eye. Routinely 20-30% of the total cell population could be transfected (data
not shown).
Each plasmid construct was tested in a time course experiment to detect optimal
protein expression of 0RF22/gH and 0RF47/gL. Expression levels were assessed
by blue cell assay after 48, 72, and 96 hours post-transfection. Several control
transfections were performed to establish the activity of the reagents and
antibodies as well as non-specific binding of the monoclonal antibodies 9E10
(ICRF) and penta-His (Qiagen). As a control for transfection efficiency
pcDNA3.1-l3-gatactosidase was used; to monitor nonspecific binding, water was
transfected; to define assay conditions, a plasmid (pSEC-GBV-C E2) encoding the
histidine and c-myc tagged glycoprotein GBV-C E2 was transfected (kind gift of
Dr R. B. Ferns). It was found that the anti-histidine monoclonal antibody failed to
detect any protein in the blue cell assay procedure. However, western blot
procedures confirmed the activity of this mAb against the histidine control protein
(see below). Therefore, the initial detection was focused on cell lines expressing
proteins with the c-myc epitope, as the histidine antibody could not be optimized
for these in-situ assay procedures.
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3.2.4.1 Blue cell assay
Plasmid constructs were transfected in 12-well dishes as described in chapter 2.2.
Detection of recombinant protein was performed by using monoclonal antibodies
specific for the myc epitope (9E10). The primary antibody was tested at different
dilutions. Unfortunately, the level of expression for the plasmids encoding
glycoprotein L was nearly undetectable (data not shown). In a confluent 31 mm2
dish only ten blue colored cells could be observed, regardless which plasmid was
used and at which time point cells were fixed. In the case of control
transformation of non expressing 293 cells the number of stained cells detected
was similar, suggesting that the low number detected was due to cross reactivity of
the primary antibody. Positive controls using the GBV-C E2 plasmid confirmed
the usual transfection efficiency and the activity of the antibody in-situ. The
establishment of stable cell lines may favor the possibility of an increase in the
number of expressing cells.
3.2.5 Detection of recombinant protein in stably transfected cells
Following transient transfection experiments, successfully transfected HEK293
cells were selected in the presence of neomycin. As soon as a reasonable number
of cells was available, cells were expanded and aliquots analyzed by a variety of
methods, as well as stored in nitrogen. The names of the selected cell lines are
listed in table 3.1.
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Cell line	 transfected plasmid	 inserted sequence
KS22S or KS22C*	 pcDNA3.3p6.KS22	 0RF22/GH (glycoprotein H)
KS47S or KS47C*	 pcDNA3.3p6.KS47	 0RF47/GL (glycoprotein L)
*S: sequences derived from BCP-1 supernatant; C: sequences derived trom
clinical sample
Table 3.1. Stable cell lines containing KSHV 0RF22/gH or 0RF47/gL.
Following transient transfection HEK2 93 cells were selected as detailed in
Material and Methods. Cell lines are positive by PCR for the appropriate insert.
3.2.5.1 Verflcation of the presence of the expression plasmids within
HEK293 cells
The presence of the expression plasmids within selected HEK293 cells was
verified by polymerase chain reaction. One hundred microliters of total genomic
DNA were prepared from approximately lO cells and one microliter subjected to
a standard PCR (see section 2.2.4.7). Amplification primers were complementary
to a region within the glycoprotein coding sequence, resulting in a 778bp
screening fragment for KSHV glycoprotein H and 320bp for glycoprotein L.
Agarose gel analysis of the PCR products revealed the presence of the appropriate
plasmids, encoding the KSI-IV glycoproteins, within the respective cell lines (see
figure 3.4).
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Figure 3.4: Polymerase chain reaction of selected I-1EK293 stable cell lines. Iota
DNA was isolated and one microliter was amplified by PCR as detailed in the text
Ten microliters were analysed on a 1% agarose gel.
(A) Analyses of cell lines expressing 0RF22/gH. Lane 1: 293KS22S.2; lane 2
293KS22C.3; lane 3: negative control
(B)Analyses of cell lines expressing 0RF47/gL. Lane 1: 293KS47S.2; lane 2
293KS47C.5; lane 3: 293KS47C.2; lane 4: pcDNA3.3p6.KS47S plasmid a
positive control.
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3.2.5.2 Screening ofprotein expressing cell lines by blue cell assay (BCA)
and indirect immunofluorescence
As mentioned above, the monoclonal antibody penta-his failed to detect histidine
tagged proteins in blue cell assay procedures. Furthermore, screening for
0RF22/gH-his by indirect immunofluorescence was unsuccessful as the antibody
could not detect protein in this assay either. A duplicate transfection, was
performed using the control plasmid pcDNA3.l-his-3-.gaIactosidase (Invitrogen).
The expressed 3-galactosidase contains six amino terminal histidine residues and
can be detected either in a color reaction using the substrate X-Gal or by using the
monoclonal antibody penta-His. Following transfection one well was stained as
detailed before and the second well reacted against the antibody. Although the
usual transfection efficiency of around 30% was seen in the first well the indirect
immunofluorescence failed to detect any recombinant protein, only nonspecific
binding being observed. Consequently, testing for the presence of the 0RF22/gH
gene product had to be based on enzyme linked immunoabsorbent assay (see
3.1.4.3) or western blot. Similarly, detection of 0RF47/gL-c-myc by
immunofluorescence was unsuccessful. Blue cell assay studies were performed to
test the stable cell lines K547S or KS47C. Selected F1EK293 cells containing the
KSHV 0RF47/gL were seeded at a density of io cells per well (48 well dish) and
grown until they reached 70-80% confluence. Following fixation and
permeabilization of the selected cells, monoclonal antibodies specific to the c-myc
protein tag failed to detect any protein in the tested cell lines; thus blue coloured
cells could not be observed. Positive controls confirmed in-situ reactivity of this
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antibody. Background staining could not be detected in non transfected 293 cells
(data not shown).
Indirect immunofluorescence studies were also performed on the same gL-
transfected stable cell lines and showed no specific staining, confirming the
previous results obtained from blue cell assays.
3.2.5.3 Detection of the 0RF22/gH gene product using a lectin based EJA
Herpesviral glycoprotein H homologs have all been identified in the cytoplasm
when expressed in a variety of systems (Duus and Grose, 1996; Pulford et al.
1995; Cranage eta!. 1988; Gompels and Minson, 1989). Therefore this detection
system was optimized for the analysis of cell lysate rather than cell supernatant.
However, initial experiments testing cell culture supernatant were negative for
protein expression (data not shown). Different formats of indirect enzyme linked
immunsorbent assays were used. Cellular lysate or supernatant was captured onto
a solid phase either directly by association with lectin, or via the C terminal
protein tag (figure 3.5). According to computer analysis, the protein product of
KSHV 0RF22/gH contains 15 glycosylation sites. This offers the opportunity to
capture the glycoprotein via lectin onto a solid phase. Lectins are able to bind
specifically to carbohydrate structures in glycoproteins. This property makes them
a useful tool in the characterisation of glycosylation patterns. The lectin used in
the following EJA derives from Ga!anthus nivalis and exhibits specificity for
terminal mannose residues. Coated on a solid phase it captures the recombinant
glycoprotein, presenting it for further detection by anti-sera.
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HRP conjugated Antibody
Detector/Primary Antibody
Antigen
Lectin
Figure 3.5: Schematic picture of the EIA performed in recombinant protein
detection. Antigen represents the HEK293 lysate or supernatant as well as water.
Detector or primary antibody is either serum or monoclonal antibody.
Antigens captured via lectin were detected with serum derived from KSHV
patients as well as with the anti-histidine monoclonal antibodies. Prior to use in
ELISA serum was tested in an indirect immunofluorescence assay using KSHV
infected BCP-1 cells. The typical nuclear stippling pattern could be observed,
indicating the presence of antibodies against the viral latent nuclear antigen
LANA-i (see figure 3.6, kindly provided by U. Ayliffe). Monoclonal antibodies
were tested in western blots (see below).
3.2.5.3a Serum detection
Stable cell lines were grown until they reached 80-90% confluence, approximately
106 cells were harvested in lOOp.l lysis buffer A (see Appendix I). To determine
non-specific binding of antibodies, non-transfected 293 cells were treated in the
same way. Serum obtained from virus-infected patients showed high background
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Figure 3.6: Indirect immunofluorescence of BCP-1 cells using
serum from KS positive patients. The picture shows the typical
stippling pattern, characteristic for antibodies against the viral
nuclear antigen (LANA). The picture was kindly provided by
U. Ayliffe.
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levels when reacted against the negative control cdl lysate. Previous experiments
revealed that this non-specific binding of the sera could be reduced by the
presence of 293 cell lysate during antibody-lysate binding (data not shown).
Therefore the primary antibody mixtures were pre-incubated for 10 mm with a
293 cellular lysate.
In the indirect EIA using lectin on the solid phase the optical density was
compared to serum dilutions, as shown in figure 3.7A and B. Despite the addition
of 293 cell lysate to the anti-sera during incubation, KSHV serum showed cross
reactivity with non-transfected 293 cell lysate (negative control) as illustrated by
black squares. Furthermore, an elevated optical density was observed when water
was used as antigen (black triangles).
In summary 293 cells containing the expression plasmid (diamond shape) showed
an increase in optical density (OD) compared to non-transfected 293 cell lysate,
also a serum dilution dependence could be noticed. A two fold dilution series of
the patient serum showed a proportional increase between the optical density and
the serum dilution. However, the observed difference in optical density between
transfected cells and non-transfected cells (293 cell lysate) was small, less than
two fold. The difference between negative control and supposedly expressing cell
lines was even less when analysing 293KS22C cells, as illustrated in picture 3.7B.
The optical density values were almost identical.
Supernatant from transfected cells was tested as described above and similar
results obtained (data not shown). None of the cell supernatants showed any
expression of recombinant glycoprotein, indeed the OD values obtained by serum
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detection were lower than the negative controls. This is unsurprising as herpesviral
glycoprotein H has been described as a cytoplasmic protein in recombinant protein
expression studies.
Figure 3.7: Detection of recombinant KSI-IV glycoprotein H in HEK293 cells
using an indirect EIA. Cellular lysate was captured via lectin onto a 96 well plate.
Antigen was detected by serum from KSHV infected patients (A,B) and using a
monoclonal antibody specific for five histidine residues (C). A: 293 cell line
transfected with pcDNA3.3p6.KS22S; B: 293 cell line transfected with
pcDNA3.3p6KS22C. C: Lysate from different stable cell lines was collected at
different time points. Numbers along the Y-axis indicate the optical density at
450nm.
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3.2.5.3b Protein tag detection
When using an EIA based on monoclonal antibodies specific for the encoded six
histidine residues a similar result was observed. Figure 3.7C shows OD values
plotted against samples, prepared at different stages during the selection process.
Cell lysate was captured via lectin onto a solid phase and tested for the presence of
histidine tagged protein. Non-specific binding could be reduced when incubated in
the presence of non transfected 293 lysate, but the detection of recombinant
protein was inconsistent, as indicated by the red and blue bars. Both elevated and
low levels of signal could be detected when analysing the gH stable cell line.
However, compared to non-transfected cells (white bars) OD values were lower,
suggesting that no recombinant gH has been produced by the selected cells.
Similar results were obtained for HEK293 cell lines transfected with plasmids
containing KSHV 0RF47/gL (data not shown). In conclusion, neither serum nor
monoclonal antibody were able to detect recombinant protein.
3.2.5.4 Western Blot
To eliminate the possibility that the complex tertiary structure of the recombinant
proteins occlude the protein tags and prevent binding of the antibodies, western
blots of cell lysate and supernatant were performed. Initially monoclonal
antibodies were tested for reactivity and western blot procedures for each antibody
optimized. HEK293 cells were transiently transfected with the control plasmid
pcDNA3.l-his-3-galactosidase (see Appendix II for plasmid map). After 48h cells
were harvested, lysed in laemmli buffer and 2x10 5 cells per well separated on a
12% SDS polyacrylamide gel. Proteins were transferred onto PVDF membrane
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and reacted with monoclonal antibodies followed by a species-specific HRP-
conjugated antisera. Proteins were detected using the ECL Plus kit (Amersham).
To test the mAb 9E10, stable cell lines expressing the c-myc tagged GBV-C E2
glycoprotein were collected and lysed using Laemmli buffer.
At a 1 in 2000 dilution the anti-His antibody showed low nonspecific staining, but
good staining of the l22kDa His tagged control protein. Similarly, the monoclonal
antibody 9E10 reacted specifically with low background at a 1 in 700 dilution
with the GBV-C E2 glycoprotein, constitutively expressed in HEK293. Figure 3.8
illustrates the 122kDA (lane 1) and the 4OkDa (lane 2) protein bands, representing
His-n-gal and the GBV-C glycoproteins respectively.
However, several attempts to demonstrate recombinant expression of KSHV
glycoprotein H and glycoprotein L in immuncthlots failed. Although reactivity of
the primary antibodies was repeatedly demonstrated for the positive controls, the
desired protein band could not be observed.
3.3 Sequencing of promoter region and insert
Recombinant expression of both viral glycoproteins could not be detected with
any assay performed, indicating either extremely low levels of protein or
mutations within the DNA sequences. Furthermore, colleagues reported similar
problems in expression studies when using vector pcDNA3.3p6. This may
indicate a general problem of the expression vector itself, rather than mutations
leading to frame shift or stop codons within the coding region.
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l22kDa -
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Figure 3.8: Testing of antibody activity. 293HEK cells were harvested and
cell lysates prepared. Samples were separated on 12% SDS-polyaciylamide
gel and analysed by Western blot using the penta-histidine antibody (Qiagen)
and the 9E10 antibody (anti-c-myc). (A) 293 cells transiently transfected
with pcDNA3.l-his--ga1; probed with the penta-his monoclonal antibody.
(B) 293 stable cell line expressing the c-myc tagged GBV-C E2 glycoprotein;
probed with the c-myc monoclonal antibody 9E10.
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Several pcDNA3.3p6 constructs were sequenced using a primer for the promoter
region (pCMV) and an anti sense primer (p3rev) specific of vector sequences
downstream of the insert. Primer sequences are listed in chapter 2.2. All sequences
obtained were aligned and analysed for possible mutations.
3.3.1 Promoter region
The promoter regions of each clone sequenced were identical with the sequence
obtained from GenBank for the hCMV MIE enhancer-promoter as well as for the
5'untranslated intron (Accession number M21295) (data not shown). Therefore
the low level or lack of expression was not due to mutations within the promoter
region.
3.3.1.1 tPA leader sequence and glycoprotein coding region
DNA fragments encoding KSI-IV gH and gL were subcloned into the expression
vector pcDNA3. Plasmids were digested with 1-lindIll and NotI restriction
enzymes after confirming that no existing restriction sites occurred within the
coding sequences. Following bi-directional sequencing using pCMV and p3rev
sequences were aligned and compared to GenBank sequences. Unexpectedly,
several minor and major mis-matches could be detected which were responsible
for the lack of expression. Figure 3.9A illustrates schematically the HindIIl/XhoI
fragments found in pcDNA3.3p6 constructs. In addition the corresponding DNA
and amino acid sequences identified are shown, including position I (Hindu! site)
to 250 (figure 3.9B). Results are identical for both KSHV open reading frames. To
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XhoI (993)
(A)
EcoRI
(184,306)
0RF22
Hindu (2)
gpl2O
EcoRl (184)
0RF47
(B)
Hindu C
/
6xllis
XhoI (2370)
c-myc
i)4)
L
Hindill
1 AAGCTTCCTA TTCCCACTGC TCATTTTTTC TCTCTGCACC ACTCTTCTCT
TTCGAAGGAT AAGGGTGACG AGTAAI\AAAG AGAGACGTGG TGAGAAGAGA
+1 CL G G C Y S	 * W F N F Y SF1
51 TTGCCTTGGT GGGTGCTACT CCTAATGGTT CAATTTTTAC TCCTTTATAT
AACGGAACCA CCCACGATGA GGATTACCAA GTTAAAAATG AGGkAATATA
+1F I * F TSP	 IV P H	 I S S	 SR S
101 TTATATAATT CACTTCTCCA ATTGTCCCTC ATATCTCCTC CTCCAGGTCT
AATATATTAA GTGAAGAGGT TAACAGGGAG TATAGAGGAG GAGGTCCAGA
+1 ED P L VT A A S V L N SN * H S
(G) EcoRI
(C)
151 GAAGATCCAC TAGTAACGGC CGCCAGTGTG CTGAATTCCA ATTGAGGTC
CTTCTAGGTG ATCATTGCCG GCGGTCACAC GACTTAAGGT TAACTTCCAG
+1	 F
	
201 GTI	 -F22 (nt 37182 to 39300)
CA	 F47 (nt 69433 to 69855)
Figure 3.9: Schematic picture of the Hindllh/XhoI fragment identified
in the pcDNA3.3p6 constructs (A) and the corresponding nucleotide sequences
between the HindU! site and the first nucleotide sencoding the respective KSHV
open reading frame (B). Blue patterned arrows/letters indicate the 3' end of 1-IIV-1
gpl2O; red arrows/letters symbolise the KSHV coding region; green blocks show
the protein tags;letters in brackets highlight the deletion. Stars represent stop codons.
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highlight the difference between the sequences found and the sequences expected,
a schematic picture and the respective DNA sequences encoding a tPA leader
sequence linked to the KSHV open reading frames are shown in figure 3.10.
3.3.1. la Leader sequence of the tissue plasminogen activator
The tPA leader sequence was supposed to be in frame with the coding sequence of
the respective KSHV reading frame. However, a major mis-match has been
identified upstream of the glycoprotein coding region; between the Hindu! site
and the first nucleotide of the glycoprotein coding region (figure 3.9b, black
letters). Sequence alignments with the original tPA leader sequence revealed that
no tPA leader sequence was present. The polylinker of the vector as well as the
KSHV open reading frame could be identified but the region between the Hindill
restriction site and the first nucleotide corresponding to the viral sequence were
unknown. Furthermore, within this region no start codon in frame with the insert
could be detected. BLAST searches showed that the 155bp unknown region is
identical with the 3 'end of HIV- I gp I 20 HxB2, nucleotide 7776 to 7621 respectively
(GenBank accession number M38432). This indicates that the constructs contain
sequences of KSHV glycoproteins linked to the C terminus of gpl2O, instead of
the tPA leader sequence. Although EcoRI/Xhol digests had been performed this
mistake has not been detected initially. Schematic pictures in figure 3.9A and
3.1OA demonstrates the HindIII/XhoI fragment with the gp-120 region and with
the tPA leader sequence. Regarding EcoRI and XhoI restriction sites, there is no
major difference between the two sequences, indicating that a simple digest would
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AGCTTCTGA GCACAGGGCT GGAGAGAAAA CCTCTGCGAG GAAAGGGAAG
TTCGAAGACT CGTGTCCCGA CCTCTCTTTT GGAGACGCTC CTTTCCCTTC
+2	 M DAM
51 GAGCAAGCCG TGAPLTTTAAG GGACGCTGTG AAGCAATT GGATGCAATG
CTCGTTCGGC ACTTAAATTC CCTGCGACAC TTCGTTAGA CCTACGTTAC
+2 KR G L CCV L L L C GAV F VS
101 AAGAGAGGGC TCTGCTGTGT GCTGCTGCTG TGTGGAGCAG TCTTCGTTTC
TTCTCTCCCG AGACGACACA CGACGACGAC ACACCTCGTC AGAPkGCAAAG
+2 p SQ El H A R FR R GA R ST
151 GCCCAGCCAG GAPATCCATG CCCGATTCAG AAGAGGAGCC AGATACTA
CGGGTCGGTC CTTTAGGTAC GGGCTAAGTC TTCTCCTCGG TCTAGGTGAT
+2S N G R Q CA G I P I E G R L T C
EcoRI
201 GTAACGGCCG CCAGTGTGCT AATTCCAA TTGAAGGTCG TTT1: ; . ::::
CATTGCCGGC GGTCACACGA CCTTAAGGTT AACTTCCAGC AAACTGTACA
Figure 3.10: Schematic picture of the HindllhIXhoI fragments, assuming a tPA
leasder sequence linked to the KSHV open reading frame (A). Corresponding
nucleotide sequences spanning the Hinifi site and the first nucleotide encoding
the respective KSI-IV open reading frame are shown in (B). Blue arrows/letters
indicate the tPA leader sequence; red arrows/letters symbolise the KSHV coding
region; green blocks show the protein tags.
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hardly have shown a different fragment pattern. The 'gp-120' sequence exhibits
no additional EcoRt or XhoI restriction site. A plasmid containing gpl2O-gH
would also result in a linearised form of the vector, a l2Obp, a 690bp and a
1380bp DNA fragment. A digest using gpl2O-gL plasmid constructs would also
only release the glycoprotein coding region. Looking at the corresponding DNA
sequences and amino acid sequences spanning this particular region (figure 3.9B)
an interesting observation can be made. A putative initiation ATG motif cannot be
detected upstream of the coding region of the KSHV glycoproteins. Thus it is
impossible to produce recombinant KSHV glycoprotein H or glycoprotein L by
using these particular plasmid constructs. These findings indicate that restriction
digest and ligation procedures leading to the genesis of vector pcDNA3.3p6 have
not been performed correctly, as were the further experiments to evaluate the
activity of this plasmid. In summary, the recombinant expression of gH and gL
using this particular vector is impossible. The engineered C terminal protein tags
will be transcribed either out of frame or early termination of transcription will
occur. Besides the non-existent tPA leader sequence a further single base deletion
of guanine in position 221 or 222 (see figure 3.1OB) was identified; indicated by
the letters in brackets in figure 3.9B (numbering with reference to the Hindu!
restriction site in position 1). Assuming the tPA leader sequence, this mutation
would have caused a frame shift or early termination of protein translation due to a
stop codon. This deletion alone would have made it impossible to detect the
engineered C terminal protein tags. Interestingly, the deletion is next to the EcoRI
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site that was involved in the clone Amp cloning strategy using uracilated
extension at the vector.
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3.4. Summary and Discussion
The herpesviral glycoprotein H can be found in any known herpesvirus, usually in
association with a second viral glycoprotein, gL. Studies have revealed that gH
plays an important role in viral penetration into the host cell as well as functions in
cell to cell fusion (Browne et a!. 1996; Wilson et a!. 1994; Anderson and
Gompels, 1999). Recently a new gamma herpesvirus, KSHV, has been identified
and implicated to be important in KS pathogenesis. Protein homology searches of
KSHV encoded proteins have identified 0RF22 and 0RF47 as gH and gL
counterparts. Open reading frame 22 exhibits features of a transmembrane protein
including a hydrophobic sequence at the N terminus, that may serve as a signal
sequence and a hydrophobic stretch near the C terminus that may indicate a
membrane spanning domain. Furthermore the glycosylation site NGTV, close to
the hydrophobic domain is also present in KSHV ORF22/gH at residues 688 to
691. This motif is highly conserved within the family of herpesviridae (McGeoch
et a!. 1995). Although this site for N-linked glycosylation is well conserved, its
function is unclear. Nevertheless, the NGTV motif within 0RF22/gl-1 supports its
classification as a gH homolog. KSHV 0RF47 also encodes a potential N terminal
signal sequence, but lacks a hydrophobic region that could function as a
transmembrane domain. To characterize these two viral glycoproteins in detail we
were interested in the establishment of stable mammalian cell lines. Since the
authentic production of glycoproteins is dependent on post-translational
modification the use of a mammalian expression system appeared to be
advantageous. As described before the expression of HIV glycoprotein gpl2O
have shown that the replacement of the natural N-terminal signal sequence by the
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tissue plasminogen activator (tPA) signal peptide can result in an increase of
glycoprotein production. Consequently DNA sequences encoding KSHV
0RF22/gH and 0RF47/gL were cloned in frame with a tPA leader sequence of the
vector pcDNA3.3p6. Transient transfection experiments and the establishment of
a cell line constitutively expressing the glycoproteins proved to be unexpectedly
difficult. Despite relatively high transfection levels, as judged by a 13-gal control
plasmid and the successful selection of PCR positive cell lines, several
immunological methods failed to detect recombinant protein. Indirect ELA
procedures gave evidence of a low amount of protein, although those results were
inconsistent. Explanations of a low expression could have been due to several
problems: firstly, toxicity of the recombinant protein causing cell death. Cells are
forced to switch off glycoprotein synthesis for their own survival. Secondly the
vector design may not be suitable for the expression of these particular
glycoproteins; thirdly, the engineered C-terminal modifications are expressed out
of frame or degraded soon after production and therefore detection using
monoclonal antibodies specific for those tags is impossible. Finally, gH and gL
might elucidate a low immune response resulting in a low titer of specific
antibodies when human serum is used. The vector pcDNA3.3p6 has been used in
other expression studies and was reported to produce reasonable amounts of
protein that can be detected by EtA and western blot. It was also unlikely that the
lack of expression was due to mutations or frame shift events as different products
were amplified from different sources. We therefore believed that the two
glycoproteins may only be produced in low amounts and sensitive methods are
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necessary to demonstrate expression. However, since EIA procedures were also
unsuccessful, we were suspicious that during vector generation, the promoter
sequence may have been altered. We decided to sequence part of the vector,
including the promoter region together with the insert. Although colleagues
repeatedly assured that this vector produces recombinant protein we made an
unexpected discovery. The tPA leader sequence could not be detected, instead
sequences encoding the 3' end of HIV-1 gpI2O were identified, missing a start
codon in frame with the KSHV fragments. This major error is most likely to have
occurred during generation of the vector. Briefly, the vector pcDNA3.3p6 is based
on other mammalian expression vectors, namely P2 and pEE6.neo. For a
description of these vectors see chapter 2.1. and the plasmid maps in Appendix II.
The promoter in pcDNA3.3p6 is derived from pEE6.neo as a BgllI/HindIII
fragment inserted into the polylinker of the pcDNA3 vector. The tPA leader
sequence was obtained from the P2 plasmid that encodes tPA-HIV-1 gpl2O. To
obtain the tPA leader sequence the vector P2 had to be digested with Hindu! and
BglII, producing several fragments of similar size, including the tPA leader
sequence and a 3'gpI2O fragment. The pcDNA3 vector containing the pEE6
promoter was then linearised using Hiridlil and BamHl. A simple ligation reaction
containing the linear form of the vector and the BglII/HindIII insert were
subsequently performed. However, these ligation reactions must have been
performed using the gp 120 fragment as insert instead of the tPA leader sequence,
thereby producing a vector with similar size to the expected one with the same
polylinker. Simple agarose gel analysis would not have identified this mistake. A
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proper restriction analysis using an enzyme, e.g. Bsp12861 that allows
discrimination between the gpl2O fragment and the tPA leader sequence (a
Bsp 12861 site is only present in the tPA leader sequence) would have identified
the mistake. Furthermore, sequencing the insert would have been useful. However,
apart from this major mis-match another mutation has been identified. This single
base deletion immediately preceding the EcoRI site would also cause early
termination of protein translation, whether or not the tPA leader sequence was
present. Regarding the location of this deletion the cloning procedure, in particular
the use of the uracilated tails, may not have been optimized and resulted in point
mutations due to the enzymes activity. In summary, the vector pcDNA3.3p6 is
defective and cannot be used for any expression studies. However, the detection
procedures developed in this chapter can be applied to further expression studies
in order to assess protein expression using a different vector. To this end, the
appropriate DNA sequences were re-amplified in full-length from different
clinical material and inserted into a commercially available mammalian
expression vector.
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4. Recombinant expression of KSHV glycoprotein H and
glycoprotein L in two different cell lines
4.1 Introduction
Expression of the KSHV 0RF22/gH and 0RF47/gL was unsuccessful using the
expression vector pcDNA3.3p6. The series of experiments described in chapter 3
demonstrated that the lack of expression was due to the vector itself rather than the
viral sequences amplified. However, it is still of interest to determine if KSHV gL
interacts as a chaperone for gil folding and mediates cell surface expression of
gH, as described for other herpesviruses (see proceeding chapter). To test this
hypothesis we were interested in the intracellular distribution of gL under two
circumstances: (a) when individually expressed and (b) in combination with
plasmids encoding the KSHV gH homolog. Glycoprotein L has been
demonstrated to be similarly dependent on gH for its cell surface localization.
When expressed alone, the protein is either secreted into the culture medium
(HSV-1, HCMV) or retained within the cytoplasm (EBV, VZV) (Westra et a!.
1997; Kaye et a!. 1992; Pulford et a!. 1995; Duus and Grose, 1996). To study the
characteristics of the KSHV gH and gL counterparts, viral open reading frames
from several patient samples were amplified and cloned into the appropriate
restriction sites within the polylinker of the commercially available vector
pcDNA3.1 (Invitrogen). Two different cell lines, the epithelial cell line HEK293
and the fibroblast cell line Cos7, were transfected with these plasmid constructs
and analysed for protein expression. Briefly, protein expression was analysed with
different procedures, varying in detection sensitivity. Overall, expression levels
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were low in both cell lines and this complicated further analysis of the cellular
localization of each glycoprotein.
However, we have obtained clear evidence that the surface location of 0RF47/gL
is dependent on the presence of the 0RF22/gH gene product.
4.2 The vector pcDNA3.1 and the choice of mammalian cell lines
The vector pcDNA3.Izeo is commonly used for the expression of recombinant
proteins in mammalian cells. A detailed vector description is given in chapter 2.1
and a schematic plasmid map is included in Appendix II. An hCMV immediately
early promoter drives high-levels of expression and the zeocin resistance gene
enables selection for stable cell lines in mammalian cells.
As described in chapter 3, the authentic expression of glycoproteins is dependent
on the competence of the cell line to perform post translational modification.
Based on extensive experiments with HIV gpl2O, one cell line of choice is the
human embryonic kidney cell line l-1EK293. Also to be considered is the possible
low amount of protein synthesized. This problem may be overcome by using the
African green monkey cell line Cos7 in combination with pcDNA3.l constructs
(see chapter 2.1). This cell line encodes the SV4O large T antigen, allowing
vectors encoding the SV4O origin of replication to replicate as an episome to a
high copy number within cells (Chittenden et a!. 1991). This may increase the
amount of protein produced per cell and be an advantage for ORFs with low
expression levels (Harvey et a!. 1997).
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4.3 Selection of patient samples
Several patients who had been diagnosed with a KSHV associated disease,
including classical KS, HI V-associated KS and primary effusion lymphoma, were
selected. A non-patient material, tissue culture supematant from KSHV positive
BCP-1 cells, was included in the study as a control and will be designated as
sample number three. Five patients were selected and total DNA extracted from
blood samples using the Qiagen Blood Kit. Two samples failed to amplify,
possibly due to DNA degradation while stored. The remaining three samples were
included in the study and both gH and gL open reading frames cloned into the
mammalian expression vector. Briefly, patient 4 is a 14-year old girl, infected with
HIV who showed subcutaneous nodular KS lesions. This patient was the subject
of a study investigating the anti-KS activity of the drug thalidomide (Soler et a!.
1996). However, the DNA sample used for our expression studies was obtained
before this treatment started.
Patient number 5 is a 40-year old male with late stage AIDS and primary effusion
lymphoma. The cell line SY, used for KSHV infection studies described in chapter
6, is derived from ascetic fluid of this patient. Finally, patient number 7 is an
elderly patient with history of classic KS.
4.4 Cloning of full-length KSHV 0RF22/gH and 0RF47/gL
4.4.1 Amplification of the respective sequences by nested PCR
Oligonucleotide primers for nested PCR were designed to amplify the complete
sequences of KSHV 0RF22/gH and 0RF47/gL (see section 2.2.2.1). To achieve
optimal protein expression levels several nucleotide motifs were included in each
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primer. For cloning purposes the restriction sites Hind!!! and Not! were introduced
into the sense and anti sense inner primer respectively, after verifying that no
possible sites for these enzymes occurred within the coding sequences.
Throughout higher eukaryotes the 5' non-coding sequence, CCACCATGG has
been described to play an important role in the recognition of ribosomes (Kozak,
1987; Kozak, 1984). Most crucial is the purine, at position -3 (mostly an A,
though 0 may occur), the G residue immediately following the AUG codon also
influences expression. The 5' non-translated Kozak sequence motif, CCACC, was
introduced immediately upstream of the AUG codon of the respective open
reading frames. Given these changes in the primer sequences the nested
amplification of full length KSHV 0RF22/gFI and 0RF47/gL required a new set
of optimizations of PCR conditions (data not shown). An optimal amplification
result could be achieved by applying the PCR conditions detailed before for
truncated forms of the respective viral ORF (see section 3.1.2.3).
4.4.1.1 Full length 0RF22/gH
The amplification of full length 0RF22/gH produced a 2,230kb fragment. To
avoid possible polymerase induced errors, the enzyme ExpandTM (Boehringer
Mannheim) was used, exhibiting proof reading abilities. One microliter of the
sample were added to a 50tl PCR reaction mixture and reactions carried out under
a variety of amplification conditions, mainly differing in oligonucleotide
concentration (200 and 4OO.tM) and annealing temperature, ranging from 44°C to
56°C. Four samples (patient 3, 4, 5, 7) out of six could be detected using the
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conditions detailed in section 2.2.2.2 (54°C, 2OOtM), but the remaining two failed
to produce the desired fragments under any of the conditions tested. Amplified
ORFs of each patient are demonstrated in figure 4.1, lanes Ito 4.
4.4.1.2 Full-length 0RF47/gL
The 0RF47/gL is smaller in size (600bp) than 0RF22/gH and therefore the
conditions described for the amplification of 0RF47/gL in section 3.1.2.3 were
successfully applied. Each patient sample was amplified and synthesized
amplicons are shown in figure 4.1 lanes 5 to 7. As observed for 0RF22/gH patient
one and two again failed to ampli1', suggesting possible degradation of the
template DNA within these samples.
4.4.2 Cloning and verification of the glycoprotein coding sequences
The amplified DNA fragments were agarose gel purified and digested with the
enzymes Hindill and NotI. The vector pcDNA3.I was linearised using the same
enzymes and dephosphorylated using shrimp alkaline phosphatase (SAP).
Following ligation and transformation bacterial colonies were analysed by PCR
and positive transformants selected for over-night culture. From each patient five
clones were chosen and plasmids purified. To verify the respective inserts each
plasmid was digested with Hindlil and NotI, and then sequenced with the
oligonucleotide primers pCMV and p3rev. As expected, restriction enzymes
released the insert leaving the vector in linearised form (data not shown). Three
plasmids showing the right fragment pattern were selected and further sequenced
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Figure 4.1: PCR amplification of KSIIV 0RF22 and 0RF47. Total DNA has been
extracted from different patient samples and one microliter was applied to PCR.
Amplicons were separated on a 1% agarose gel.
M: 1kb DNA ladder (Life Technologies)
Lane 1: 0RF22 from BCP- 1 supematant, designated as sample number 3
Lane 2: 0RF22 from patient 4
Lane 3: 0RF22 from patient 5
Lane 4: 0RF22 from patient 7
Lane 5: 0RF47 from BCP-1 supernatant, designated as sample number 3
Lane 7: 0RF47 from patient 4
Lane 8: 0RF47 from patient 5
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to confirm the presence of the Kozak sequence and the start codon in frame with
the glycoprotein coding sequence as well as the C terminal protein tag. All
0RF47/gL constructs were sequenced in full, whereas for 0RF22/gH only 350bp
at the 5' and 3' end were analysed.
In summary, coding sequences were all in frame with the Kozak sequence and the
ATG start codon. Sequences encoding 0RF47/gL were in frame with the c-myc
epitope and no differences from the published KSHV sequences were observed.
Plasmid constructs containing 0RF22/gH were in frame with the Kozak sequences
and the initiation motif ATG. At the 3' end the nucleotide motif for the histidine
residues (0RF22/gH) could be detected, together with the stop codon. The
schematic picture in figure 4.2 illustrates the inserted glycoprotein coding
sequences within pcDNA3.l.
Plasm ids were named with respect to the inserted sequences (gH or gL), the
patient number and the number of the clone selected. For example, 0RF22/gH
derived from patient number 4 was labeled pcDNA3.lgI-14.6; number six, being
the clone selected.
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Figure 4.2: Schematic diagram of KSHV 0RF22/gH and ORF47IgL inserted into
the Hindlil/Noti polylinker of pcDNA3.1. Sequence motif (blue color) indicates
the Kozak sequence; red arrow: glycoprotein coding sequence; green: protein tag.
The arrows in the upper figure indicate the ends of the regions of 0RF22/gH
sequenced, (0RF47/gL was sequenced in full). Numbers below the arrows refer to
nucleotide position.
4.5 Recombinant expression of KSHV 0RF22/gH and 0RF47/gL
Recombinant expression studies using full-length constructs of KSHV 0RF22/gH
and 0RF47/gL, can be subdivided into three parts. Firstly, transient transfection
experiments tested the level of expression of each plasmid; secondly, larger scale
transient transfections using larger amounts of cells were analysed by western blot
to estimate the molecular mass of the protein. Finally, stable cell lines were
established that produced constitutively the protein of interest, allowing a more
precise in vitro analysis. In this case transient as well as stable expression levels
were low, requiring sensitive detection methods, including indirect
immunofluorescence assay (IFA) and flow cytometry. Furthermore, the influence
of sodium butyrate on the expression level of transfected cell lines was examined.
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Throughout these experiments 0RF22/gl-1 could only be demonstrated using
certain detection procedures, including western blot and flow cytometry. This was
ascribed to inconsistent results produced by the monoclonal antibody "penta-his",
even when using the control protein his-3-galactosidase (see chapter 3.1, section 3
and 4.2). The data obtained will be discussed in more detail below.
4.5.1 The 293HEK cell line
As described in chapter 3, transient transfections allow a high level of expression
within a short time period, making this procedure ideal for initial expression
experiments. 0RF47/gL plasmids were tested for their level of expression in "blue
cell assays" (described in chapter 3), once expression was demonstrated the
plasmid was used for further experiments. Detection of the 0RF22/gH gene
product was only visible by western blot procedures. Using the control plasmid
pSEC-GBV-C E2 (see Appendix H for plasmid map) in duplicate transfections,
staining with the monoclonal antibody 9E10 for the c-myc epitope indicated high
levels of transfection and expression, whereas using the penta-his monoclonal
antibody in IFA no specific fluorescence could be observed (data not shown). A
similar result was obtained when detecting expression of the control protein his-j3-
galactosidase by flow cytometry (see below). As a consequence the detection of
0RF22/gH was limited to western blot methods and hence the distribution of
recombinant KSHV gH within the cell could not be directly established using this
particular antibody. However, as discussed later in this chapter, 0RF22/gH can be
identified indirectly when co expressed with 0RF47/gL, assuming an interaction
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between those two glycoproteins. This situation also applied to the expression
studies using COS7 cells discussed later in this chapter.
4.5.1.1 Optimization of transient transfections using a reporter plasmid
A new transfection reagent was available, Effectene (Qiagen), that was claimed to
result in very high transfection efficiencies. Effectene is a non-liposomal lipid
reagent that transfers DNA into mammalian cells in combination with a special
DNA-condensing reagent, named 'enhancer'. Optimal transfection is influenced
by several parameters, including the DNA-effectene ratio, the DNA- enhancer
ratio, the type of cell line used and the plasmid construct that is to be transfected.
Initially, cells were transfected with the control plasmid pcDNA3.l-his-3-GaI as
the detection of the 3-galactosidase is simple and less time consuming, but would
give a rapid answer about the response of HEK293 cells to the transfection
procedure.
HEK293 cells were transfected in 60 mm dishes according to the 'pipetting
scheme' given by the manufacturer. Different amounts of DNA (0.5tg, I g and
2tg) were transfected and the enhancer and effectene adjusted with respect to
these DNA concentrations. Exact DNA-Effectene ratios are given in the legend of
figure 4.3. Following 48h of incubation, cells were harvested for western blot as
described in chapter 3 using Laemmli buffer followed by sonication. A small cell
patch was left in the dish to stain for -galactosidase expression using X-gal.
Lysates were separated on a 7% SDS-PAGE, approximately 2x10 5 cells being
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Figure 4.3: Optimization of transient transfection using effectene as
a transfection reagent. The control plasmid pcDNA3. 1-his--galactosidase
was transfected into F1EK293 cells under various conditions. After two
days incubation cells were harvested, lysed in Laemmli buffer and analysed by
(7%) SDS-PAGE. PVDF membranes were probed with the Mab penta-bis
and a goat-anti-mouse-secondaiy HRP-conjugated antibody.
M: Molecular weight marker, Rainbow marker (Amersham)
Lane 1: O.5p.g DNA; 4p.l enhancer; 12.5il effectene (1/25 DNA-effectene ratio)
Lane 2: lp.g DNA, 8jti enhancer; 25j.tl effectene (1/25 DNA-effectene ratio)
Lane 3: 2pg DNA, 16tl enhancer; 5OpJ effectene (1/25 DNA-effectene ratio)
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loaded per well. Proteins were transferred to PVDF membrane and stained for the
presence of the histidine tagged protein.
Following transfection, proportional association between the effectene
concentration and cell death could be observed; the more effectene, the more the
cells died or their growth was inhibited. An optimal transfection has to
compromise between this cell death and yields of protein. To reduce cell death,
growth medium was replaced by fresh complete medium 24 hours post-
transfection. In figure 4.3 the immunoblot demonstrates the amount of protein
produced under various transfection conditions. An optimal result was obtained
using I tg or 2.tg of DNA and effectene at a 1 in 25 dilution (lane 2 and 3).
Although the 3-galactosidase could be detected when using lower amounts of
DNA, transfection was less efficient as judged by the intensity of the protein band.
In addition, the cell patches remaining in the dishes were stained (data not shown),
reflecting the western blot observation. To conclude, a high amount of effectene is
necessary to transfer DNA into HEK293 cells. All further transfection experiments
were performed at the concentrations used above (for 60mm dishes, I pg DNA; I
in 25 effectene ratio). In cases of smaller culture vessels or lower numbers of cells,
e.g. in 12, or 24 well dishes, the transfection procedure was adjusted, respectively.
4.5.1.2 Expression levels of different gL plasmid constructs
Each plasmid construct was evaluated in transient transfections followed by
simple histochemical staining procedures (blue cell assay) as previously described
(chapter 3). The antibody penta-his failed to detect 0RF22/gH recombinant
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protein using this assay, although the control protein was known to encode
histidine residues and known to be expressed and subsequent western blot
experiments showed the 0RF22/gH protein (see below). Consequently, only
plasmid constructs encoding KSHV 0RF47/gL were tested. Controls include the
galactosidase plasmid, to monitor transfection efficiency, and a c-myc tagged
control plasm Id (pSEC-GBV-C.E2) (data not shown), together with cells that had
been mock-transfected. Transfection was performed in 24 well dishes (0.3tg
DNA; 1/50 DNA-effectene ratio) and cells fixed 48 hours post transfection. After
24 hours of incubation cells started to detach. The growth medium was replaced
and the incubation continued, but cell loss was still high compared to the negative
control at the time of methanol/acetone fixation. Following staining procedures,
the differences in expression between the transfection controls and the plasmid
constructs of interest was surprising. In figure 4.4, several tested plasmids are
illustrated, indicating that gL 4.2 (A) and gL 5.10 (B) could be detected more
readily than the other constructs. The number of blue cells produced by the gL
encoding plasmids was low in comparison to the positive control (F; >50%),
although clearly positive when compared to the negative HEK293 cells (E). On
average, >5% of cells stained blue, while the positive control showed more than
50% transfection efficiency. The blue cell assay pictures also illustrate the
decrease in cell growth, in that discrete patches of cells were formed instead of the
uniform monolayer seen for cells transfected with pcDNA3. I -3-gal (figure 4.4F).
Despite the low levels of expression this result demonstrates promoter activity and
the ability of these plasmids to produce recombinant protein. There may be a
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Figure 4.4: Analysis of the expression levels of different 0RF47/gL plasmids in
transient transfections. Plasmids were transiently transfected into 293 1-IEK cells
and stained 48 hours post-transfection. Cells were fixed in methanol/acetone,
incubated with primary mAb 9E 10 and bound antibody was detected with a
3-galactosidase conjugated anti-mouse secondary antibody.
A: pcDNA3.1-4.2gL
B: pcDNA3.1-5.lOgL
C: pcDNA3.1-5.3gL
D: pcDNA3.1-3.2gL
E: Mock transfected cells
F: pcDNA3.1-3-galactosidase, positive control
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possibility that the amount of protein could be increased by changing certain
transfection parameters. Possibly the combination of transfection reagent and
DNA may not be optimal, causing the cell death or inhibition of cell growth, seen
after incubation. However, the lack of this problem for the two control plasmids
used lead us to conclude that an 0RF47/gL associated toxicity is a more probable
explanation.
4.5.1.3 Re-evaluation of transfection procedure using the plasmid
pcDNA3. 1-4.2gL
To further improve the transfection conditions specifically for gL expressing
plasmids, the plasmid pcDNA3.l- gL 4.2 was prepared in larger quantities. As
described above, recombinant protein could be successfully detected when
transfecting this plasmid into HEK293 cells. To establish transient transfections
with high levels of recombinant protein but a low decline in cell number, various
combinations of DNA and effectene were examined. Experiments were performed
in both 60 mm and 24 well dishes, followed by western blot and blue cell assays.
Although when effectene concentrations were lowered cell death was reduced, an
increase in protein expression was not observed. Using 0.3.tg DNA and a 1/50
DNA-effectene ratio staining procedures were most successful in 24 well dishes
(data not shown). DNA concentrations greater than O.3tg needed increasing
amounts of effectene, but resulted in inhibition of cell growth and rapid
detachment of cells from the surface. Furthermore, attempts to detect the
glycoprotein in western blots using the monoclonal antibody specific for the c-
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myc epitope (mAb 9E10) failed at any condition (data not shown). KSHV
0RF47/gL is predicted to encode a 167 amino acid protein with an estimated size
of I5kDa prior to post transitional modifications (>2OkDa after glycosylations).
Neither cell culture supernatant nor the soluble or the insoluble protein fraction
showed any band migrating between 20 to 4OkDa by western blot.
4.5.1.4 Reporter plasmid as an internal control shows high recombinant
protein expression
All previous experiments indicated that the level of protein expression by
plasmids encoding 0RF47/gL is low in transient transfections. The reason behind
this observation may be due to the toxicity of the protein itself or may be caused
by the transfection method chosen. To monitor the transfection efficiency of a
particular DNA sample, we decided to co-transfect the gL plasmid along with a
reporter plasmid. The plasmid pcDNA3.1-his--galactosidase was selected,
allowing for direct blue cell assay detection (via 3-galactosidase) and western blot
analyses (via histidine residues); for gL, expression plasmid 4.2 was chosen.
HEK293 cells were transfected in 60 mm dishes and different ratios of the two
plasmids assessed (control plasmid/gL: 1/1 and ¼). Cells were harvested 48 hours
post transfection as described before. A small patch of cells was left in the dish,
fixed in methanol/acetone and stained for 3-galactosidase expression. Cell lysates
were prepared by mixing harvested cells with an equal volume of Laemmli buffer
followed by sonication and boiling. Cell supernatant or around iO cells were run
on 12% SDS-PAGE and analysed by western blot; firstly probed for 0RF47/gL
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expression with the monoclonal antibody 9E10 and secondly, after stripping the
membrane, probed with penta-his. The corresponding protein band patterns are
shown in figure 4.5.
4.5.1. 4a Detection of the c-myc epitope (ORF4 7/gL-c-myc)
Unfortunately, a distinct cross-reactivity of the antibody with mock-transfected
cell supernatant as well as cellular lysate (data not shown) could be observed
(figure 4.5A). Western blot analyses showed in each lane, including the mock-
transfected 293 sample, a protein migrating at approximately 66kDa. The
estimated molecular weight of this protein may suggest fetal calf serum (FCS) as a
target. In contrast, the c-myc positive control confirmed the activity of the
antibodies and no cross-reactivity with FCS could be detected (data not shown).
However, regarding the expression of 0RF47/gL, no protein could be detected,
between 20-4OkDa. Unless the KSHV gL homolog may form a complex or
associates with a cellular protein, these results confirm previous detection
attempts. Namely, that transient transfections produce amounts of recombinant
0RF47/gL lower than the detection limit of western blots.
4.5.1. 4b Detection of the His-/3-galactosidase expression
The histidine tagged -galactosidase can be detected in two ways; histochemically
using the substrate X-Gal or by immunoblot. As the membrane can be stripped
western blot allows a direct comparison between the level of expression of the f3-
galactosidase and 0RF47/gL for each sample.
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Figure 4.5: Western blot analyses of 293HEK cells transfected with both
the reporter plasmid and pcDNA3.1-4.2gL under various transfection
conditions (detailed above the picture). Lysates were obtained 48 hours
post-transfection and subjected to 12% SDS-PAGE. 0RF47 was detected by the
Mab 9E10 (A) and the reporter protein his-galactosidase (see arrow) was
identified with the Mab penta-his (B). As a negative control supernatant from
mock-transfected cells was used. Numbers on the left are molecular masses
in kilodaltons (kDa).
Supernatant (S) or lysate (LY) are indicated on the bottom of each lane
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Blue cell assays showed a low number of positive cells, when compared to the
control transfection (data not shown). This may be due to the presence of the
second plasmid which prevents optimal transfer into the cell. Overall, the
transfection efficiency is satisfactory and should enable protein detection in
western blot procedures. Using the monoclonal penta-His the l2OkDa 3-
galactosidase could be detected, (figure 4.5B) The protein is present in each lysate,
although at a lower concentration than seen before (see figure 4.3). The intensity
of the respective bands differ, but corresponded to the amount of blue cells
detected. Evidently, the expression level of both plasmids is different, one protein
being detectable in western blots (3-galactosidase) whereas the other seems to be
missing. These results show that, using this transfection procedure, a sufficient
amount of protein can be produced, as indicated by the reporter plasmid. This
suggests that in transient transfection systems using 293HEK cells the
recombinant expression of KSHV 0RF47/gL only possible at levels undetectable
by western blot procedures.
4.5.1.5 Transient expression of KSHV 0RF22, the gH homolog
The second protein to be expressed is encoded by KSHV 0RF22/gH and has an
estimated molecular weight of 79kDa, prior to post translational modifications.
Previous blue cell assays and indirect immunofluorescence assays showed that the
detection of any histidine tagged protein using anti-histidine antibodies is
unsuccessful, even for positive control proteins. Therefore the study of the
0RF22/gH gene product was limited to western blot procedures.
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Several different 0RF22/gH plasmids (pcDNA3.1-4.6gH; pcDNA3.1-5.lgH;
pcDNA3.1-5 .2gH; pcDNA3.1-7.11 gH) were transiently transfected into HEK293
cells using effectene and the conditions described for the control plasmid
pcDNA3. 1 -his-3-galactosidase. During the transfection of 0RF22/gH encoding
plasmids an increase in cell detachment could also be observed. Cells were
harvested 48 hours post-transfection and soluble/insoluble protein fractions
separated along with cell culture supernatant as described in section 2.2.7.1 and
analysed on a 12% SDS-PAGE followed by western blot (figure 4.6). A number
of proteins which reacted with the penta-his antibody were found in the insoluble
protein fraction of all the samples tested. The protein profile for each plasmid
contained a group of reactive proteins ranging from 38 to l5OkDa with a
prominent band at 66kDa. The predicted molecular weight of 0RF22/gH is
suggested to be between 75 and 79kDa, without glycosylation. It is therefore
possible that some bands seen in the western blot may correspond to incompletely
glycosylated forms, breakdown products or the fully processed form of the
0RF22/gH gene product. Their origin has not been determined as no antibody
specific for KSHV 0RF22/gH is available. However, lysate from mock-
transfected cells showed a relatively similar pattern, as illustrated in figure 4.6; no.
5. There is no significant difference between lysate derived from mock-transfected
or plasmid transfected cells. Given this observation, it is likely that the situation
seen for 0RF47/gL may apply to 0RF22/gH as well. The amount of protein
produced being too low to be detected by immunoblot.
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Figure 4.6: Western blot analysis of transiently expressed KSHV 0RF22. HEK293
cells were transiently transfected with a number of 0RF22 encoding plasmids. Cells
were harvested after 48hours and supernatant, cell lysate (soluble and insoluble
protein fraction) analysed by 12% SDS-PAGE. PVDF membranes were probed with
the penta-his Mab.
1: pcDNA3.1-4.6gH
2: pcDNA3.1-5.lgH
3: pcDNA3.l-5.2gH
4: pcDNA3.1-7.11gH
5: Mock-transfected 293HEK cells
Type of sample is indicated at the bottom of each lane: Supernatant (S), insoluble (IN)
or soluble (SOL).
Estimated molecular weight (in kDa) are shown in the left margins.
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In summary, the expression of recombinant KSHV 0RF22/gH and 0RF47/gL was
restricted in transient transfection systems. In particular for 0RF22/gH the
detection of low protein expression is limited to western blot procedures for the
reasons mentioned earlier. Thus, higher amounts of protein are necessary. The
establishment of stable cell lines expressing constitutively the protein of interest
may increase the amount of protein synthesized and allow more distinct analyses
of the two viral glycoproteins. The individual characterization of gH and gL
proved to be more complex than initially anticipated. Consequently, experiments,
examining a possible interaction between these two proteins were carried out at a
later stage.
4.5.2 Stable 293HEK cell lines
In a transient transfection, cells represent a heterogeneous population, varying in
their ability to produce recombinant protein. To produce a cell population where
the majority express the protein, single cell clones have to be selected. The vector
encodes the zeocin resistance gene allowing the growth of a positive transfectant
in the presence of the drug zeocin. The minimum concentration required to kill
HEK293 cells was determined in a kill curve experiment (data not shown).
Transfected cells were routinely selected in the presence of 200-300.tg/ml.
Mammalian cells were transfected as described before and incubated for 48 hours
in complete growth medium. Cells were then split in a 1 in 10 ratio and transferred
to complete medium containing 200.tgIml zeocin. After 10-14 days resistant cells
were obtained, and aliquots of these stored in nitrogen. In addition cells were
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cloned by limited dilution in 96 well plates (see section 2.2.6.5). Once clones were
detected, cells were expanded and transferred to 12 well plates and subsequently
tested for expression either by indirect immunofluorescence or by western blot.
Six different plasm ids, pcDNA3. I -4.2gL; pcDNA3. 1-4.4; pcDNA3.1-5 .3gL;
pcDNA3.1-5.IOgL; pcDNA3.1-4.6gH and pcDNA3.I-5.2gH were transfected and
single cell clones obtained and analysed.
4.5.2.1 Initial screening of selected cells by FCR and indirect
immunofluorescence
All cell lines established were initially screened by PCR for the presence of the
insert. Cells were harvested and total DNA extracted using an extraction kit
(Qiagen). A PCR mix was prepared containing the oligonucleotide primers
described in chapter 3. Briefly, cell clones containing the gL construct should
produce a 320bp fragment, and cell clones encoding the KSI-IV 0RF22/gH a
778bp fragment. All cell lines tested were positive for their respective insert (data
not shown).
To test for expression gL positive cell lines were seeded in cover slips and grown
to 70% confluence, cells fixed in methanol/acetone and analysed for the c-myc
tagged protein. Although these cells were cloned previously, the expression level
was unexpectedly low in the majority of cell lines tested, with less than 15-20% of
the cell population producing protein by IFA (data not shown). Some clones were
found to be negative. The most promising cell lines were chosen and expanded for
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more detailed analyses. Table 4.1 gives the names of the chosen stable cell lines,
the plasmids transfected and their expression levels.
Name of cell line 	 Transfected plasmid	 Expression level
293.4.2gL	 pcDNA3.l-4.2gL	 highest in IF, FACS,<30%
293.4.4gL	 pcDNA3.1-4.4gL	 relatively low, IF, <20%
293.5.3gL	 pcDNA3.1-5.3gL	 relatively low, IF, <20%
293.5.lOgL	 pcDNA3.1-5.IOgL	 high in IF, FACS, <30%
293.4.6gH	 pcDNA3.1-4.6gH	 relatively low, FACS, <20%
293.5.2gH	 pcDNA3.l-5.2gH	 relatively low, FACS, <20%
Table 4.1: Established 293HEK 0RF22/gH or 0RF47/gL stable cell lines. Cells
were single cell cloned and tested by PCR as well as by a variety of methods,
including indirect immunofluorescence; FACS analysis, western blot and blue cell
assay.
Since recombinant 0RF22/gH production could not be determined by IFA for the
reasons described in chapter 3 and earlier in this chapter, PCR positive cells were
expanded and tested by western blot. Results are discussed later in this chapter.
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4.5.2.2 Analyses of stable cell lines
Cloned cell lines were expanded in selection media until a reasonable amount was
available to test by a variety of procedures (Blue cell assay, indirect
immunofluorescence, FACS, western blot). Cell growth was monitored and
healthy cell cultures developed in the presence of zeocin.
4.5.2.2.a 0RF47/gL expressing cell lines
Despite the selection process, the amount of protein produced in each cell line
remained low. Blue cell assays were performed at each stage of the selection
process to monitor protein expression. A constant decline in the number of blue
cells could be observed (data not shown). However, a basic level of expression
remained. Stable 0RF47/gL cell lines were labeled with the monoclonal antibody
9E10 to measure the number of cells synthesizing protein. Expression could be
observed, but at low levels. In figure 4.7A the fluorescence staining pattern, as
well as the corresponding transmission picture demonstrate that approximately
one or two cells out of every ten show fluorescence (10-20%). This result was
confirmed by flow cytometry. Approximately 3x10 5 cells were fixed,
permeabilized and labeled with primary and secondary antibody in solution as
described in chapter 2.2, section 7.7. Using a FACScan (Becton-Dickinson), 1O
cells were counted and analysed for their fluorescence intensity; a histogram is
shown in figure 4.7B. The level of fluorescence attributed to non-specific antibody
interactions was determined by incubating the cells of interest with the FITC-
conjugated secondary antibody alone (black line). Similarly, auto fluorescence of
the cells themselves as well as the background noise of the
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Figure 4.7: Evaluation of the expression level of gL expressing 293F1EK stable
cell lines. Cells were examined by 1FA and flow cytometry as described in
chapter 2.2. Cells were immunostained with Mab 9E10 and a goat anti-mouse
FITC conjugated antibody. Pictures were taken with a confocal microscope.
(A) Fluorescence and transmission image. (B) Flow cytometry histogram; red
line indicates cells stained with the Mab 9E 10 followed by FITC-
conjugated secondary antibody, while the black line shows non-specific binding
of the secondary antibody. Fluorescence intensity is shown on the x axis,
and the relative number of cells is indicated on the y axis. This particular stable
cell line (293.5.lOgL) is typical of results obtained with all 0RF47-expressing
stable lines.
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primary antibody were determined (data not shown). Background fluorescence
intensity for the primary antibody (9E10), anti-mouse FITC conjugate and the cell
line itself was on average 11.5 (Geo mean) and 8 (median) when 97% of the total
cell population were gated (indicated by marker, Ml in figure). Fluorescence
histograms show that two cell populations could be distinguished when negative
control (cells incubated with FITC-conjugated secondary antibody only) and
labeled cells (red line) were overlaid. One cell population having a similar
fluorescence intensity as the negative control (black line), suggesting that these
cells are unlikely to produce the recombinant protein and the signal is probably
due to unspecific binding of the secondary antibody. In contrast, the second
population showing a significant increase in fluorescence intensity, on average the
Geometric mean was above 350 and the median mostly above 300 (marker, M2).
In total approximately 10-20% of the total cell population seemed to express
ORF47IgL in the cell lines tested.
Finally, to estimate the molecular weight of this protein and to examine whether
the recombinant gL products were synthesized as soluble or insoluble proteins in
mammalian cells, we collected cell lysates from a large number of cells (2x1 07)
and monitored them by western blot. Cell lysates were harvested as described
before, sonicated and stored at -20°C. To detect recombinant protein secreted into
the culture medium, as described for HSV-I gL, supernatant was also collected
and concentrated using a Centricon-lO microconcentrator, for 2 hours at 6000 rpm
and 4°C. All supernatant aliquots were negative for KSHV gL (data not shown).
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The cell line 293.5.IOgL synthesized a protein with an apparent molecular weight
of 25-27kDa, that reacted with the monoclonal antibody 9E 10 (see arrow in figure
4.8). Surprisingly, this protein could be predominantly found in the soluble protein
fractions, rather than in the insoluble fraction as described for the gL homolog
encoded by EBV (Pulford et a!. 1995). The insoluble protein fractions all
contained a faint protein band, migrating at the same size. This may be due to
soluble protein contaminants.
As a control for non-specific binding, cell lysate from the parental 293HEK cell
line was loaded in lanes 3 and 4. Only minor cross-reactivity could be detected,
leading to the conclusion that the 25-27kDa protein corresponds to recombinant
0RF47/gL. Taking into account the two glycosylation sites, this protein found in
293HEK cells may represent the fully-processed form of 0RF47/gL. Additional
experiments using an anti-0RF47/gL monoclonal antibody are essential to
confirm these assumptions. However, at the time of writing such reagents do not
exist. Further experiments confirmed that KSI-IV 0RF47/gL can be predominantly
detected in the soluble part of cell lysate (data not shown). The cell line described
above was chosen for all further expression and localization studies of KSI-IV
0RF47/gL.
4.5.2. 2b Cell lines encoding 0RF22/gH give a complex protein pattern
The 0RF22/gH gene product synthesized in several cell lines was also analysed
by western blot and flow cytometry as described above. Cell supernatant and
lysates (soluble/insoluble) were collected and results are illustrated in figure 4.9.
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Figure 4.8: Western blot analysis of the gL expressing stable cell lines. Lysates
were collected at different time points and loaded onto (12%)
SDS-PAGE, electroblotted and examined with the Mab 9E10. Soluble (SOL)
and insoluble (IN) protein fractions were analysed separately. Supernatant and
cell lysate derived from the gL expressing cell line 293.5.10 are presented. The
arrow indicates the 27kDa protein. As a negative control the parental cell
line (293HEK) was also analysed by western blot as was the 293.GBV-C E2
stable cell line (positive control).
M: Molecular weight marker (Bio Rad)
Lane 1: 293.5.lOgL, soluble protein fraction
Lane 2: 293.5.lOgL, insoluble protein fraction
Lane 3: 293F1EK, soluble protein fraction
Lane 4: 293HEK, insoluble protein fraction
Lane 5: 293.GBV-C E2, supernatant
Lane 6: 293.GBV-C E2, lysate (in Laemmli buffer)
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Figure 4.9: Western blot analysis of the gH expressing stable cell lines.
Lysates were collected at different time points and loaded onto (7%)
SDS-PAGE, electroblotted and examined with the penta-his monoclonal
antibody. Soluble and insoluble protein fractions were analysed separately.
Arrow indicates the putative KSHV gH protein mentioned in the text.
Lane 1: 293.5.2gH, soluble (SOL) protein fraction
Lane 2: 293.5.2gH, insoluble (iN) protein fraction
Lane 3: 293.4.6gH, soluble protein fraction
Lane 4: 293.4.6gH. insoluble protein fraction
M: Molecular Weight marker (Bio Rad)
Lane 5: 2931-IEK, soluble protein fraction
Lane 6: 293HEK, insoluble protein fraction
*The 80-85kDa protein band can be seen weakly in lane 4. For a better
visualization see figure 4.13, lanes 2 and 4.
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Once more, protein expression was low and detailed studies of the recombinant
protein were complicated. Both cell lines, 293.4.6gH and 293.5.2gH (illustrated in
lane 1, 2, 3, 4), synthesized the earlier described 66kDa protein and a weakly
reacting additional protein of 80-85kDa that was limited to the insoluble protein
fraction (for a better result see figure 4.13) and was absent in the negative control
(lanes 5 and 6). Furthermore, a band with less electrophoretic mobility (app.
1 lOkDa) was also detected in the soluble protein fraction of cells harboring the
ORF22/gH from patient 4 (lane 3). However, several proteins produced by the
parental, non-transfected, 293HEK cells, also reacted with the histidine specific
antibody, making the result difficult to interpret. With respect to the negative
control lysate, the 85kDa protein, synthesized by the selected cell lines may
correspond to KSHV 0RF22/H, but an exact identification would need
confirmation by an anti-0RF22/gH antibody.
FACS analyses of cell lines encoding 0RF22/gH demonstrate that less than 20%
of the total cell population had elevated fluorescence levels, distinguishable from
the negative control (data not shown). A control cell line expressing the reporter
protein his-3-galactosidase was used to determine the binding activity of the
penta-his monoclonal antibody in this particular assay. The control plasmid
pcDNA3. I -his-3-galactosidase was transfected in duplicate to test for protein
expression by two independent methods, flow cytometry (detecting the histidine
tag) and X-Gal staining, detecting the 3-galactosidase. Surprisingly, FACS
analyses and histochemical staining procedures of the same transfected cells did
not correspond, blue cells could be detected routinely, but flow cytometric
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methods showed no significant increase in fluorescence (data not shown). Thus,
any results obtained with the penta-his antibody were interpreted with care.
However, since the cell line 293 .4.6g1-1 expressed the highest amount of the 85kDa
protein, under the circumstances described, it was chosen for further studies.
To conclude, these experiments show that, despite single cell cloning, the level of
expression could not be increased to 100%. Flow cytometry experiments
estimated that only 20-30% of cells produce recombinant protein. For examination
of biochemical properties, such as glycosylation pattern or possible in vitro
complex formation between 0RF22/gH and 0RF47/gL, proteins need to be
available at higher amounts. A final approach was made to manipulate protein
expression. Sodium butyrate was added to the culture medium of stable cell lines
and its influence on expression level monitored. For intracellular distribution
studies these stable cell lines were examined by confocal microscopy. Results are
detailed later chapter 5.
4.5.2.3 Sodium butyrate induction of stably selected cell lines
Some promoters are susceptible to chemical stimuli and can be influenced in their
ability to regulate gene expression, e.g. herpesviral lytic expression can be induced
by the addition of sodium butyrate (see chapter 1). Sodium butyrate has been
demonstrated to affect transcription regulation and enhance gene expression in
eukaryotic cells (Kruh, 1982). Studies showed that butyrate significantly enhances
expression of genes controlled by either the CMV-IE promoter/enhancer or the
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SV4O promoter (Condreay et a!. 1999). The addition of butyrate to the growth
medium markedly elevates gene expression of a recombinant protein in several
cell lines (CHO; HeLa; Cos-7; HEK293) when under the control of the respective
promoter (Palermo et a!. 1991; Condreay et a!. 1999). Butyrate has a variety of
effects on different cell types, the underlying mechanism behind this ability to
stimulate transcription is thought to be mediated by inhibition of the enzyme
histone deacetylase (Kruh, 1982).
To increase the expression level of the established stable cell lines a range (1, 2, 5
and 10mM) of butyrate concentrations were tested. The chemical was added to the
growth medium and cells monitored for detachment. Concentrations above 10mM
markedly inhibited cell growth; lower concentrations were tolerated though cell
growth was slowed down (data not shown). For expression purposes cells have to
be in S-phase as the CM V-based mammalian expression vector are cell cycle and
serum dependent (Brightwell et a!. 1997). Thus, 2-8mM of the chemical were
used in the following induction studies.
4.5.2.3a Influence of chemical stimuli on protein expression analysed by
IFA andflow cytomety
Chemical induction of protein expression was focused on 0RF47/gL-expressing
cell lines, since studies using the penta-his antibody for these specific detection
assays were inconsistent. Experiments were performed in duplicate, cells being
seeded into cover slips for IFA and into 60mm dishes for flow cytometry.
Following 24 hours incubation culture medium was removed and replaced by
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fresh medium supplemented with different concentrations of sodium butyrate
(2mM, 5mM). Cells were incubated for a further 16 hours. Harvest, fixation and
subsequent staining was performed as set out in chapter 2.2, section 7.6.
Recombinant protein expression was considerably increased in the presence of
butyrate. Both, confocal micrographs and the corresponding flow cytometry
histogram obtained following induction with n-butyrate are shown in figure 4.10.
The concentration of n-butyrate is shown above each picture. In comparison to
untreated cells (compare figure 4.10 to figure 4.7) it is clear that butyrate has a
significant influence on 0RF47/GL expression. Cells incubated in the presence of
butyrate (figure 4.10) exhibit an intense green color on IFA. This observation is
also reflected in the corresponding FACS histograms (panel B). Two populations
can be distinguished throughout, but the fluorescence intensity of the right curve
(red), representing gL-expressing cells, is increased when butyrate is added, in
particular where both curves overlap (see arrow).
Figure 4.10 (next page): Sodium butyrate induction of gL encoding 293 stable
cell lines. Cells were incubated over night with sodium butyrate; concentrations
are indicated above each IFA image. Protein expression was analysed by (A) IFA
and (B) flow cytometry as detailed in Material and Methods. Following induction
cells were fixed or harvested and stained with the Mab 9E10. Bound antibody was
detected with FITC-conjugated goat anti-mouse antibody. Red line: cells labeled
with primary and secondary antibody; black line: cells labeled with secondary
antibody only. The arrow highlights differences in expression level.
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This data indicates an increase in the number of cells synthesizing 0RF47/gL
when under the influence of n-butyrate. To summarize the effect of butyrate on
recombinant expression, the percentage of cells exhibiting fluorescence is plotted
against the concentration of butyrate added, 2, 5 and 10mM respectively (figure
4.11). The influence of 10mM butyrate was also assessed by flow cytometry but
the effect was reversed. A further increase in expression, in comparison to 5mM,
could not be noticed. It is probable, that at this high concentration, cell growth was
inhibited and as a consequence the amount of protein reduced.
Sodium butyrate concentration
Figure 4.11: Influence of sodium butyrate on recombinant protein expression in
the stable cell line 293.5.lOgL. Cells were incubated over night in the presence of
different concentrations of sodium butyrate. Following fixation, cells were
examined by flow cytometry as detailed before. Histograms were prepared using
the computer software WinMDI. Approximately 97% of the total negative cell
population was gated and the amount of cells exhibiting gL expression
determined. The mean fluorescence intensity ranged from 250 to 300.
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This data suggests that stable cell lines contain the appropriate insert but the level
of 0RF47/gL expression is low despite single cell cloning. To complete the
expression studies in HEK293 cells lysates obtained from butyrate-treated cells
were examined by western blot.
4.5.2.3b Final western Blot showing recombinant 0RF47/gL and
0RF22/gH gene products
Encouraged by these elevated expression levels, all stable cell lines were re-
evaluated in western blot procedures after being treated with 8mM sodium
butyrate. Cells were harvested as before, soluble and insoluble protein fractions
separated and approximately 106 cells loaded per well of a 7% or 12% SDS-
PAGE. Proteins were transferred to PVDF membrane and probed with either 9E 10
or penta-his monoclonal antibody.
Figure 4.12 demonstrates the recombinant 0RF47/gL produced after butyrate
induction of the stable cell lines 293.4.2gL and 293.5.lOgL. Several bands reacted
with the 9ElO Mab. A faint and diffuse band, migrating at 27kDa could be
visualized in the soluble part of 293 cells transfected with the 5.10 plasmid, in
contrast to the 293.4.2gL cell line, where this protein was absent. This protein has
been described before (section 4.5.2.2.a) and most likely corresponds to the
mature form of 0RF47/gL. The diffuse pattern also indicates possibly
glycosylation. Other experiments, using different concentrations of butyrate and
analysing expression by western blot, confirmed data obtained earlier by flow
cytometry, in that the expression level is directly dependent on the concentration
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Figure 4.12: Re-evaluation of gL expressing 293 stable cell lines following
sodium butyrate induction. Each cell line was induced with 8mM (f.c.)
sodium butyrate over night. Cell lysate was prepared as described before
and approximately O cells were loaded per well of a 12% denaturing
polyacrylamide gel. Proteins were transferred to PVDF membrane and
labeled with the monoclonal antibody 9E10. Arrow indicates KSHV 0RF47/gL
gene product.
M: Molecular Weight marker (Bio Rad)
Lane 1: 293 HEK, soluble protein fraction
Lane 2: 293HEK, insoluble protein fraction
Lane 3: 293.5.lOgL insoluble protein fraction
Lane 4: 293.5.lOgL soluble protein fraction
Lane 5: 293.4.2gL soluble protein fraction
Lane 6: 293.4.2gL insoluble protein fraction
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of butyrate added to the culture (data not shown). The western blot shown in
figure 4.12 represents the highest amount of recombinant protein we could achieve
by using a small amount of cells and inducing them over night.
Several other slow migrating proteins could also be visualized in the non-
transfected cell line (>4IkDa; lanes I and 2), suggesting cross-reactivity.
However, no band was present at 27kDa within the parental cell line, indicating
that 293HEK cells are able to fully process 0RF47/gL as a soluble protein.
Cell lysates from 0RF22/gH-encoding cell lines were also subjected to SDS-
PAGE and analysed by western blot using the penta-his monoclonal antibody. As
hoped, a positive result was also obtained for those cell lines, as demonstrated in
figure 4.13. Several protein species could be identified, ranging from
approximately 80-l8OkDa. The 80-85kDa band was present predominantly in the
insoluble protein fraction, together with a protein migrating more slowly (100-
11 OkDa). This 80-85kDa band had already been detected in transient transfections
and may correspond to an alternatively processed form of 0RF22/gH (the
predicted mass, without sugar, is approximately 79kDa). The second protein
reacting with the monoclonal antibody is likely to represent the mature form of
0RF22/gl-1. To further confirm this statement studies examining the glycosylation
pattern of 0RF22/gH would have to be performed. The soluble part of the cell
lysates also contained the 80-85kDa protein, although at a lower level. Within
lysates derived from non-transfected 293HEK cells the proteins described above
were absent (lane 5 and 6). Lane 7 shows the antibodies activity towards the
transiently expressed control protein, his-galactosidase. Overall, the expression
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pattern is consistent with the proteins seen in previous transfection experiments
and supports the conclusion that 293HEK cells produce several forms of
ORF22IgH as insoluble protein.
To conclude, using sodium butyrate, detection of the two glycoproteins could be
achieved and their approximate molecular weights estimated. Further
investigations using monoclonal antibodies specific for these KSHV open reading
frames will be essential to rule out possible cross reactivity of the monoclonal
antibodies 9E10 and (especially) penta-his.
The expression of 0RF47/gL and 0RF22/gH seems to be complex, a cell line
expressing higher levels of protein without chemical induction would be desirable
as the influence of sodium butyrate on the biochemical properties of the proteins
of interest is not known.
Figure 4.13 (next page): Re-evaluation of gH expressing 293 stable cell lines
following sodium butyrate induction. Each cell line was induced with 8mM (f.c.)
sodium butyrate over night. Cell lysate was prepared as described before and
approximately 106 cells were loaded per well of a 7% denaturing polyacrylamide
gel. Proteins were transferred to PVDF membrane and labeled with the penta-his
antibody. Arrow indicates the putative KSHV 0RF22 gene product. Molecular
weight marker is indicated on the left. (SOL) soluble; (IN) insoluble, (LY) lysate.
(A) Lane 1: 293.5 .2gH soluble protein fraction (SOL)
Lane 2: 293.5.2gH insoluble protein fraction (IN)
Lane 3: 293 .4.6gH soluble protein fraction (SOL)
Lane 4: 293 .4.6g1-1 insoluble protein fraction (IN)
(B) Lane 5: 293HEK parental cell line, soluble protein fraction
Lane 6: 293HEK parental cell line, insoluble protein fraction
Lane 7: 29311EK, transiently transfected with pcDNA3.1-3-galactosidase, in
Laemmli buffer.
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4.5.3 The Cos7 cell line
4.5.3.1 Recombinant expression in Cos7 cells
As described earlier in this chapter, Cos7 cells encode the SV4O large T-antigen
and therefore support episomal replication of expression vectors containing an
SV4O origin of replication, such as pcDNA3.l. Transfected cells may therefore
contain several copies of the vector, leading to a theoretical increase in the
synthesis of recombinant protein per cell. We therefore chose to determine
expression of gH and gL in this second cell line.
Optimal transfection conditions were determined using the control plasmid
pcDNA-his-3-galactosidase and the transfection reagent effectene as described
above. Approximately 1 p.g DNA and an effectene ratio of I in 25 resulted in the
highest level of expression as judged by blue cell staining and western blot (data
not shown). To establish the expression level of the plasmids indirect IFA and
flow cytometry analyses were performed. Both methods indicated a low level of
transient expression by IFA and made western blot procedures unnecessary (see
below). Several stable Cos7 cell lines were established and tested for the presence
of recombinant ORF22/gH and 0RF47/gL. Although the respective sequences
could be detected by PCR for each cell line, the level of expression was low as
measured by IFA and FACS analyses (data not shown). In conclusion, the
construction of cell lines constitutively expressing these KSI-IV ORFs appears to
be a rare event (and rather time consuming). Subsequent experiments therefore
focused on a transient transfection system in combination with sodium butyrate
induction.
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4.5.3. la Cos7 cells show no improved expression pattern
To compare the expression with 293 cells, the same plasmids, including 4.2gL,
5.IOgL and each together with 4.6gH or 5.2gH, were transfected into Cos7 cells.
The following morning cell culture medium was replaced as a significant amount
of cell detachment could be observed. After an additional 24 hours, cells were
fixed in methanol/acetone and indirect immunofluorescence performed with the
monoclonal antibody 9E10. A FITC image and the corresponding transmission
image showing gL transfected Cos7 cells are shown in figure 4.14A.
A similar result was obtained with gH/gL co transfections (data not shown). The
number of fluorescent cells was low, regardless of which plasmid was transfected.
Interestingly, the cells which did express the protein had a "damaged" phenotype
when compared to mock transfected cells (see transmission image, figure 4.14C).
This observation suggests that the expression of 0RF47/GL could effect cell
growth, possibly forcing the host cell to inhibit recombinant protein production to
survive. Additional flow cytometry analyses confirmed the IFA results and
allowed us to quantify the number of expressing cells. Around 10-15% of the total
cell population could be detected, with a mean fluorescence intensity in the range
of 100 to 183, and background values between 30 and 40. Overall, the expression
pattern of 0RF47/GL in Cos7 cells shows no remarkable difference from
transiently or stably transfected 293 cells. In addition several attempts were made
to demonstrate the two glycoproteins in immunoblots (data not shown). As
expected from IFA studies and FACS for 0RF47/gL, the amount of protein was
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insufficient to be detected by this method. Unfortunately, there was no alternative
method to detect the synthesis of 0RF22/gH when singly transfected.
Further studies therefore concentrated on transient transfections combined with
sodium butyrate induction and confocal microscopy of cells expressing gL alone
or together with gH.
Figure 4.14 (next page): Immunofluorescence analyses of gL expression in Cos7
cells after transient transfection. Cells were transfected in cover slips and fixed in
methanol/acetone 48 hours post-transfection. Fixed cells were then reacted with
the Mab 9E 10, bound antibody was detected by reaction with FITC-conjugated
goat anti-mouse antibody. Cells were subsequently viewed by confocal
microscopy. Both, the FITC image (A) and the corresponding transmission images
(B) are shown. Arrows indicate corresponding cells. In panel C mock-transfected
Cos7 cells are shown. Cos7 cells transfected with pcDNA3. I -4.2gL represent data
obtained with other plasmids.
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4.5.3.2 Sodium bulyrate, an inducer of recombinant protein expression
Although SV4O large T antigen positive cells were expected to produce higher
amounts of recombinant protein, our experiments revealed the opposite for KSHV
0RF22/gH and 0RF47/gL. Protein levels remained low, even after clonal cell
lines had been obtained. As a consequence a transient expression system was
developed where transfectants were chemically induced shortly after transfection,
with the aim to enhance protein expression. Previous studies using the control
plasmid demonstrated that the transfection efficiency is satisfactory
(approximately 50%), the addition of sodium butyrate after the transfection may
result in an increase in expression.
Cells were transfected in duplicate with different gH and gL encoding plasmids.
After 16 hours supernatant was removed and fresh growth medium, supplemented
with 5mM sodium butyrate, added and the cells incubated for a further 24 hours.
Supernatants were collected and cells analysed by western blot and flow
cytometry. Higher amounts of butyrate could not be used because of its inhibition
and toxicity for cell growth (data not shown).
4.5.3.2a The 0RF47/gL gene product expressed in Cos7 cells
Cell supernatants, soluble and insoluble protein fractions were separated on a 12%
SDS-PAGE, transferred to PVDF membrane and probed with the monoclonal
antibody 9ElO (Figure 4.15).
A prominent band was present in the soluble protein fraction of gL-transfected
cells (lanes 1 and 3), but absent in the negative control. The protein was 27kDa in
size, concomitant with the pattern previously seen in 293 cells. This protein most
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Figure 4.15: Proteins expression in Cos7 cells after transient transfection combined
with sodium butyrate induction. Cells were transfected with KSHV 0RF47 plasmids,
induced after 24 hours and incubated for an additional 24 hours.
Supernatant was collected and cells harvested as described before. Protein extracts
were resolved on 12% denaturing polyacrylamide gel, transferred to PVDF
membrane and probed with the Mab 9E10. Arrows indicate KSHV 0RF47 gene
product.
Lane 1: pcDNA3.1-4.2gL, soluble protein fraction
Lane 2: pcDNA3.l-4.2gL, insoluble protein fraction
Lane 3: pcDNA3.1-5.lOgL, soluble protein fraction
Lane 4: pcDNA3.1-5.lOgL. insoluble protein fraction
Lane 5: Cosl cells, mock-transfected, soluble protein fraction
Lane 6: Cosl cells; mock transfected, insoluble protein fraction
Molecular weight is indicated at the left side.
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likely corresponds to a processed form of KSHV 0RF47/gL. Interestingly, a
second protein not seen in 293 stable cell lines, with an approximate size of2lkDa
was also detected in lanes I and 3. This protein reacted only weakly with the
antibody and may represent an immature form of 0RF47/gL. As seen with 293
stable cell lines, cells transfected with the pcDNA3.1-5.lOgL plasmid appear to
produce gL more efficiently than cells harboring the 4.2gL plasmid. Reasons for
this difference remain to be determined.
Overall, these data suggest that Cos7 cells are able to produce 0RF47/gL and to
perform post-translational modifications for most of the protein synthesized,
though less efficiently than stable 293HEK cell lines.
4.5.3. 2b The 0RF22/gH gene product expressed in Cos 7 cells
Cos7 cells were also transfected with 0RF22/gH expressing plasmids and cell
lysates prepared following sodium butyrate induction. The western blot is shown
in figure 4.16. The gH protein profile contained a major band with an apparent
mass of approximately 80-85kDa, predominantly found in the insoluble protein
fraction. Furthermore, a second band, 11 OkDa in size, that reacted weakly with the
penta-his antibody could also be detected. As described for 293 cells, this band
may represent a processed form of 0RF22/gH, whereas the 80-85kDa most likely
corresponds to the pre-protein form. Both plasmids exhibited a similar expression
level, as judged by the band intensity. Mock-transfected lysate did not produce a
protein at this size that reacted with the monoclonal antibody (data not shown).
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Figure 4.16: Proteins expression in Cos7 cells after transient transfection combined
with sodium butyrate induction. Cells were transfected with KSHV 0RF22 plasmids,
induced after 24 hours and incubated for an additional 24 hours.
Supematant was collected and cells harvested as described before. Protein extracts
were resolved on 7% denaturing polyacrylamide gel, transferred to PVDF membrane
and probed with the penta-his Mab. Putative proteins are indicated by an arrow.
Lane 1: pcDNA3.1-5 .2gH, soluble protein fraction
Lane 2: pcDNA3.1-5.2gH, insoluble protein fraction
Lane 3: pcDNA3.1-4.6gH, soluble protein fraction
Lane 4: pcDNA3.1-4.6gH, insoluble protein fraction
Lane 5: Cos7 cells, mock-transfected, soluble protein fraction
Lane 6: Cos7 cells; mock transfected, insoluble protein fraction
Mock-transfected Cos7 cells were analysed separately, showing no band at the same
position as transfected cells (data not shown).
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4.5.3.2c Co- expression of both gHandgL
Cellular lysates obtained from co transfections were also examined for protein
expression and results are shown in figure 4.17. The membrane was first probed
with the penta-his antibody (A), subsequently stripped according to the
manufacturers instructions, and re-probed by 9E 10 (B).
Interestingly, co transfected cells produced a similar protein pattern as seen for
individual transfected cells. 0RF22/gH was expressed predominantly as an
insoluble 80-85kDa protein (lane 2) and no increase of processed 0RF22/gH
could be observed. Also the co expression did not result in larger amounts of
soluble protein. In contrast, 0RF47/gL was fully processed and only the 27kDa
glycoprotein was present in the soluble protein fraction (panel B, lane 1). The
immature (2lkDa) form of 0RF47/gL seemed to have disappeared; no protein
similar in size reacted with the 9E10 monoclonal antibody. Whether this is caused
by the presence of 0RF22/gl-1 remains to be determined, but it would be hard to
prove as the amount observed in single transfections was already low.
In summary, this chapter details a series of experiments which eventually led to a
reliable system whereby both proteins 0RF22/gH and 0RF47/gL could be
successfully expressed in both 293HEK and Cos7 cells. The results obtained are
more or less similar and indicate that 0RF47/gL exists mostly in its processed
form, whereas 0RF22/gH is also produced as a pre-protein. In the following
chapter localization studies focused on the distribution pattern of 0RF47/gL with
and without 0RF22/gH.
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Figure 4.17: Transient co expression of KSHV 0RF47/gL and 0RF22/gH in Cos7
cells following sodium butyrate induction. Cells were co-transfected with both
plasmids, induced after 24 hours and incubated for an additional 24 hours.
Cells were harvested as described before and protein extracts resolved on (A) 12
and (B) 7% denaturing polyacrylamide gel, transferred to PVDF membrane and
probed with the 9E1 0 Mab or the penta-his Mab. (SOL) soluble; (IN) insoluble.
Lane 1: pcDNA3.1-5.1 OgL/pcDNA3. 1-5 .2gH; soluble protein fraction
Lane 2: pcDNA3.1-5.1 OgL/pcDNA3.1-5 .2gH; insoluble protein fraction
Arrows indicate the KSHV 0RF22 and 0RF47 gene products.
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4.6 Summary and Discussion
Intracellular transport and processing of a variety of herpesviral gH and gL
homologs have been analysed, mostly in transient expression systems, including
recombinant vaccinia virus in mammalian cells or baculovirus in insect cells
(Browne et a!. 1993; Dubin and Jiang, 1995; Duus et a!. 1995; Duus and Grose,
1996; Foa-Tomasi eta!. 1991; Forrester eta!. 1991; Gompels and Minson, 1989;
Hutchinson et al. 1992; Li eta!. 1995; Pulford et a!. 1995; Liu et al. 1993; Roberts
et a!. 1991; Spaete et a!. 1993; Westra et a!. 1997; Yaswen et a!. 1993). The gL
homologs appear to play an important role in transport and processing of their
respective gH homologs. Complex formation between these two proteins is well
established and it is generally assumed that this complex is essential for viral
infectivity. Therefore the gH and gL homologs encoded by the newly identified
gammaherpesvirus KSHV are most likely to exhibit analogous properties. Both
nucleotide sequences 0RF22/gH and 0RF47/gL were PCR amplified and cloned
into the mammalian expression vector pcDNA3.1 (Invitrogen). The amplification
primers were designed to encode C terminal protein tags to facilitate protein
detection; the c-myc epitope for 0RF47/gL, and six histidine residues for
0RF22/gH. The resulting clones pcDNA3. 1-gL/pcDNA3. I -gH were transfected
either singly or together into COS7 or HEK293 cells. The subsequent protein
characterization was complicated as the amount of protein produced by these cell
lines was very low, unless sodium butyrate was supplemented with the growth
medium after transfection. In addition, several 293HEK stable cell lines,
constitutively expressing 0RF22/gl-1 or 0RF47/gL were established, which also
synthesized low amounts of protein under 'non-induced' conditions. A basic
229
characterization of both viral glycoproteins was achieved, indicating several
similar, but also some surprisingly different properties to other gH and gL
homologs. It has to be emphasized that these expression systems may not reflect
the situation in an in vivo herpesviral infection. The amounts of expressed protein
in transient transfection systems is different and may not accurately reflect the
amounts made during viral infection.
4.6.1 KSHV 0RF22/gH and 0RF47/gL expressed in mammalian cells
Both KSHV glycoproteins encoded by 0RF22/gH and 0RF47/gL could be
successfully detected after chemical induction of 293HEK stable cell lines and
transiently transfected Cos7 cells. The overall expression pattern within those two
cell lines was similar, although glycosylation processes appear to be more efficient
in 293HEK cells, in particular for 0RF47/gL. Cos7 transiently transfected with
ORF47IgL plasmids produced two proteins, 21 and 27kDa in size, which both
reacted with the monoclonal antibody 9E10. Although no glycosylation studies
have been performed it is likely that the 27kDa protein corresponds to the fully
processed form, whereas the smaller protein may represent a precursor of
0RF47/gL. Unlike HSV-1 gL which is secreted into the cell culture medium, both
forms of KSHV gL were predominantly found in the soluble cell protein fraction.
In 293 cells no reactive protein migrated at 2lkDa, suggesting that this cell line
performs more efficient post translational modifications. Cell-type dependent
processing of gL has been reported before for the HSV-1 homolog, where gL
precursor proteins could be detected in Cos and Vero cells, but L cells mainly
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expressed the fully processed form (Dubin and Jiang, 1995). Furthermore, the
results presented confirm observations with HIV-1 gpI2O, that 293 cells are able
to perform efficient post-translational modifications (Fox eta!. 1997).
In contrast, both cell lines seemed less able to perform secondary modifications of
recombinant 0RF22/gH. The synthesised product was identical in both cell lines,
293HEK and Cos7, when analysed by immunoblot. Cells produced an 80-85kDa
protein that was found in the insoluble protein fraction. This protein is most likely
to represent the precursor of gH, as the size corresponds to the predicted
(unmodfied) molecular weight of 0RF22/gH. Additional minor bands were
observed with a molecular mass of approximately 1 lOkDa, probably
corresponding to processed form of gH. This reflects data reported for other
herpesviral gH homologs where gH has been expressed as an insoluble protein
which is incompletely processed when expressed alone (Westra et a!. 1997;
Pulford et a!. 1995).
4.6.2 0RF47/gL and its chaperone function
As mentioned before herpesviral gH is dependent on the presence of gL for fully
processing. When cells were co-transfected with gH and gL they synthesized a
recombinant gH protein similar in size to the wild-type homolog, whereas singly
transfected with gH the recombinant protein is smaller in size, apparently missing
essential glycosylations (Foa Tomasi el a!. 1991; Pulford et a!. 1994; Gompels
and Minson, 1989; Cranage eta!. 1988; Heineman eta!. 1988). Our co expression
studies with 0RF47/gL and 0RF22/gH using our transfection system did not
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result in either an increase in processed gil or in larger amounts of soluble gH
gene product. This result suggests that for KSHV, gL appears to have less
influence on gH than is seen in other herpesviruses.
Recently a third protein has been identified that associates with the gH-gL
complex. So far this tripartite viral glycoprotein complex has only been described
for HCMV and EBV. In EBV the third component has no obvious influence on
gH-gL complex formation, whereas in I-ICMV the third protein, gO, was essential
for the formation of mature gH-gL-gO complexes at the plasma membrane (Li et
a!. 1995, Huber and Compton, 1999). Neither gH nor gL were fully processed or
could be detected at the surface membrane, unless gO was present. A similar
situation may apply for KSHV, that is an additional as yet unknown protein may
be an explanation for the lack of post-translational modifications of gH.
4.6.3 The Low expression level in both cell lines
Unexpectedly, the amounts of protein produced were low even when the
transfection procedures were optimized. Studies using a control plasmid
(pcDNA3.1 -his-3-galactosidase) demonstrated an excellent transfection efficiency
(50%) when transfected alone or in combination with 0RF47/gL plasmids.
Furthermore, expression levels showed no improvement when cells were cloned
and stable cell lines established. Overall, we were unable to detect recombinant
0RF22/gH and 0RF47/gL by western blot without chemical induction, regardless
which cell line was used. Only by collecting of a very large number of cells (>l0)
could recombinant protein be demonstrated, allowing estimates of the molecular
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weight. Whether the recombinant protein itself or the promoter encoded by the
vector was responsible for the low levels of protein remains to be determined
formally. However, following transient transfections, a high number of detached
cells and inhibition of cell growth could be seen, implying a possible toxic effect
of these respective proteins. However, transient expression of herpesviral gH and
gL homologs have been widely described with no major complications reported.
As evident from IFA studies, which showed multinucleated cells following gL
transfection, KSHV gL may exhibit properties that induce cell fusion and
consequently cell death. Therefore surviving transfected cells may express only a
limited amount of protein. Another possibility could be that the protein, or its c-
myc epitope, is rapidly degraded during expression.
We were unable to investigate the intracellular distribution of 0RF22/gH because
of methodological problems, therefore it is difficult to explain the lack of
expression in simple transient transfection experiments. We cannot exclude the
possibility that gH may be retained in the endoplasmatic reticulum and be rapidly
degraded. It could also be the case that gH is toxic and causes cell death. It has
been reported that the establishment of stable cell lines expressing I-ISV-I gH
constitutively appears to be a rare event and in these cell lines the expression of
gH seems low (Foa-Toamsi ci al. 1991). Reduced gH expression has been
demonstrated in HCMV strains that are resistant to neutralizing antibodies (Li et
a!. 1995), it has been suggested that this antibody-resistant phenotype can develop
independently of genetic changes and maybe regulated by environmental factors
(Li ci al. 1995). Analyses of gH mRNA stability and the
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promoter of HSV-1 gH have not provided any evidence for translational
regulation. It is thought to be more likely that the expression of gH is dependent
on post-translational events. This may explain why the expression of 0RF22/gH
in mammalian cells is complex and cells produce low amounts of protein. Further
studies will be necessary, examining the intracellular distribution of 0RF22/gH by
indirect immunofluorescence, to address these problems of low expression as well
as to directly investigate its influence on cell-to-cell fusion and gL surface
expression.
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5. Localization studies of recombinant KSHV 0RF47/gL
5.1 Introduction
Herpesviral glycoprotein L has been described as a chaperone for gH processing
and cell surface expression. When gL is expressed alone, in vitro studies showed
that the protein is either secreted into the culture supernatant (HSV-1) or retained
in the cytoplasm (EBV) (Pulford et a!. 1995; Westra et a!. 1997). This expression
pattern is altered when co expressed with gH; gL and gH form a complex that can
be identified at the cell surface. Recently, reports have identified a third
component in HCMV and EBV that may be important during the transport of gH
and gL. However, a possible homolog of this third protein has not yet been
identified in KSHV. So far, the interaction of KSHV 0RF22 and 0RF47, the
predicted gH and gL homologues, has not been studied. Using the established 293
stable cell lines and the transiently transfected Cos7 cells the intracellular
distribution of 0RF47 when transfected alone or with 0RF22 was examined by
confocal microscopy. Co transfection studies were mostly performed with Cos7
cells. However, the pattern observed was similar in both cell lines, (Cosl and 293
cells) the KSHV gL homolog exhibited similar properties to other herpesviruses.
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5.2 Initial IFA studies
Stable cell lines and transiently transfected Cos7 cells have been examined by IFA
to determine expression efficiency (see chapter 4). This procedure was optimized
and could be used for detail analyses of the intracellular distribution of 0RF47/gL.
However, the localization of gH when expressed alone, was problematic. The
antibody penta-his was found to be unable to detect the histidine tag of a known
control protein. Therefore, the expression of gU could only be demonstrated
indirectly, assuming complex formation of gH and gL along with surface
expression. Several experiments were initially performed testing various
concentrations of primary (9E10, anti-c-myc) and secondary (F[TC-conjugated
anti-mouse) antibodies to optimize signal intensity (for optimal conditions see
section 2.2.7.6). Experiments were repeated several times to assure that the results
were reproducible and the protein could be detected in a similar pattern.
Other experiments were performed that addressed fixation and permeabilization of
the cells. Different reagents were tested for their ability to fix and permeabilize
cells. Methanol/acetone (1:1) produced the most consistent results, although 2%
paraformadehyde in combination with acetone was similarly successful active. In
contrast, 2% paraformaldehyde and Triton-X-lOO resulted both in the loss of cells
and in background fluorescence. As a consequence ce!ls were routinely
methanol/acetone fixed and stained as described before. Several hundred pictures
were taken, a representative selection are presented in this chapter.
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5.3 Intracellular distribution of 0RF47, and its possible function
Cells transfected with gL plasmids were permeabilized and intense fluorescence
observed in both transiently transfected Cos7 cells and in stable 293 cell lines.
Overall, the fluorescence pattern in both cell lines was similar. Background
fluorescence levels were low, as judged by the mock transfected Cos7 or 293 cells
shown in figure 5.IC. When gL was transfected alone the c-myc-tagged gene
product was detected in the cytoplasm, predominantly at the nuclear membrane, as
shown in figure 5.IA. The fluorescent signal was localized and often shaped in a
triangular pattern as indicated by the white arrow. This observation corresponds to
other studies expressing EBV gL and VZV gL, where the protein is possibly
retained in the ER (Pulford el a!. 1995; Duus et a!. 1996). Interestingly, in a
minority of KSHV gL expressing cells the signal was distributed throughout the
cell processes that attach to neighboring cells (see figure 5.1 B). These data suggest
that KSHV gL is not exclusively restricted to the pen-nuclear membrane.
Figure 5.1: Confocal microscopy analyses of c-myc tagged KSHV gL expression
in mammalian cells. Transient transfected Cos7 or stable 293 cells were fixed in
methanol/acetone and incubated with primary antibody 9E10 and a FITC-
conjugated goat anti-mouse antibody.
(A) 'Triangular' staining pattern (see white arrow) in 293.5.lOgL and Cos7 cells
transiently transfected with pcDNA3.l-4.2gL
(B) Diffuse (cell process) cytoplasmic staining pattern in 293.5.lOgL and Cos7
cells transiently transfected with pcDNA3.1-5.lOgL
(C) Mock-transfected 293HEK cells
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Figure 5.1:
(A)
293.5lOgL cell line 	 Cos7 cell line; 4.2gL
(B)
293.5.lOgL cell line Cos7 cell line, 5.lOgL
(C)
293HEK cell line
238
Moreover, the recombinant protein seems to traffic through the cytoplasm and
may even be anchored to the plasma membrane, independently from gU. The
possibility that KSI-!V gL can be found elsewhere than associated with the
perinuclear membrane was further supported by the detection of multinucleated
cells (figure 5.2). Although seen more frequently in 2931-IEK cells (panel A, B and
C), Cos7 cells also exhibited this association of cells, some highly fluorescent
(figure 5.2D). Some polykaryons showed a diffuse fluorescent pattern, in
particular when a large number of cells were involved. In other multinucleated
293HEK cells, as shown in figure 5.3, a strong signal can be observed that is
restricted to the surroundings of the nuclei, although faint signals can also be
detected in areas towards the cell processes (see arrows). Polykaryons have been
previously described in co expression experiments of herpesviral gH and gL.
Those studies have shown that both proteins, glycoprotein H and glycoprotein L
were required to mediate cell fusion. Cells transfected with either of the two
proteins alone did not exhibit a fusogenic phenotype. It is therefore surprising that
the KSHV gL appears to exhibit fusogenic properties. To directly induce cell to
cell fusion gL has to be localized at the cell surface. Further experiments to
examine cell surface expression of 0RF47/gL could not confirm this assumption.
Transient transfected Cos7 cells as well as 293 stable sell lines were analysed by
several staining procedures, specifically targeting the cell membrane. However,
neither staining live cells on ice nor staining non-permeabilized cells resulted in
significant fluorescence intensity. In contrast, methanol/acetone fixed cells
showed the usual staining pattern for gL expressing cells (data not shown).
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(A)	 (B)
293.5.lOgL cell line	 293.4.2gL cell line
(C)	 (D)
293.4.2gL cell line 	 Cos7 cell line; 4.2gL
Figure 5.2: Confocal microscopy analyses of C-myc tagged KSHV gL expression
in mammalian cells. Transient transfected Cos7 or stable 293 cells were fixed in
methanol/acetone and incubated with primary antibody 9E1 0 and FITC-conjugated
goat-mouse antibody.
(A) Multinucleated 293 cells formed by cells stably transfected with KSFIV gL (5.10).
(B)Polykayron formation in 293.4.2gL, cells following butyrate induction. A single cell
(white arrow) is shown in comparison to multinucleated cell.
(C) Polykayron detected in 293 .4.2gL cells.
(D) Multinucleated cell formed by transient transfection of Cos7 cells with
pcDNA3. 1 -4.2gL.
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293.4.4gL cell line	 293.5.lOgL cell line
Figure 5.3: Multinucelated 293HEK stable cells (293.4.4gL and 293.5. lOgL)
exhibiting extensive perinuclear staining and limited trafficking into the processors
(white arrows). Stable 293 cells were fixed in methanolfacetone and incubated with
primary antibody 9E10 and a F1TC-conjugated goat anti-mouse antibody.
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/However, the C terminus of the recombinant protein may project into the
cytoplasm and hence the C terminal c-myc epitope was inaccessible to the primary
antibody when stained under these modified conditions. To investigate gL surface
expression an antibody specific for exposed N-terminal epitopes is essential.
5.4 KSHV gL and Golgi organelles
Previous studies (chapter 4) suggested that recombinant KSHV gL is glycosylated,
it therefore must traverse the Golgi compartments to be completely processed. To
examine the localization of gL in more detail dual labeling experiments were
performed using a fluorescent ceramide derivative that preferentially stains Golgi
organelles (Bodiby FL-0 5 ceramide, Molecular Probes). Images are shown in
figure 5.4. Cells were labeled as before and the dye added to the secondary FITC-
conjugated antibody. Labeling of the Golgi was detected by examining cells with
a filter that detects the red light emitted by the ceramide dye.
Figure 5.4: Co-localization of c-myc tagged KSHV gL with Bodiby FL-05
ceramide in the Golgi organelles of the cell line 293.5.lOgL. Cells were grown on
cover slips until 80% confluent. Following fixation cells were incubated with the
Mab 9E10 and the FITC conjugated antibody added together with Bodiby FL-05
ceramide prior to examination by confocal microscopy. Single cells (A) and
multinucleated cells (B) were examined.
(1) Green fluorescence emitted by the FITC-conjugated antibody, indicating gL
expression
(2) Fluorescence emitted by the Bodiby FL-0 5 ceramide, represented by a red
color and indicating Golgi organelles
(3) Co-localization of the red and green signals of panel I and 2, represented by a
yellow color when electronically merged. (*): Due to technical problems the
red and green color in this picture are inverted (see text for further details).
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Figure 5.4A:
(1)
(2)
(3*)
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(B)
(1)
(2
244
The same cells were immediately examined with a second filter that was used to
detect light emitted by the FITC-conjugated secondary antibody. Two images
were obtained and merged to form a two-color image. The orange/yellow colour in
figure 5.4A3 and 5.4B3 represents areas where both signals co localize.
Unfortunatly, we experienced some electronical problems while performing the
color merge of the single cell, shown in panel A. During the color merge the two
colors red and green were inverted, namely areas exhibiting green fluorescence
(gL expression) are shown in red instead of green. However, despite this techinal
problem a small area, colored in orange/yellow could be detected, indicating co
localization of the two signals.
Several single cells as well as polykaryons were analysed and a general pattern
could be deduced. Within a single cell (figure 5.4A) the yellow color in the cell
shown in panel 3 is restricted to a small region of the entire area that is stained
green by 9E10. Additional 'red' (supposed to be green) signal can be observed
that did not colocalize with the portion stained by the dye (panel I). This pattern
suggests that gL is found in the Golgi compartment, but is possibly also retained
in the ER, indicating the presence of pre-protein. In contrast, polykaryons, dually
labeled with ceramide and 9ElO, resulted in a different distribution of gL as
shown in figure 5.4B. The yellow color in panel 3 can be more frequently detected
than in single cells, indicating gL colocalization predominantly with Golgi
organelles in polykaryons. This suggests that in these multinucleated cells gL is
mostly present in its mature form.
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5.5 Can 0RF22/gH and 0RF47/gL interact?
As described for other herpesviruses, gL is required for gH maturation and cell
surface localization. The intracellular distribution of KSHV gL alone has been
described above, whereas the recombinant expression of KSHV gH was limited to
co-transfection experiments with both plasmids. However, efficient co-
transfection of two plasm ids is dependent on the ratio of the two constructs. It is
hence rather unlikely that the two proteins will be expressed in the exact relative
amounts required to only form complexes within the cell. Therefore several
intermediate forms of expression patterns were expected, including diffuse
cytoplasmic signals, cytoplasmic signals with surface expression, the triangular
shape as seen before, etc. To determine just cell surface expression transfected
cells were stained prior to fixation on ice without being permeabilized. This
allows surface staining as endocytosis of the antibody is prevented, while cells are
on ice. Also by staining live cells, rather than fixed/permeabilized ones, the
recombinant protein remains in its native conformation. Possible changes in
localization that may be induced by the fixative can be prevented. Co transfected
cells stained on ice have been analysed by confocal microscopy, but were mostly
negative, only a few cells could be detected that showed elevated fluorescence
intensity, more or less restricted to the cell surface (data not shown). However,
compared to cells stained following permeabilization, these fluorescent signals
were insignificant. The molecular mechanism behind gH/gL complex formation
has not been studied in detail for many herpesviruses A model of HSV-1 gL
complexed with gH has recently been described that would allow surface staining
via the detection of a protein tag encoded at the C terminus of KSHV gL.
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Truncated forms of gFl and gL were co-expressed and the minimal region of both
proteins required to interact defined. Together with data about the antigenically
active sites a model was developed where the complex is anchored through the gH
transmembrane domain and gL is localized extracellularly, with its N-terminus
hidden within the confines of gl-I (Peng eta!. 1998). However, whether this is the
case for KSHV gH and gL is not known. The possibility that the C-terminal c-myc
tag may be within the cell cannot be excluded (see above). Studies using
antibodies specific for other regions of KSHV gL are necessary to address this
question. Hence, cells were methanol/acetone fixed, stained as before at room
temperature and examined by confocal microscopy for possible surface
local ization.
Results are shown in figures 5.5 and 5.6, illustrating different staining patterns.
Strong fluorescent signals associated with the perinuclear membrane could be
observed in most co transfected cells (figure 5.5A). In contrast, in a minority of
cells the signal was diffusely distributed throughout the cytoplasm, as
demonstrated by the Cos7 cells in panel B. Both patterns have been observed with
cells expressing gL alone where, despite faint cytoplasmic staining, gL was
strongly associated with the perinuclear membrane. However, some cells could be
detected that did show an altered intracellular distribution when co transfected
with gH and gL plasmids (figure 5.6). In particular 293HEK stable cells exhibited
fluorescent signals associated with areas other than the pen-nuclear membrane.
Unfortunately a green signal could not be localized to the cell surface in any cell
analysed.
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Cos7 cell line; 5.10/5.2 (gL/gH)
(A)	 (B)
Cos7 cell line; 4.2/4.6 (gL/gH)
Cos7 cell line; 5.10/5.1 (gL/gH)	 Cos7 cell line; 4.4/4.6 (gL/gH)
Figure 5.5: Confocal microscopy of Cos7 cells transiently co transfected with 0RF22
and 0RF47 plasmids exhibiting an 'intermediate' staining pattern. Cells were
co-transfected on cover slips with a variety of expression constructs and analysed by IFA
as described before using the Mab 9E10. Cells were then viewed by confocal microscopy.
Transfected plasmids are indicated above each picture.
(A) Cells exhibiting pen-nuclear staining as well as cytoplasmic staining
(B) Cells exhibiting diffuse cytoplasmic staining
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(A)
2931-IEK cell line; 5.10/5.2 (gL/gFI)	 29311EK cell line; 4.4/4.6 (gL/gH)
(B)
Cos7 cell line; 4.2/4.6 (gL/gH)
Figure 5.6: Indirect immunofluorescence staining of gFI/gL co-transfected 293HEK
and Cos7 cells. Cells were transiently transfected, methanollacetone fixed and
following 48 hours of incubation and analysed by IFA as described in the text. Cells
were viewed by confocal microscopy. Transfected plasmids are indicated above each
picture.
(A) 29311EK cells transiently co-transfected showing altered intracellular distribution.
(B) Cos7 cells transiently co-transfected, exhibiting diffuse staining pattern.
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Whether the 0RF22 gene product was directly responsible for this altered gL
trafficking in co transfected cells is impossible to demonstrate without an anti-
0RF22 antibody. We can only assume, as this pattern was absent from gL-
expressing cells, that gH interacts with gL and causes this new distribution. A
similar result was obtained with transiently co-transfected Cos7 cells. Most cells
showed a diffuse cytoplasmic distribution when stained for gL expression (see
figure 5.6B). Despite co transfection a difference in intracellular localization of gL
could not be observed. To conclude, we were unable to demonstrate distinct
surface expression of KSHV 0RF47/gL when transfected along with 0RF22/gH.
5.6 Dual labeling of co transfected cells
Similar to the analyses of gL transfected cells, co-transfected cells were examined
for the co localization of gL and Golgi organelles. Cells were transiently
transfected with gi-! and gL plasmids and stained as described before. Following
labelling cells were analysed with different filters and images were merged to
identify regions that were stained with both the antibody and the fluorescent dye.
The number of cells successfully dually labeled and demonstrating altered
intracellular distribution was limited. However, colocalization of the antibody
9E10 and Golgi organelles could not be detected, although cytoplasmic and
mainly pen nuclear staining could be observed (data not shown). A series of
experiments were performed but cells that showed a yellow color after the merge
of two images could not be found, indicating that 0RF47/gL did not colocalize
with Golgi organelles when co-expressed with 0RF22/gl-l.
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5.7 Summary and discussion
Complex formation between herpesvirus glycoprotein H and glycoprotein L
homologs is well established. It is generally assumed that the gl-1-gL complex
plays a major role during penetration and cell-to-cell spread. So far, studies have
shown that both proteins are necessary to mediate entry as well as fusion.
Similarly, immunofluorescence studies have demonstrated that gL is required for
processing and cell surface localization of gH. It has been reported that when
expressed in insect cells from recombinant baculovirus, gH (HSV-l; HCMV) can
be detected on the cell surface in the absence of gL (Ghiasi eta!. 1991; Urban et
a!. 1996; Ghiasi et a!. 1991). However, this has not been confirmed by others, who
showed that gH only reaches the plasma membrane when gL is present (Westra el
a!. 1997). Unfortunately, the antibody we used to detect recombinant 0RF22/gH
reacted only weakly in immunofluorescence assays, so that corresponding
experiments with KSHV 0RF22/gl-1 were not possible. Instead we focused on
localization studies of KSHV 0RF47, the predicted gL homolog. and monitored
alterations of the gL distribution pattern when co-expressed with 0RF22/gI-1. In
the two different cell lines analysed the overall expression pattern was similar.
Immunofluorescence studies confirmed western blot data showing that
recombinant 0RF47/gL is not secreted into the cell culture medium. 0RF47/gL
seems to be retained within the cytoplasm, in particular the ER, when expressed in
mammalian cells. Confocal microscopy showed that KSI-IV gL can be associated
with the nuclear membrane but also traffics through the cytoplasm and can be
found in cell processes, when expressed individually. These observations
corresponds to reports demonstrating that post translational processing and
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intracellular transport of other herpesviral gL homologs in transfected cells do not
require gH expression (Dubin and Jiang, 1995; Pulford et a!. 1995). It is possible
that the ORF47IgL product might be anchored to the cell surface via its amino
terminal signal like sequence, although this has not been described for other
herpesvirus gL products. Secretion of gL into the culture medium has so far only
been reported for I-ISV-I, whereas for VZV and EBV recombinant gL is retained
within the cell, most likely in the endoplasniatic reticulum (Pulford el a!. 1995;
Duus and Grose, 1996).
Interestingly, in our studies an association with the cell surface could not be
demonstrated specifically, but the formation of polykaryons was observed,
suggesting that some gL may be localized to the cell surface and induce cell to cell
fusion. This observation is rather surprising as in other herpesviruses gH
homologs have usually been described as the key factor in herpesviral induced cell
to cell fusion. Neutralizing antibodies specific for gH inhibited HCMV induced
cell fusion (Mime ci a!. 1998). Others have found residues within the C terminal
tail of HSV-1 gH that are essential for fusion events (Wilson ci al. 1994).
However, limited data is available that addresses the function of gL homologs in
cell to cell fusion. Studies using a herpesvirus mutant, where gL is deleted,
showed that in HSV-1 gL is similarly dependent on gil for viral infectivity (Roop
ci a!. 1993). Furthermore, antibodies against HSV-1 gL have been shown to
effectively inhibit cell fusion, indicating a role for gL in this process (Novotny el
a!. 1996). There has been evidence that co expression of EBV gL and gil may not
be required for cell surface transport of gL, but a fusogenic phenotype depends on
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the expression of both (Li et a!. 1995). It is hence possible that the gL homolog
encoded by KSHV may exhibit fusogenic properties.
Since we were able to detect the KSHV gL homolog by confocal microscopy we
decided to examine whether gL co localizes with certain cellular organelles,
particularly the Golgi. Secretory and membrane proteins are synthesized by
ribosomes bound to the ER. From there glycoproteins are transferred to the Golgi
organelles, where the trimming and terminal glycosylations of the
oligosaccharides units takes place (Stryer, 1995). Therefore, fully processed gL
will traverse through the Golgi during maturation. Confocal microscopy
examining the association of gL and Golgi organelles showed differences between
single cells and polykaryons. In single cells that express gL, oni) a small area can
be detected that co localizes with the Golgi, whereas the majority of the protein is
associated with the nuclear membrane, most likely with the ER. as indicated by
the shape of the fluorescent signal (Lippincott-Schwartz et a!. 1990). In contrast,
polykaryons show a reverse pattern, with the fluorescent signal being mainly
found in the Golgi. These data leads us to speculate that a proportion of cells
express gL as a possible inactive precursor protein and therefore remain as single
cells. Other cells, however, may produce the fully glycosylated form of gL which
travels through the Golgi and is able to induce the formation of multinucleated
cells and consequently lead to cell death. This hypothesis would help in explaining
the low amount of protein produced by both mammalian cell lines, described in
chapter 4. Cellular over-expression of mature ORF47/gL gene product would be
disadvantageous to the cell because the gL protein, apparently, encodes fusogenic
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domains and causes cell death. Therefore, surviving cells may have down
regulated this expression, with only a minority of cells expressing the protein.
Overall the findings that gL may be involved in fusion are interesting, as gL has
so far been identified as a chaperone-like protein only, essential for proper
processing and targeting of fusogenic gH. En our studies KS!-IV gL seems to have
a more active function and appears to directly contribute to cell-cell fusion.
During our experiments localization studies of 0RF22/gH were impossible as the
antibody penta-his did not recognize the C terminal histidine tag in indirect
immunofluorescence studies. Therefore intracellular distribution of gH could not
be examined, thus its possible cell surface expression or retention in the cytoplasm
when expressed alone remain to be determined.
5.7.1 Do the gene products of KSHV ORF22/gH and 0RF47/gL form a
complex?
Co-expression studies were predominantly performed in Cos7 cells transiently
transfected with 0RF47/gL and ORF22/gH plasmids. Different ratios of the
plasm ids were assessed and showed a variety of expression patterns. We were
unable to obtain cell surface expression and the results shown are only based on
the detection of gL. However, the intracellular distribution of gL was altered in
some cells when co expressed with gH. Fluorescent signals were localized to other
areas than the nuclear membrane. Most cells showed the fluorescent pattern seen
in cells transfected with gL alone. Therefore the pattern seen in some co-
transfected cells could be due to gL being expressed alone. We were unable to
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detect gE-I by confocal microscopy for the reasons discussed and therefore cannot
exclude that gH may not be involved directly in gL trafficking. Western blot
analyses showed no significant difference in molecular weight for either proteins
when co expressed. There may be some increase in fully processed 0RF47/gL
when co expressed with 0RF22/gH, but this result could not be consistently
quantified.
As mentioned in chapter 4 the fact that a third protein associates with the y-
herpesvirus EBV gl-l/gL complex may imply a similar scenario for KSHV. That is
cell surface expression of KSHV gI-l/gL may be influenced by a viral protein yet
to be identified.
To conclude, recombinant KSHV 0RF47/gL gene product. produced in
mammalian cells can be found within the cytoplasm and may be involved in cell
to cell fusion. Our studies were limited to the detection of C-terminal protein tags
engineered during PCR amplification, confirmation with monoclonal antibodies
specific for the individual proteins would be desirable. Also, the lack of direct gH
detection in immunofluorescence studies made it difficult to analyse the
interaction between gH and gL in more detail.
255
6. Propagation of KSHV in the hepatoma cell line HepG2
6.1 Introduction
The molecular pathogenesis of KSHV has remained elusive, as de novo infections are
rare. Several B cell lines derived from PEL patients have been established that harbor
the virus. The majority of these cells maintain a latent KSHV infection and, following
treatment with phorbol ester or sodium butyrate, support lytic replication. However,
all cells in these culture systems are already infected, making it impossible to study
viral infectivity. Attempts to transmit infection to other cell lines by inoculation with
B cell derived material have been made. Many cell lines of fibroblastic, epithelial,
endothelial or lymphoid origin were susceptible for KSHV, but infection was both
inefficient and abortive, the KSI-IV genome being lost upon passage. Recently, some
endothelial based cell culture systems have also been described that were stably
infected with KSHV and developed a spindle cell shape resembling KS spindle cells
in vitro. For a detailed background of the propagation of KSHV in vitro see chapter 1.
To test the fusogenic properties of the gH/gL complex of KSHV we were interested in
finding a possible target cell of KSHV. From our experience of maintaining BCP-1
cells in culture we identified the human hepatoma cell line HepG2 as a useful feeder
layer that increased viability of BCP-1 cells. Moreover, it was noted that in some
BCP-1 feeder layers HepG2 cells developed aberrant morphology. Hence, the
susceptibility of HepG2 cells for KSHV infection was tested. Cells were inoculated
with KSHV derived from a singly infected B cell line (BCP-1) and with virus
obtained from SY cells which are infected with both
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KSHV and EBV. At different time points during incubation HepG2 cells and
supernatant fluid were analysed by PCR for the presence of KSHV specific DNA.
Surprisingly, we were only able to detect viral DNA over an extended period of time
when inoculating with virus derived from SY cells, suggesting a possible influence of
EBV. However, after only a few passages the viral genome was not maintained,
indicating an abortive infection.
Infection experiments were performed several times and the results were consistent.
These sets of data are discussed below.
6.2 The KSHV donor cell lines: BCP-1 and SY
The KSHV positive cell line, BCP-1, has been established from the peripheral blood
of an HIV sero-negative patient with PEL (Boshoffet a!. 1998). BCP-1 cells injected
intraperitoneally into mice were demonstrated to induce the development of ascites
and diffuse infiltration of organs, without obvious solid tumor formation, this
pathology resembles the primary effusion lymphomas seen in humans. BCP-1 cells
are singly infected with KSHV and contain on average 30-50 KSHV genomes per cell
(Howard M, PhD thesis, 1999). The second cell line, SY, is derived from the ascitic
fluid of an HIV positive patient with PEL. Following nested quantitative PCR, KSHV
and EBV sequences have been detected in a 150 to I ratio (personal communication,
U. Ayliffe). The cell line has been established in our laboratory; but further
characterizations have not been performed. Both cell lines, BCP-1 and SY, showed
only 50% cell viability, judged by trypan blue exclusion, when propagated in
complete RPMI culture medium. An
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improvement in cell viability was observed when these cells were maintained in
association with a feeder-monolayer of human embryonic lung cells (HEL) (M
Howard, PhD thesis 1999). Therefore, cell cultures of B cells derived from individuals
with PEL were routinely co-cultured with a monolayer of HEL cells. Interestingly,
apoptotic BCP-1 or SY cells remained attached to the feeder layer, whereas healthy
cells were detected in suspension (M Howard, PhD thesis 1999).
Both cell lines were positive by nested PCR for the presence of KSHV. The SY cells
were also positive for EBV (data not shown).
6.3 The recipient cell line: HepG2
The human hepatoma cell line, HepG2, exhibits several features of normal
hepatocytes. This cell line is well differentiated and retains the ability to synthesize
hepatic proteins (Bouma et a!. 1989) and has been the target for several viral studies,
including Hepatitis B virus receptor studies together with HCV and HHV6/HHV7
infection studies (Mabit eta!. 1996; Seipp eta!. 1997; Garson eta!. 1999; Cermelli et
a!. 1996). HepG2 cells appear to be permissive for infection by other herpesviruses,
such as HHV6/HHV7 and their replication can be induced by treatment with phorbol
esters (Cermelli et a!. 1996). EBV, the closest human homolog to KSHV, has been
associated with liver disease during infectious mononucleosis and post-transplantation
lymphoproliferative disorders (Markin, 1994). For these reasons HepG2 cells may be
a possible target for KSI-IV infection. Furthermore, we have shown that I-IepG2 cells
can function as a feeder-
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monolayer for the maintenance of BCP-1 cells, similar to HEL cells (personal
communication, U. Ayliffe).
Prior to infection studies, nested PCR of HepG2 cells was performed to assess the
presence of other herpesviruses. Cells were negative for HSV-1, HSV-2, HCMV,
VZV, HHV-6, KSHV and EBV (data not shown).
6.4 Transient Infection studies
To determine HepG2 susceptibility to KSHV, transient infection studies were initially
performed. Since BCP-1 cells are singly infected with KSHV, this cell line was used
as the source of viral particles. Cell-free supernatant was prepared from fresh BCP-1
cell cultures by centrifugation of the supernatant for 30 mm at 5000rpm. This
supernatant was added in serial dilutions to HepG2 cells grown in six well dishes,
aliquots (20O.il) of the inoculum in each well collected and the viral genome copy
numbers assessed by limiting dilution PCR (day 0). Copy numbers ranged from io to
6x107 per well. As a negative control cells were mock-infected. All cell monolayers
were exposed to the inoculum for a total of 7 days.
Aliquots (20O.tl) of supernatant fluid were collected at 1 day post-infection (P1), 4
days P1 and 7 days Pt. On day seven supernatant was removed, cells washed three
times in PBS and the final wash as well as 10 000 cells harvested (7 days P1). Total
genomic DNA was extracted from all samples and KSHV infection assayed by nested
qualitative and quantitative PCR.
259
6.4.1 The nested qualitative PCR
The nested PCR for the detection of KSHV specific DNA was established previously
as part of M. Howard's PhD theses (1999). Oligonucleotide primers were designed to
detect the viral DNA fragment, KS33OBam, described in the original identification of
KSHV (Chang et a!. 1994). The first round primers specifically amplif' this fragment,
which is part of the KSHV 0RF26 (minor capsid gene). Sequence analyses of KSHV
strains showed that genetic variation of 0RF26 is low, allowing the design of a nested
PCR (Zong et a!. 1997; Zong et a!. 1999). Thus, a primer set sited internally to the
already published primers was designed enabling the amplification of a 172bp DNA
fragment (M. Howard, PhD thesis 1999). PCR conditions were optimized and the
sensitivity of the amplification assay assessed using viral DNA purified from a
KSHV-containing B cell line. Consistent with other researchers, who also designed a
nested PCR specific for 0RF26, we determined the sensitivity as 10 copies of the
viral genome (Boshoff et al. 1995; M Howard, PhD thesis, 1999). However, on
occasions it was possible to obtain limited sensitivity, detecting one copy of the viral
genome (see chapter 7, figure 7.3). Oligonucleotide primers are listed in chapter 2.2,
along with a detailed description of the amplification protocol. A more detailed
description of the 0RF26 sequence variation among different KSHV isolates is
discussed in chapter 7, as part of the establishment of a KSHV quantitative assay.
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6.4.2 HepG2 cells are permissive for KSHV
Gel electrophoresis of transient infection samples, shown in figure 6.1A,
demonstrated that the PCR yielded consistently strong signals for each sample,
including supernatant, wash and cell lysate. The quantity of virus added to the cell
monolayer was less significant, as any dilution produced similar results. In addition to
the supernatant being positive for KSHV throughout the experiments, HepG2 cells,
harvested 7 days post-infection (P1) also contained viral DNA (indicated by C for
cells in panel A), although with a reduced signal intensity. This result may not reflect
internalized DNA, as the third wash (W) was also positive by PCR. It is hence
possible that KSHV may associate with the cell surface and can therefore be detected
by PCR when analysing the HepG2 cell lysate. Subsequent quantification of the viral
copies within the 'washing' sample and the cell lysate using a quantification assay
(ELONA) revealed that a difference in the copy number between third wash and cell
lysate did exist. These data are graphically illustrated in figure 6.2, black bars indicate
the number of copies identified within the cell lysate, the third wash samples are
represented by white bars. Wash samples only contained a few viral copies (<50
copies/tl), whereas cell lysates harbored many more viral sequences (up to 600
copies/tl). The quantification assay will be described in detail in chapter 7. Briefly, a
single round PCR was performed and the amplification products were compared to
standards of known copy number by means of a chemiluminescent reaction.
Following the fitting of a regression line to these data, copy numbers were estimated
by interpolation.
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Figure 6.1: Detection of KSHV DNA sequences in HepG2 cells following 7 days exposure
to BCP- 1 cell culture supernatant. HepG2 cells were seeded in 6 well dishes and inoculated
with serial dilutions of supernatant (indicated above each lane). Samples were harvested at
the days indicated and analysed by nested PCR as detailed in the text. In panel A an arrow
indicates the KSHV specific 1 72bp DNA fragment, (+) indicates positive control sample
(BCP-1 supematant); (M) denotes molecular size markers.
(A) Samples obtained from inoculated cultures.
(B) Samples obtained from mock-infected HepG2 cells.
(S) supematant fluid; (W) third PBS wash; (C) cell lysate.
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Figure 6.2: Quantification of viral DNA present in third wash and cell
lysate samples that have been inoculated with KSI-IV. Samples were
collected 7 days post-inoculation and subjected to a single round of
PCR, followed by a 96 well based quantification assay (ELONA, see
chapter 7). Data obtained was analysed using the computer software
Genesis Version 2.20. White bars indicate third wash samples; black
bars illustrate the amount of viral amplicons found in cell lysate.
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As a negative control, non-infected HepG2 cell cultures were treated similarly and
showed no viral DNA signal following qualitative (figure 6.1B). PCR. All
experiments were repeated and performed in duplicate.
In summary, this result suggests that HepG2 cells can be transiently infected with
KSHV derived from BCP-1 cells. KSHV may cell-associate but only a minority of
virus appears to be able to infect HepG2 cells. To establish whether KSI-IV can be
serially transmitted in HepG2 cells, long term propagation studies were performed and
the presence of viral DNA monitored over time by nested PCR.
6.5 Serial Passage of KSHV in HepG2 cells
Transient infection of KSHV has been demonstrated for a variety of different cell
lines, we were interested whether HepG2 cells could maintain the viral genome over
an extended time period. Two separate experiments were performed using virus
derived from two different B cell lines.
A) KSHV derived from the BCP-1 cell line, infected with only KSHV.
B) KSHV derived from the SY cell line, dually infected with both KSHV and
EBV.
This second cell line was selected in response to recent studies reporting that the
presence of EBV may influence KSHV infection of B cells (Kliche eta!. 1998).
The experiments were performed under identical conditions and repeated several
times. Initial time-course experiments were performed, passaging cells after 3 days
and 7 days exposure to virus. PCR analyses showed that an extended period of
infection (up to 7 days) was necessary to obtain a positive PCR signal within HepG2
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cells. Three day studies demonstrated that viral DNA could be infrequently detected
in some samples prior to the first passage, including supernatant (S), third wash (W)
and HepG2 cells (C) harvested three days P1 (see figure 6.3). The amount of virus
added initially appeared to play a minor role, as HepG2 cells exposed to a high viral
titer (10) could not be infected repeatedly. However, these PCR signals were lost in
every sample tested after the cells had been split, both by analysing I Id or I 0j.d (data
not shown) in a nested PCR. Since viral DNA was absent from wash samples and lost
after passage, HepG2 cells appear to be susceptible to low level infections. However,
it cannot be excluded that the initial positive signal within the HepG2 cells may have
been due to cell-surface associated KSHV DNA and these residual KSHV particles
may have contaminated the cell lysate samples.
In contrast, seven day experiments were more successful and are discussed below. As
a consequence of these observations, in all studies the inoculum was removed from
each long term infection study after 7 days of incubation. The infection protocol was
as follows: an equal number of HepG2 cells were transferred to four tissue culture
flasks (T25) and grown to 50-60% confluence. BCP-I or SY supernatant was
harvested as described above and HepG2 cells inoculated with different dilutions of
the cell-free supernatant. Flask 1 was overlaid with a BCP-I or SY supernatant
containing 108 copies; flask 2 was exposed to 5x107 copies and flask 3 to 2.5xl07 viral
copies. As a negative control, a 4th flask of HepG2 cells was incubated with culture
medium alone and treated similarly to the infected flasks. Aliquots of the supematant
were taken immediately after inoculation, 3 days and 7 days P1. Seven days post-
infection the inoculum was removed and cells split in a I in 2 ratio (see arrow
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Figure 6.3: Serial passages of HepG2 cells inoculated for 3 days with supematant
fluid obtained from BCP-1 cell cultures. HepG2 cells were grown in tissue culture
flasks and inoculated with different amounts of KSHV particles, as stated above
each lane. Samples were collected over a period of 5 to 7 weeks and total DNA
extracted and tested by nested PCR. Days post-infection are noted. Time of cell
culture passages are indicated by arrows. S: cell culture supematant; W: third wash
sample; C: Cell lysate sample; (+) positive control (BCP-1 supematant); (-) negative
control (non-infected HepG2 cell lysate).
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indicating cell culture passages), transferred to a new culture flask and incubation
continued until cells were confluent (approximately one week). Prior to each passage
samples were taken, including aliquots of supematant, final wash and cells. Total
DNA was extracted from each sample (200p.I, or 10 000 cells resuspended in 200tl of
PBS) and one or ten microliters analysed by nested PCR. Amplicons were analysed
on a 1% agarose gel for the presence of the 172bp fragment (figure 6.5 and 6.6).
Negative and positive controls were included in all PCR reactions. As a positive
control a PCR mix contained I tl of BCP-1 supernatant was used.
6.5.1 KSHV infection using supernatant derived from BCP-1 cells
6.5.1.1 Phenotypic changes of inoculated HepG2 cells
Supernatant, third wash and cell lysate samples were collected during the experiment
and subsequently examined by PCR (see below). Interestingly, an increase in
cytotoxicity could be observed in cells incubated with B cell derived supernatant for 7
days. During culture HepG2 cells started to round up, detach from the plastic and
clump together, suggesting apoptotic cell death. The majority of these cells remained
attached to the cell monolayer, resembling the apoptotic BCP-1 cells that attach to
HEL monolayers. In figure 6.4 mock-infected FlepG2 (A) cells together with KSHV
infected cells (B) are shown. A white arrow indicates aggregated HepG2 cells. Some
dead cells could be detected within the mock-infected control flask as well, but
compared to KSHV infected cells, no aggregation was observed.
On day 7 the inoculum was removed, cells washed and harvested as described before.
Samples were stored for PCR testing and cells seeded into new flasks. Following the
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Figure 6.4: Cytotoxic effects on HepG2 cells that have been infected by KSHVin vitro. Panel A shows uninfected HepG2 cells after incubation for the numbers
of days shown. Panel B shows the appearance of KSFIV inoculated HepG2 cells
after being passaged once. The blue arrow highlights detached and aggregated
cells. Phenotypic changes were similar, regardless of which viral isolate was used.
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first passage a further increase in detached cells could be observed within the culture
of inoculated HepG2 cells. Cells reached confluence after an additional week and
further sampling, together with a second culture passage, was performed. As the
amount of detached cells in the supematant was significant at the time of harvest, the
supematant was centrifuged, the pellet washed three times with PBS and resuspended
in 200 j.tl of PBS. These samples were referred to as the 'apoptotic fraction'. HepG2
cells were further incubated but cell viability was below 30% (as assessed by trypan
blue exclusion). Culture medium was changed repeatedly and the cells slowly
recovered. Cells were passaged when confluent and sampling continued over 6-7
weeks.
6.5.1.2 PCR analyses of HepG2 cells, following cell culture passages
Supernatant fluids collected during the one week exposure period were all positive for
KSHV DNA as illustrated in figure 6.5. However, following cell propagation, KSHV
specific DNA could only be found in a limited number of samples, in particular in the
supematant samples derived from cells originally inoculated with a high number of
KSHV particles (inoculum: 108, day 14) and in the cell lysate from cells inoculated
with 5x107 KSHV particle. In contrast, other supernatant fluids were negative, as were
all third wash samples and cell lysates. This has been observed in the 3-day study
described above, where cells could only be infected infrequer1ly. However, due to the
increased amount of detached cells, the 'apoptotic fraction' was also tested.
Interestingly, although cell lysates were negative, the collected detached cells
(apoptotic fraction, AP) were positive throughout, suggesting that KSHV may infect
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Figure 6.5: Infection of HepG2 cells by KSHV derived from BCP-1 cells.
Cells were exposed to the BCP- 1 supernatant for 7 days. Samples were
collected as indicated by numbers above the lane (time), total DNA extracted
and tested for viral DNA by PCR. Amount of virus contained in the inoculum
together with the degree of cytotoxicity are mentioned on top. S: cell
culture supernatant fluid; W: third wash sample; C: Cell lysate sample;
AF: apoptotic fraction; (+) positive control (BCP-1 supernatant); (-) negative
control (non-infected HepG2 cell lysate).
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cells and induce cell detachment. This would explain the increase in detached cells
observed throughout the experiment.
Unfortunately, PCR analyses showed that the KSHV genome was lost in culture after
cells have been split a second time (data not shown). To be certain that no KSHV
DNA was present, we maintained each HepG2 cell culture for two further passages
and monitored supernatant, third wash together with cell lysate by PCR. Gel
electrophoresis of the PCR products confirmed the previous result, no KSHV
amplification products could be visualized (data not shown).
Overall, it appears that HepG2 cells are 'semi-permissive' for KSHV after an
extended period of exposure. Cytotoxic effects could be observed in HepG2 cell
cultures exposed to KSI-IV-containing supernatant. However, infection over serial
passages could not be demonstrated, suggesting that this HepG2 infection was
abortive. Whether the apoptotic effect seen was due to the presence of KSHV remains
to be determined, though the presence of KSHV in the AF, when absent from the cell
formation makes this probable.
6.5.2 KSHV derived from the SY cell line (KSHV/EBV)
6.5.2.1 Phenotypic changes in inoculated HepG2 cells
HepG2 cells were inoculated with cell free supernatant derived from SY cells under
similar conditions as detailed above. Sampling was performed immediately after
inoculation, I day P1, 3 days P1, 7 days P1, 14 days P1, 28 days P1, 35 days P1, 42 days
P1, etc.. Initially the cytotoxic effect was not as prominent as described for the HepG2
cells inoculated with BCP-1 derived inoculum, even though cell growth was slightly
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reduced. No significant phenotypic difference between inoculated cells and the mock-
infected cells could be observed. Only after cells were propagated could an apoptotic
phenotype and an increasing amount of detached cells be found in the supernatant.
Similar to the studies described above, HepG2 cells continued to detonate and cell
culture medium had to be changed repeatedly. Following the second cell culture
passage cells recovered slowly and after 2 weeks of incubation a sufficient number of
cells were available to continue sampling. Unfortunately, cells remained prone to
cytotoxicity and maintaining healthy cultures was difficult. Cells were propagated for
three additional passages and finally recovered completely as the frequency of
detached cells declined.
6.5.2.2 PCR analyses of SY exposed HepG2 cells
The amplification patterns of the samples taken during the 6 weeks of incubation are
shown in figure 6.6. KSHV specific DNA was found in all samples prior to the first
cell culture passage, including supernatant, third wash and cell lysate. Analogous to
infection of HepG2 cells with BCP-1 material, certain samples remained positive after
the first propagation. However, in contrast to BCP-l-infected HepG2 cells, strong
PCR signals were detected for both cell lysate samples and the apoptotic fraction.
Cells that were initially exposed to the highest and the lowest amount of viral particles
were consistently positive for KSHV DNA (inoculum: io; 2,5x10 7; day 14).
A slightly different amplification pattern could be observed after cells were split a
second time. Supematant fluid and the third wash were negative for KSHV infection,
whereas HepG2 cell samples and the corresponding apoptotic fraction of cells
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Figure 6.6: Long term infection of HepG2 cells inoculated with KSHV derived
from the B cell line SY. Cells were inoculated for 7 days as described in the
text. Samples were collected over a period of 6-7 weeks and analysed by nested
PCR. Time of cell culture passages are indicated by arrows. S: cell
culture supematant W: third wash sample; C: Cell lysate sample; AF:
apoptotic fraction; (+) positive control (SY supematant); (-) negative control
(non-infected HepG2 cells). Degree of cytotoxicity is mentioned on top of each lane
together with the amount of virus present in the inoculum. Mock-infected HepG2 cells
were negative throughout the experiments (data not sho).
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inoculated with io genome copies still contained viral DNA. However, this data
could only be obtained when HepG2 cells were originally incubated with the highest
viral titer. Cells being exposed to dilutions of infectious supernatant only showed
positive amplification when analysing the apoptotic fraction (inoculum: 5x10 7), or the
signal was lost completely (inoculum: 2,5x107).
The next culture passage was delayed (28 days P1), due to elevated cell detachment.
Unfortunately, viral DNA could not be found after additional culture passage, all
samples taken at later time points being negative. This may have been due to the poor
condition of the infected HepG2 cells. The loss of PCR amplification maybe related to
the immense cell death observed for each dilution. Surprisingly, KSHV DNA
disappeared and the cells recovered, indicating that the virus may play a role in cell
death within infected HepG2 cells. In comparison to the BCP-1 infection study, viral
DNA derived from SY supernatant was maintained more efficiently, as judged by the
intensity of the band, than from singly infected B cells. As SY cell supernatant
contained both EBV and KSHV it appears that EBV may influence the ability of
KSHV to infect HepG2 cells. All samples obtained from mock-infected HepG2 cells
were negative for KSHV DNA (data not shown).
6.5.3 Sodium butyrate treatment of KSH V-infected HepG2 cells
Studies described above only investigated the presence of KSI-IV DNA, but do not
address whether HepG2 cells are able to support viral replication or the production of
viral particles. Attempts were therefore made to establish whether HepG2 cells
support KSHV replication when induced with sodium butyrate. Sodium butyrate has
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repeatedly been shown to selectively induce KSHV replication in B cell lines co-
infected with EBV (Miller et al. 1997; Renne et al. 1996). HepG2 cells were infected
with KSHV as described above and sodium butyrate added to the culture medium
following the second cell culture passage at a final concentration of lOtM. Cells were
incubated for 48 hours and samples taken. Productive infection was expected to result
in the presence of KSHV within the supernatant or an increase in PCR signal intensity
of HepG2 cell lysate. However, no increase in viral DNA within the supernatant or
cell lysate was detected (data not shown). In fact the infected I-IepG2 cells remained
susceptible to apoptosis and the viral genome was either lost or a weak signal
remained (data not shown). Overall, sodium butyrate treatment did not change the
amplification pattern compared to non-induced control cultures. This data suggests
that KSHV infection of HepG2 cells is likely to be inefficient and production of viral
progeny is either extremely low or non-existent. However, the lack of viral replication
may be due to the loss of the viral genome. Further induction studies have not been
performed as infection of HepG2 cells with KSHV was inconsistent.
To conclude, the data presented indicates that HepG2 cells do have a susceptibility to
KSHV derived from SY cells. Furthermore during the experiment an association
between KSHV and an incraesed number of dead cells, compared to the non-infected
cell culture, could be observed. To begin with, viral DNA was found in viable cells,
whereas further on in the experiment the PCR signal was lost from healthy cells and
predominantly associated with detached, apoptotic cells, indicating that KSHV may
induce cytotoxicity. More detailed studies are necessary to confirm this observation.
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6.6 Summary and discussion
The successful propagation of KSHV in cell lines other than the established B cells
derived from PEL patients has been limited. Certain epithelial cell lines, in particular
primary or immortalized dermal microvascular endothelial cells (DMVEC) and
certain other primary endothelial cells have been shown to support a long term
productive infection (Panyutich et al. 1998; Moses et a!. 1999; Flore ci a!. 1998).
These infected cell lines developed a spindle shape, resembling KS spindle cells in
vivo (Moses ci a!. 1999). Although KSHV sequences could be found in other cells
with different origin, including lymphoid tissue, PBMCs, semen and saliva, studies
show that in vitro infection is mostly abortive and the genome is lost upon passage
(Renne et a!. 1998; Foreman et a!. 1997; Vieira et a!. 1997; Moore ci a!. 1996). A
similar observation was made in the present study using the hepatoma cell line
HepG2. This cell line was 'semi-permissive' for KSHV infection, in that cells
supported the entry of the virus.
This suggests that HepG2 cells may possibly express a surface receptor that facilitates
KSHV entry. Since the viral genome was lost in serial passages and viral replication
could not be induced by chemical stimuli, it is likely that this infection was abortive.
Quantification of the PCR signal indicated that a minority of HepG2 cells harbored
the viral genome. This corresponds to data obtained with other primary cell lines,
where less than 10% of KSH V-challenged cells could be infected (Flore et a!. 1998;
Panyutich eta!. 1998; Renne eta!. 1998).
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6.6.1 Viral replication may induce apoptosis
Interestingly, infection correlated with cell death of HepG2 cells and hence the
maintenance of KSHV infected cells in culture was difficult. KSHV induced apoptosis
has been reported previously for the embryonic kidney cell line 293 when using viral
isolates derived from KS lesions (Foreman et aL 1997; Friborg et a!. 1998). In
contrast, virus derived from a PEL cell line was not able to induce apoptosis in 293
cells and serial passages were ineffective (Friborg et a!. 1998). Further sequence
analysis identified strain variability among different KSHV isolates, particularly
between those derived from KS lesions and B cell lymphomas (Zong et a!. 1997;
Friborg et a!. 1998). Assuming that apoptosis may be the result of viral replication,
KSHV-infected HepG2 cells were further induced with sodium butyrate. However,
the production of virus could not be confirmed as judged by the negative PCR results
of supematant and cell lysate samples. Cytotoxicity could be ascribed to a number of
factors other than the virus itself, such as culture conditions or senescence.
Interestingly, HepG2 cells have been reported to support KSHV replication, when
analysed in an RT-PCR based assay specific for a spliced mRNA (U. Ayliffe,
personal communication; Renne et a!. 1998). This suggests that the lack of expression
described here may be due to methodological problems, such as growth conditions,
the differentiation state of HepG2 cells or the insensitivity of the detection method. To
detect low levels of replication the analysis of RNA rather than DNA may be
advantageous. Further studies investigating the gene expression pattern using
monoclonal antibodies against lytic viral proteins would address these questions.
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6.6.2 The presence of EBV
In our study the presence of the gammaherpesvirus EBV appeared to promote
maintenance of KSHV in HepG2 cells. Viral DNA was found more consistently in
HepG2 cells that had been inoculated with supernatant from the dually infected cell
line SY (KSl-lV/EBV). In contrast, inoculation with KSHV only resulted only in
transient infection and the genome was lost after the first cell culture passage. The fact
that KSHV could be more readily detected when EBV was present is interesting.
Recent data examining KSHV de novo infections of PBMC, revealed that for a stable
infection, EBV is necessary (Kilche et a!. 1998). B cells infected with both viruses,
KSHV and EBV appear to possess a growth advantage, suggesting that one virus may
exhibit transforming properties whereas the other provides growth-promoting co-
factors. This model is further supported by the fact that most PEL derived B cell lines
are co infected with KSHV and EBV. It has been suggested that EBV can promote the
replication of other viruses in vitro, e.g. the replication of the Hepatitis C virus (HCV)
(Sugawara et a!. 1999). EBV has been frequently detected in association with HCV in
patients with heptatocellular carcinoma. Studies of these two viruses suggests that the
EBV latent nuclear antigen EBNA1 may to be responsible for the support of HCV
replication. EBNAI is a DNA binding protein with affinity to certain sequence motifs
within the origin of latent viral DNA. It functions in the maintenance and replication
of the EBV episome but may also be involved in regulating the transcription of
foreign genes (Rawlins et a!. 1985; Reisman and Sugden, 1986; Liebowitz, 1993).
The interaction of EBV and HCV has also been confirmed in HepG2 cells and it is
possible that EBV functions as a helper virus, similar to adeno-associated virus, which
requires co-infection with a second virus (Adenovirus or herpesvirus) for productive
278
infection (Berns and Giraud, 1996). I-IepG2 cells are permissive for EBV, although
the primary EBV receptor, CD2 1, is not expressed. A restricted pattern of latent viral
gene transcription can be observed, including the proteins EBNAI, EBER and
LMP2A (Imai et a!. 1998). In the present study the EBV latent expression pattern was
not analysed, but one can assume that a similar scenario will apply in HepG2 cells
inoculated with SY supernatant. Therefore, it could be possible that KSHV replication
is similarly influenced by EBV. KSHV encodes analogs of EBV nuclear antigens,
including the latency associated nuclear antigen, LNA-1. This protein associates with
the mitotic chromosome and may have a similar function to the EBV nuclear antigens.
However, studies have shown that in B cells co-infected with KSHV and EBV,
EBNA1 and LNA-1 do not colocalize, implying that the proteins bind to different
nuclear domains (Szekely eta!. 1998). EBNAI may transactivate certain KSHV genes
or assist in the maintenance of the KSHV genome in culture. If EBNAI does enhance
KSHV replication the increase in apoptotic cells could be explained and analyses of
protein expression soon after inoculation should be positive. However KSHV-
infection of the EBV-positive Burkitt's B-lymphorna cell line Raji was unsuccessful.
The KSHV genome was lost with serial passages and productive lytic replication was
limited (Moore et a!. 1996). It hence cannot be excluded that EBV is non-essential for
KSI-IV infection in HepG2 cells. Studies, in which HepG2 cells were infected with
EBV and subsequently exposed to supernatant derived from BCP-1 cells
(KSHV+IEBV-) are important to assess whether EBV influences KSI-IV infection in
HepG2 cells. More detailed studies of the KSHV expression pattern in HepG2 cells at
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different times during infection are important to determine whether HepG2 cells do
indeed allow viral replication.
In summary, the human hepatoma cell line HepG2 is susceptible to KSHV infection,
but how supportive this cell line is for viral replication in the long term remains to be
established. Unfortunately, during the KSHV infection study HepG2 cells could not
be maintained in culture for a prolonged period of time. Thus, no long term culture
system could be established. Whether the virus itself was responsible for the increased
number of cells deteriorating remains to be determined.
The findings that KSHV can infect this hepatoma cell line may have considerable
relevance to the in vivo situation. There is a possibility that viral infection is not only
associated with epithelial cells of the skin, but also with cells of the liver. However,
there is so far no evidence in vivo that KSHV may infect the liver.
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7. Development of a KSHV quantitative assay
7.1 Introduction
Human herpesviruses can both cause primary disease and reactivate during
immunosuppression, resulting in severe or life-threatening illnesses, such as
shingles, CMV retinitis and lymphoproliferative disorders. In KS lesions and
primary effusion lymphomas the majority of cells are latently infected as judged
by in situ studies. However, there is little known about primary infection of KSHV
and the molecular mechanism of KSHV reactivation. In PEL cells lytic replication
can be induced using chemical stimuli. There are several virally encoded proteins
that have been demonstrated to exhibit transactivating properties, but the factors
which may trigger viral reactivation in vivo remain to be established. To study
KSHV pathogenesis, and to monitor the influence of antiviral therapy on viral
replication, an easy and rapid quantification assay would be highly desirable. So
far several approaches have been described, mainly based on PCR procedures (Bai
et a!. 1997; Gessain et a!. 1997; Lock et a!. 1997). Some are 'semi-quantitative',
others are based on the co-amplification of unknown quantitative target sequence
with a known amount of a competitive template (Hodinka, 1998; Lock et a!.
1997). The assay described in this chapter is based on the nested PCR primers
described in chapter 6 and is designed to be performed in a 96 well plate.
Amplicons are detected by complementary probes that produce a quantifiable
chemiluminescent signal, analogous to an EIA. To determine the viral copy
number external standards are included in the assay that encompass a 51og10
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dynamic range. A variety of samples, including tissue culture material and blood
samples, have been tested and the assay enabled their successful quantification.
7.2 The design of the quantification assay
The PCR-based quantification assay design used here was originally developed for
the quantitative detection of Hepatitis C RNA (Whitby and Garson, 1995). Figure
7.1 illustrates a schematic diagram of this assay, called qPCR (for quantitative
PCR) or ELONA (for Enzyme Linked Oligonucleotide Assay). Its principal can be
applied to any infectious diseases where a quantitative result is required. The
assay can be divided into three stages, the extraction of nucleic acid, the specific
amplification of target sequences and ,finally, detection. Figure 7.1 illustrates the
detection process which includes capture of biotinylated PCR product onto
streptavidin coated plates (1), subsequent denaturing of double stranded DNA (2),
hybridisation of an alkaline phosphatase oligonucleotide probe (3) and finally an
enzymatic reaction which produces a quantifiable chemiluminescent signal (4). A
detailed description of each step is given below.
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Denaturing	 Hybridisation"capture"
(1)	 (2)	 (3)
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LIGHT	 ______ 4
(4)
Figure 7.1: Schematic picture of the KSHV quantification assay. Kindly provided
by Dr K Whitby. B: Biotin; SA: Streptavidin; AP: alkaline phophatase
7.2.1 Extraction of total DNA
KSHV DNA was extracted from each sample using a commercially available
extraction kit (Qiagen, QlAamp blood mini kit). It is important for the successful
amplification of the target sequence to remove potential PCR inhibitors, such as
heparin or hemoglobin. In order to monitor extraction efficiency a known amount
of control DNA (derived from a different virus) may be added to each sample
prior to DNA purification. I-Ierpesvirus saimiri or the murine herpesvirus 68, both
closely related to KSHV, would be an ideal control target. Oligonucleotide
primers have to be designed that co-amplify both viruses, KSHV and the second
gammaherpesvirus, together with subsequent detection procedure to differentiate
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between the two viral species. This method to assess extraction efficiency has
been successfully applied for a hCMV quantitative assay, using murine CMV as
an internal control (Dr W Preiser, personal communication). However, for the
quantification assay presented here this internal control has been omitted, but
could be included with a minor modification of the amplification reactions.
7.2.2 The amplification process
Following DNA extraction, viral DNA is amplified in a single round PCR. To
enable immobilization of the amplification product the 5' end of one of the
oligonucleotide primers has been biotinylated, allowing capture onto a
streptavidin coated plate. The amplification primers, together with the alkaline
phosphatase oligonucleotide probe, were carefully selected from sequence
alignments of all known KSHV. To cover a diversity of samples of different
origin, it is essential to choose amplification target sequences that are well
conserved. The KSHV open reading frame 26 appears to be an ideal choice since
its gene product, the viral minor capsid protein, is well-conserved among the
gammaherpesviruses, displaying 60% amino acid identity (Zong et aL 1997).
Furthermore, 0RF26 has been the subject of several epidemiological and
evolutionary studies, showing that sequence variability in this region is low,
approximately 2% (Moore and Chang, 1995; Zong et a!. 1997). Based on the first
available viral sequences of KSHV, soon after its identification, a nested PCR was
designed by M. Howard in 1997 and was available for this study. In addition, a
hybridisation probe was designed as part of a multiplex assay for the detection of
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all human herpesviruses (M Howard, PhD thesis, 1999; for further details see
chapter 2 and 6 of this thesis). However, since more sequence data was available
to us the oligonucleotide primers were re-evaluated to ascertain whether they
matched the majority of samples. Following BLAST searches, all available
sequence data was aligned and examined for possible mis-matches within the
primer regions. Unfortunately, the published data are restricted to just part of
0RF26, giving alignments covering only the inner primer sites. In consequence,
further analyses focused on this region, as mis-matches that may affect primer
binding of the outer set could not be excluded.
As highlighted by the sequence alignment in figure 7.2, no sequence variation
could be observed between the majority of samples, including sequences derived
from patients with classical KS (CKS), AIDS-associated KS (AKS), endemic KS
(AFR) and PEL cell culture derived material. In contrast, the original alkaline
phosphatase probe showed one variation, highlighted in red. Since this single base
pair polymorphism is located within a l4bp primer, it is unlikely to affect
hybridization reactions. However, it has to be taken in consideration and less
stringent hybridisation conditions may be required.
In summary, the inner set of oligonucleotides are located within a conserved
region and were selected for the amplification of KSHV specific DNA as part of
the quantitative assay.
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7.2.3 The detection process
Once amplicons were immobilized on streptavidin coated microtiter plates, the
DNA was denatured with sodium hydroxide (150 mM) and hybridised with an
alkaline phosphatase conjugated oligonucleotide probe. Following addition of a
dioxetane-based chemiluminescent substrate, Lumiphos (Lumigen Inc.), the
intensity of emitted light was measured by a luminometer (TopCount, Canberra
Packard Inc.). To allow quantification, calibration standards containing a known
amount of KSHV DNA (defined by limit dilution PCR) were included in each
amplification set. These calibrators were serially diluted, as described below, to
cover a range of quantities. The standards were amplified in separate tubes
(external controls) and allowed the establishment of a calibration curve against
which the signal obtained from each sample was plotted.
7.2.4 Data analysis
Optimal quantification is achieved when the viral DNA is exponentially amplified.
Under such conditions the concentration of the amplicon is proportional to the
amount of target sequence originally added and therefore allows accurate
quantification. Briefly, each sample has been analysed in duplicate and the mean
calculated. In the case of poor duplicates (<20% difference) quantification was
repeated. Using the data produced by the calibration standards a calibration curve
('curve of best fit') was generated. Following simple algebraic equations
(interpolation), the viral copy number of the test samples could be determined.
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7.2.5 The calibration standards
Controls (standards) can be either external or internal, depending whether they are
amplified in the same reaction tube as the sample (internal) or separately
(external). In the case of the KSHV quantitative assay, external standards were
prepared from a BCP-I cell culture. As described before, this cell line is singly
infected with KSHV and hence is an ideal calibration standard for the
quantification assay. Cell culture supernatant was collected and total DNA was
extracted from 200p.l aliquots. Total DNA was resuspended in 50tl of nuclease-
free water. The number of viral genomes within these samples was determined by
limiting dilution PCR as detailed in chapter 2. Serial dilutions were prepared at the
limit dilution end point, each set comprising 10 tubes, to obtain a sufficient
frequency of positive and negative amplifications. Reactions were separated by gel
electrophoresis, negatives scored and the copy number calculated. In figure 7.3 the
last two dilutions, 10 and iO respectively, showing amplification are shown.
From these assays we concluded that the selected sample contained a high amount
of viral DNA, 105400 copies per microliter. For the quantification assay seven
standards are prepared, a true negative (no DNA), a second negative that contains
'more or less 0 copies' (10 dilution, 0.1 copies) and four controls that cover a
range of copy numbers. This dilution series was freshly prepared for each test to
avoid possible template DNA degradation. Aliquots of the limit dilution
quantified total DNA were stored at -20°C and one sample used at a time. The
standards described here were used throughout the study and copy numbers were
10540; 1054; 105; 10; 1; 0.1 and water as a negative control respectively.
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Figure 7.3: Endpoint dilution PCR of BCP-1 supernatant (Poisson distribution).
BCP-1 supernatant (200xl) was collected and total DNA extracted. Total DNA was
diluted 1/100 followed by 10 fold dilutions. Viral DNA was amplified by nested PCR
and analysed by 1% agarose gel electrophoresis (for detailed method see chapter 2).
Lane 1-10: 106 dilution
Lane 11-20: i0 7 dilution
M: 1kb DNA marker (Life Technologies)
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7.3 Optimization of the quantitative assay
The PCR conditions and the subsequent detection conditions were optimized
using the calibration standards described above.
7.3.1 The ELONA-PCR
The quantification assay presented in this chapter is based on a 'single round'
PCR (see section 7.2.2 for further details). To avoid non-specific binding of the
probe during the detection step, the amplification of satellite products has to be
minimised. Reaction conditions were optimized using the standards as target
DNA. The polymerase TaqGold (Perkin Elmer) was used, allowing a 'hot start
PCR' (12mm at 95°C). Primer concentrations were assessed and amplicons
examined on a 1% agarose gel. Figure 7.4 illustrates DNA fragments amplified
with (A) 200nM and (B) 500nM final concentration of each primer. The extracted
DNA was serially diluted in water and used for a single round PCR using the PCR
conditions described for the nested PCR, except for the initial denaturing step
which was extended to 12mm at 95°C. As evident from figure 7.4, the higher
concentration of primers resulted in a more prominent amplification, in particular
at lower template concentrations (lane 9 and 10). All subsequent reactions were
therefore performed using 500nM (f.c.) of oligonucleotide primers.
7.3.2 The ELONA
The amplification products were captured onto a microtiter plate and different
concentrations of the detection probe evaluated. Briefly, calibration curves were
similar, though higher concentration of the probe resulted in increased signal
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Figure 7.4: Single round PCR of KSHV calibration standards. DNA derived from
BCP- 1 supernatant was serially diluted as detailed in the text. Following a PCR for 35
cycles amplicons were separated on a 1% agarose gel. Dilution factors are indicated at
the bottom of each lane; M indicates the 1kb ladder.
(A) PCR using 200nM f.c. oligonucleotide primers
Lane 1: 102
Lane 2: iO
Lane 3: iO
Lane 4: iO
Lane 5: 106
Lane 6: iO
(B) PCR using 500nM tic. oligonucleotide primers
Lane 7: 102
Lane 8: lO
Lane 9: 1O
Lane 10: iO
Lane 11: 10
Lane 12: iO
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intensities for negative controls (data not shown). Consequently, a dilution which
produced little background but a high signal for positive samples was used
throughout the study, 1 in 1800 (2.7nM f.c).
7.3.3 The optimal combination of PCR and ELONA
Following PCR and probe optimization, cycle conditions were assessed. The aim
was to establish a system that identified low viral copy numbers, rather than high
copy numbers. For this, the most important distinction was that between the
'likely negative' (<1 copy) sample and the last positive sample (1 copy). As a
consequence 35 and 38 cycles of amplification were compared. The assay was
performed as detailed in chapter 2 and data analysed using the computer software
Genesis. Both calibration curves are shown in figure 7.5. Triangles represent each
duplicate. With the increase in cycle numbers the assay changed its dynamic
range. More cycles of amplification result in a more accurate 'bottom end', but
higher amounts of input DNA enter the plateau phase, making it difficult to
distinguish between higher viral load samples. In contrast, fewer cycles produced
a reversed situation, favoring discrimination between higher copy numbers. For
research purposes, studying KSHV reactivation or drug susceptibility, an assay
quantifying low copy numbers appeared to be more valuable. Thus, in the
following series of experiments all samples were amplified in a 38 cycle PCR,
using 500mM (f.c.) of oligonucleotides primers.
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Figure 7.5: Calibration curves after optimization of the PCR cycle number.
KSHV calibration standards were amplified by non-nested PCR and genome copy
numbers determined by ELONA as detailed in the text. Calibration samples were
analysed in duplicates. Each value is indicated by a triangle.
(A) 35 cycles of amplification
(B) 38 cycles of amplification
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7.4 Quantification of a variety of samples, including whole blood,
plasma, and tissue culture material
Once the viral DNA standards had been optimized and the assay could be
consistently reproduced, samples that were positive and negative by nested PCR
were tested. These included tissue culture samples obtained as part of the HepG2
infection study (see chapter 6) and EDTA-blood, plasma and serum samples from
HI V-infected individuals with and without KS were tested.
The EDTA-blood was separated by centrifugation and the plasma collected and
replaced by an equal volume of PBS (reconstituted blood). All serum samples
were obtained as frozen aliquots from UCH diagnostic service. Total DNA was
purified from 2OOtl aliquots of all samples using a commercial extraction kit (see
chapter 2). The DNA was diluted in 50pJ of nuclease-free water and 1tl (tissue
culture material) or lOpi were analysed by quantitative PCR.
7.4.1 Tissue culture material
Chapter 6 describes the infection of HepG2 cells with different amounts of KSHV
inoculum. Samples were collected over a period of time and analysed by nested
PCR for the presence of viral DNA. These samples were expected to contain a
high amount of virus as judged by the intensity of the nested PCR amplicon (see
chapter 6). Several samples were selected, including different HepG2 cells
inoculated with different dilutions of the viral DNA, and re-tested using the
quantification assay. Copy numbers within each sample are demonstrated in figure
7.6. together with a gel picture of the single round PCR products.
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Figure 7.6: KSHV quantitative analyses of HepG2 cell culture samples. Cell culture
supernatant from HepG2 cells inoculated with KSHV were collected 7 days post-
Infection as described in chapter 6. Total DNA was extracted and tested by qPCR.
Each number represents the mean of 2 duplicate determinants. Undiluted SY
supernatant (SY) was also analysed, but the genome copy number was out of range for
this assay, therefore only the amplification product is shown.
(A) 1% agarose gel showing the 172bp amplicons.
(B) Calculated copy numbers per microliter of extracted DNA, detected in tissue
culture samples derived from KSIIV infected HepG2 cell cultures.
S: supernatant; W: wash; C: cell lysate; neg: negative; M: 1kb marker. Numbers on top
of each lane refer to the initial KSHV inoculum.
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The figure (panel B) of the viral copy numbers shows a decrease in viral DNA
across each set of samples, concomitant with the band intensity shown in panel A.
This confirms that HepG2 cells were exposed to serial dilutions of the viral
inoculum. The number of copies within the inoculum is indicated above each lane
in panel A. This demonstrates that this assay is able to quantify viral load in tissue
culture samples and that the amount of viral genomes calculated roughly
corresponds to the band intensity of the PCR. In summary, the ELONA produced
reliable results and may support further infection studies.
Samples with higher loads of virus, e.g. supernatant derived from SY cells were
also tested and produced a signal that was outside the dynamic range of this assay
(data not shown). This result is unsurprising as the calibration standards were
based on viral DNA derived from tissue culture material. To quantify SY
supematant or other high titer samples a dilution series would be necessary.
7.4.2 Whole blood, separated plasma and serum
In a similar assay to that described above, blood samples obtained from three KS
positive patients were tested by both nested and quantitative PCR (qPCR). Serum
samples from the same patients, but taken at a different time point than the blood
samples, were also analysed by qPCR. Following DNA extraction from plasma,
whole blood and serum samples, KSHV viral load was quantified. The genome
copy numbers obtained are shown in figure 7.7, together with a photograph of the
nested PCR products.
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Figure 7.7: KSHV viral load in blood samples obtained from individuals with
AIDS-associated KS. Total DNA was extracted from reconstituted blood (Blood),
EDTA-plasma and serum samples. One or ten microliters of total DNA were
analysed by nested and quantitative PCR. Each number represents the mean of
duplicate determinants.
(A) Nested PCR of patient sample 1, 1 and lOp.l are indicated; M: 1kb DNA
marker. Lane 1 and 2: EDTA-blood; lane 3 and 4: EDTA-plasma; lane 5: positive
control (BCP- 1 supernatant).
(B) Quantification of blood samples from patient 1 and 3.
298
Unfortunately, only two sets of samples were positive for KSHV by nested and
quantitative PCR, regardless of the DNA input amount. Although KS was
diagnosed in patient 2, KSHV could not be detected by nested PCR in any sample.
KSHV viral load within the nested PCR positive samples (patients 1 and 3) was
subsequently determined and the data indicated that KSHV was more abundant in
plasma (panel B, black bar) and whole blood (white bar) than in serum (shaded
bar). This corresponds to reports for other viruses, e.g. HIV RNA, where the
genome cannot be detected as efficiently in serum than in plasma or whole blood
(Semple et aL 1991). Furthermore, these serum samples had been freeze/thawed
several times and hence may not represent the initial viral load after sampling.
However, this study does demonstrate that KSHV can be found in blood, in
particular in plasma, and to a limited amount in serum samples, from individuals
with KS. Further studies, including a greater number of samples and plasma/serum
pairs taken at the same time point will be necessary to investigate the association
between plasma and serum viral load and are ongoing.
7.4.3 Plasma samples and serum samples from a KS cohort
Our initial series of experiments showed that KSHV viral load can be estimated
using plasma samples. We were interested in testing samples to examine the
association of viral load and antibody titer within KS patients as part of a
collaboration with Dr C Boshoff (Molecular Pathology). To do this, further
plasma and corresponding serum samples were tested. A total of 50 pairs of
plasma and serum samples were selected from a cohort of HIV-infected
individuals with unknown KS status to investigate viral load within both types of
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samples. The majority of this cohort included mainly homosexual men with less
than 5% HI V-infected women. These samples had been stored for some time at -
80°C and may have been freeze/thawed a number of times.
Epidemiological studies showed that KSHV is more prevalent in I-IIV-infected
individuals than in the general population, therefore a proportion of these samples
was expected to be positive. Since KS had not been diagnosed within these
patients at the time of sampling, the viral titer was expected to be low, when
detectable at all. Total DNA was extracted from each sample as described before,
lOp.l applied to a single round PCR and KSHV viral load quantified. Firstly, the
plasma samples were tested by qPCR for KSHV DNA as described above.
Subsequently, the corresponding serum samples for the KSHV positive plasma
samples were also quantified. These data are summarized in figure 7.8.
Only 5 plasma samples (10%) were positive for KSHV DNA, with less than 1000
copies per ml of plasma. This data agrees with previous epidemiological studies
where the virus has been described to be present in 5-30% of HIV-infected gay
men. In contrast, corresponding serum samples did not reflect a similar viral
frequency, KSHV being found in only one sample, containing -50 copies per ml.
This indicates that the detection of KSHV is relatively unreliable in serum
samples, though the virus can be identified in plasma samples. Viral particles
present in serum samples are more often subject to degradation, viral genomes
seem to be more stable when stored as plasma, in particular EDTA-plasma (P.
Grant; personal communication). It is possible that the EDTA present in plasma
samples acts as a nucleic acid 'preservative' by chelating Mg 2 from the sample
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and hence inactivating nucleases. From this experiments we may conclude that
studies of KSHV incidence and quantity using only serum samples could not be
performed. However, the KSHV quantification assay presented in this chapter can
be successfully used to investigate in more detail epidemiological as well as other
aspects that are relevant for KSHV pathogenesis.
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Figure 7.8: KSHV viral load in plasma and corresponding serum samples from
HI V-positive individuals without a history of KS. A total of 50 patients was
analysed by qPCR as detailed in the text. Samples were obtained from a cohort of
HI V-infected individuals, including homosexual men and less than 5% women.
(A) Positive plasma samples and viral loads
(B) Serum samples corresponding to positive plasma samples and viral loads
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7.5 Summary and Discussion
Serological findings indicate that KSHV infection is rare in the general population
but significantly higher in certain risk groups, including areas where KS is
endemic, HI V-infected individuals (in particular homosexual men) and
immunosuppressed patients. Little is yet known about the primary infection or the
exact route of transmission of KSHV. Epidemiological studies imply sexual
transmission, as HIV-infected homosexual men appear to be at high risk for
developing KS. In contrast, in areas with endemic KS many children are infected
indicating infection during childhood. Detailed analyses of KSHV transmission
and primary as well as secondary infections have been restricted to serological
methods or qualitative PCR. So far there is limited data available that investigated
viral load and disease association. The development of a reliable quantification
assay would greatly support such studies. For example in HIV research
quantitative analyses of viral load has been widely applied and hence allowed
further insight into the pathogenesis of the virus, in particular demonstrating the
association of plasma viral load with disease stage (Ho et a!. 1989; Semple et a!.
1991). The detection of high levels of HIV-1 RNA in PBMCs or plasma correlated
with disease stage. Lower titers of HIV-1 could be found in asymptomatic
patients, whereas symptomatic patients contained higher viral loads. Similarly, in
EBV-associated disease EBV DNA could be detected more frequently and at
higher levels during the acute phase of the illness (Yamamoto et aL 1995).
Recently, KSHV viral load has been determined in PBMCs from HIV-infected
individuals. The study revealed that high amounts of KSHV are a predictor of KS
development (Mm and Katzenstein, 1999). Similarly, in organ transplant patients,
302
increased levels of KSHV in peripheral blood lymphocytes have been associated
with the development of KS (Mendez et a!. 1999). There are several clinically
relevant aspects that would greatly benefit from the development of a KSHV
quantitative assay, such as monitoring disease progression as well as anti-
retroviral therapy and assessing the risk of perinatal transmission. The latter may
be more relevant for areas where KS is endemic as there is evidence that KS may
be transmitted from mother to child (Angeloni et al. 1998).
The KSHV qPCR presented in this chapter is designed to analyse a variety of
different sample material within a short period of time. This allows studies into
viral load in wide population cohorts. The 96-well microtiter format supports the
simultaneous analyses of a very large number of samples, making it attractive for
epidemiological research purposes. The assay has been tested successfully using
different sample material, including tissue culture samples, whole blood, human
plasma and serum. Testing matching plasma and serum samples from HIV -
infected individuals, we noted that KSHV could be detected more consistently in
plasma samples and whole blood. This has been previously reported when testing
PBMCs and plasma from KS patients, PCR detection demonstrated that KSHV
sequences found in PBMCs correlated with the level found in plasma (Harrington
ci al. 1996). In our study plasma was the most successful PCR template which led
us to test a small cohort of samples obtained from HI V-infected patients without
KS. The cohort included both women (<4%) and gay men. Overall, 5/50 patients
were identified to contain KSHV in their plasma. This correlates with the sero-
prevalence being elevated within this risk group (20-25%) (Gao eta!. 1996;
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Simpson et a!. 1996; Chatlynne and Ablashi, 1999; Martin et al. 1998). In
particular homosexual men show high rates of anti-KSHV antibodies in contrast to
HI V-infected women, where approximately 4% contain serum antibodies (Kedes
et a!. 1997; Lennette et a!. 1996). In our study only 10% of the EDTA-plasma
samples were positive for KSHV, which may have been due to the selection of
men and women for this study. KSHV appears to be sexually transmitted and
studies showed that the number of homosexual intercourse correlates with an
elevated risk for KS in Europe (Melbye et al. 1998). Since there was no detailed
data about the sexual behavior of this cohort available we cannot exclude that this
aspect may have an influence on the low detection rate reported in this chapter.
However, when we analysed the corresponding serum samples, the virus could not
be found in most of the samples, indicating that serum is a poor sample source for
KSI-IV viral load testing. Several studies examining the stability of other viruses,
such as HIV-I or HCMV have shown that the viral genome can be more
frequently found in cell-free plasma than in serum samples (Holodniy et a!. 1995;
Ginocchio et a!. 1997).
Several localization studies indicated that KSHV is harbored in PBMCs and
testing of whole blood may be indicated (LaDuca eta!. 1998; Rizzieri eta!. 1997);
Harrington et a!. 1996). We detected KSHV with almost the same frequency in
whole blood and plasma, concluding that both sample source can be used in viral
load studies. However, larger population-based studies would be required to
identi1' the test material of choice and to introduce this assay into routine
diagnostic testing.
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Clinically a KSHV quantification assay has applications for the diagnosis and
management of individuals with KS as well as individuals that are HIV positive
without KS. Studies showed that the detection of KSHV in the blood of HIV-
infected individuals is a predictor for the development of KS (Kennedy ci al.
1998; Gao ci a!. 1996; Moore et a!. 1996b; Whitby et a!. 1995). Early detection
would allow efficient treatment and the possibility to prevent the development of
KS. This would be desirable, as KS is the most common neoplasm in AIDS
patients. Furthermore, using this assay KSHV viral load can be monitored in
response to highly active anti-retroviral therapy (HAART) and may help in
identifying effective treatment procedures.
Besides clinical applications viral load analyses can support investigating the
transmission route of KSHV. As mentioned before (see chapter 1), in Africa
KSHV can be found with a high frequency in children and therefore may be
transmitted from mother to child (Angeloni ci a!. 1998). Serological studies using
serum sample pairs from mothers and children suggest that high antibody titer
correlate with high viral load and therefore indicate transmission from mother to
child (Bourboulia ci a!. 1998). However, whether high titer of KSHV antibodies
correlate with high viral load is contradictory (Campbell and Borok, 1999) and
requires more detailed studies using a reliable quantification assay.
However, the data presented in this chapter indicates that this quantification assay
is able to determine KSHV viral load within a variety of samples. Further studies
comparing this qPCR assay to other existing quantification assays, such as limit
dilution/Poisson distribution, semi-quantitative or TaqMan based assays are
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necessary to compare the assays' sensitivity. Finally the introduction of an internal
control has to be considered to monitor DNA extraction efficiency. Nevertheless,
this type of assay has been successfully applied in the past to quantify other viral
infections, and from the data presented here it is most likely to be beneficial for
KSI-IV research as well as diagnostic purposes. The very broad dynamic range, 4
to 5 log 10, is able to encompass a wide viral load range and will assist in
examining different viraemia levels within KS patients, risk groups, general
populations or individuals with KS undergoing anti-viral therapy. Using this assay
a number of studies addressing epidemiological and molecular aspects of KSHV,
can be performed.
306
8. Final Conclusions
The newly identified herpesvirus KSHV (HHV8) is associated with Kaposi's
sarcoma and the lymphoproliferative disorders primary effusion lymphoma and
multicentric Castleman's disease. KSHV is unique within the herpesviral family
as it encodes an exceptional large number of proteins with homology to cell cycle
regulatory proteins and inflammatory cytokines. Some of these cellular proteins as
well as their viral counterparts, have been shown to exhibit oncogenic properties
and hence may play an important role in tumorgenesis. Before KSHV was
identified studies showed KS to be highly associated with inflammatory cytokines,
which support the growth of the spindle cells characteristic of a KS lesion (Ensoli
et a!. 1992; Ensoli et a!. 1989). These findings, and the repertoire of KSHV
encoded cytokines, suggest that KSHV is at least a co-factor in the pathogenesis of
KS. Furthermore, epidemiological studies support the hypothesis that KSHV is the
most likely causative agent of KS. Within the general population the sero-
prevalence is low, compared to the sero-prevalence within risk groups
(Mediterranean Europe, Africa, HIV-infected homo- and bisexual men and
immunosuppressed individuals) where KSHV can be found more frequently (Gao
et a!. 1996; Kedes et al. 1996; Simpson et a!. 1996; Calabro et a!. 1998; Lennette et
aL1996; Chandran et al.1998). In addition to epidemiological studies, several
investigations have concentrated on the in-vitro characterization of KSHV ORFs
that may exhibit oncogenic properties. Several viral proteins have been
demonstrated to influence tumor suppressor pathways (0RF72; v-cyc) as well as
other cell signaling pathways (0RF74; vGPCR), inhibit apoptosis (ORFI6; vbcl-
2) or induce cell transformation (ORFKI). By acting in concert and forming a
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complex cascade, these viral proteins could play a key role in the development of
uncontrolled cell growth. However to date the data is limited to recombinant
expression of isolated genes and has not yet been confirmed by in-vitro viral
infection studies. In addition, little is known about the viral entry mechanism and
the envelope glycoproteins of KSHV. KSHV glycoprotein B (gB) has been
recently described and analysis of the intracellular processing and expression of
this viral protein has revealed similar structural features to previously
characterized herpesviral gB, in particular EBV gpl 10. However, this study also
showed that there are functional differences. Although KSHV gB and EBV gpl 10
can form hybrids, KSHV gB was unable to complement gpl 10-negative EBV
mutants (Pertel et al. 1998). Besides KSHV gB, no other surface glycoprotein has
been analysed so far. Studies into virus-host cell interactions have been limited,
which may have been due to the lack of a de nova infection system for KSHV.
From PCR and in-situ analysis of a variety of different cells it is clear that the KS-
typical spindle cells harbor KSHV as do PBMCs and monocytes (Boshoff et
al.1995; Blasig et al.1997). However, which cell in particular is targeted by the
virus is unknown. Recently, endothelial cell tines have been successfully infected
with KSHV long-term, indicating the presence of receptor molecules (Moses et at.
1999). Several aspects of KSHV have been addressed in this project, all
contributing in their own terms to a better understanding of viral pathogenesis.
The main objective of this project was to characterize certain KSHV envelope
glycoproteins and possibly examine cell surface interactions with host cells. In
addition a target cell line has been identified that is semi-permissive for KSHV
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which implies that the virus exhibits a relatively broad cell tropism. Finally, an
assay has been established that allows the rapid quantification of KSHV and may
contribute to epidemiological as well as molecular questions.
8.1 KSHV 0RF22/gH and 0RF47/gL, two tricky proteins
Soon after the identification of KSHV, a small subset of the viral genome was
available, including the open reading frames encoding the tegument protein,
thymidine kinase, glycoprotein H and the major and minor capsid proteins. To
study possible viral interactions with the host cell 0RF22, predicted to encode
glycoprotein H, appeared to be a reasonable choice. Considering the well
described association of gH with gL in other herpesviruses, the KSHV gL
homologue was included in the study. Herpesviral gH and gL mediate cell to cell
fusion and are described to contribute to viral penetration into the host cell. The
exact mechanism is unknown, although gH is believed to play the key role in
fusion events, whereas gL appears as a chaperone that influences gH processing
and transport to the cell surface. Thus, this protein family would be ideal to
examine viral interactions with the cell surface. However, the recombinant
expression of both proteins was unexpectedly complicated and made receptor
studies impossible within the given time frame. However, basic characteristics of
KSHV glycoprotein L could be identified. The data presented here indicates that
KSHV gL has a similar pattern of intracellular localization as the gL homologs
encoded by EBV or HCMV. The recombinant protein was predominantly found in
the cytoplasm, most likely retained in the ER and the nuclear membrane.
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Interestingly, unlike its homologs, there is evidence that KSHV gL expressed in
the epithelial cell line 293HEK and in the fibroblast cell line Cos7 may induce cell
to cell fusion. Overall, data from dual labeling studies and western blot analyses
indicate that multinucleated cells contain an elevated amount of soluble and
processed KSHV gL. This observation further indicates that gL appears to induce
fusion when recombinantly expressed in 293HEK or Cos7 cells. Although more
definitive localization studies are required to confirm our observations, the current
data suggests that KSI-IV gL itself contributes to cellular fusion, contradictory to
the general opinion that gH is the major factor in the fusion process. However, we
cannot exclude that the formation of multinucleated cells was due to over
expression of the protein rather than a fusogenic epitope. In addition, the lack of a
direct detection system for recombinant KSHV 0RF22/gl-1 made detailed studies
difficult. We were unable to distinguish gH in co-expression studies and therefore
syncytia formation in dually transfected cells may have been induced by gL alone,
instead of the gH/gL complex, as seen in other herpesviruses. For further studies
the use of monoclonal antibodies or different protein tags are advisable to examine
the intracellular distribution of 0RF22/gH. Distinct surface expression in cells co-
transfected with KSHV gH and gL could not be observed, only minor changes in
the localization pattern of the fluorescent signal were detected. Further studies
analysing the co-localization of Golgi and gL expression in co-transfected cells
were unsuccessful. However, these particular studies were limited as the
expression level was low and the altered intracellular distribution pattern itself
was restricted to a minority of cells. As mentioned above several studies will be
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required to confirm the data presented, in particular the expression of KSHV gH
has yet to be studied in detail.
As the butyrate induction studies revealed higher expression, it is likely that both
proteins exhibit toxicity. Perhaps a vector system where the protein production can
be controlled will assist in studying recombinant expression in more detail, as
possible toxic effects by the recombinant protein could be prevented. The
production of monoclonal antibodies would also simplify the detection process
and will allow more detailed analyses of the recombinant protein, including
epitope mapping. In summary, these basic studies show that the expression pattern
of both proteins is complex and that different vector systems may be useful to
further analyse KSHV gH and gL. To conclude, although the examination of
possible viral-host cell interactions could not be completed, KSHV gL appears to
have some influence in the fusion process, which suggests that more
investigations should concentrate on this protein's properties.
Apart from gH/gL a third protein may be required that allows authentic complex
formation. With the description of a third viral component associating with the
gH/gL complex in EBV and HCMV, the possibility that the recombinant
expression of KSHV gil and gL similarly depends on another viral protein cannot
be ruled out and should be addressed in future. Monoclonal antibodies specific for
gH or gL, when available, can assist in precipitating the gH/gL complex from PEL
cell lines and will give insights into the processing of these two viral
glycoproteins.
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8.2 KSHV, EBV and the liver?
B cell lines derived from primary effusion lymphomas are mostly co infected with
KSHV and EBV. Analyses of the expression pattern of EBV revealed that these
cells express EBNA I and to a lower level LMP I, whereas essential latent antigens
which are usually expressed in lymphoblastoid cell lines could not be detected
(Horenstein et a!. 1997). This indicates that KSHV has some influence on EBV
expression either directly, or indirectly by inducing cellular proteins which then
regulate the EBV latency expression pattern. As part of this project the hepatoma
cell line HepG2 was inoculated with KSI-IV, susceptibility to KSHV could be
increased when using supernatant from an EBV/KSI-IV dually infected B cell line.
HepG2 cells are the first epithelial cell line that can be dually infected with KSHV
and EBV. KSHV infection was associated with cytotoxicity, indicating possible
viral replication. Unfortunately, KSHV replication could not be demonstrated and
a long-term culture system could not be established, possibly as a result of
enhanced cytotoxicity. Apoptosis has been observed in B cell lines infected with
KSHV that have been established from patients with PEL. These cell lines tend to
exhibit a necrotic phenotype in culture unless they are co-cultured with a feeder-
layer cell line, such as HEL cells. This indicates that the HEL cells produce
factor(s) that influence the ability of KSHV to induce apoptosis. The nature of this
factor remains to be established. KSHV encodes two proteins that have been
demonstrated to inhibit apoptosis, vbcl-I and vFLIP (see chapter 1). However,
both proteins are expressed during latency, although vbcl-2 only at low levels
(Sand et a!. 1997), and may under certain circumstances, such as in vitro cell
culture conditions or cell-type specific conditions, induce rather then inhibit
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apoptosis. Identil'ing the factor(s) produced by the feeder-layer that influences
PEL cell growth could be important in the understanding of the association
between KSHV and apoptosis as well as in facilitating the growth of these
particular cell lines and possibly other culture systems.
Several factors have been demonstrated to influence KSHV replication, such as
chemical stimuli and viral proteins. Recently, it has been shown that infection of a
KSHV infected PEL cell line with HIV resulted in the induction of lytic KSHV
replication and enhanced transmission of KSI-IV to uninfected target cells (293
cells) (Varthakavi et al.1999). Furthermore a soluble factor has been shown to
stimulate KSHV lytic replication in this system, but its identity remains to be
defined. Early reports examining the association of KSHV and HIV showed that
the HIV transactivator protein, Tat , can activate KSHV replication in PBMCs
from KS individuals (Harrington et al.1997). Overall, these data indicate that
KSHV is able to interact with other viruses. However, the mechanism behind this
interaction is far from understood. It is most likely that KSHV and EBV also
interact, since co-infected B cells have been found regularly in PEL. Interestingly,
KSHV encodes proteins that are similar to the cellular proteins induced after EBV
infection, e.g. v-cyc and cellular D-type cyclin. This may indicate a link between
these two viruses, with EBV regulating the expression of KSHV genes or the
reverse. Our transient culture system may assist in studying these questions further
using an epithelial cell line rather than B cells. Although further studies are
required to explore the EBV and KSHV expression pattern, HepG2 cells have
been clearly shown to be semi-permissive for KSHV, suggesting viral-host cell
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interactions. So far KSHV has not been associated with liver-derived cells.
Therefore to study the impact that KSHV infection may have on the HepG2 cell
life cycle is interesting and may provide further insights into KSHV cell tropism.
It is also possible that like EBV KSHV is associated with liver disease.
Although KSHV expression could not be demonstrated in HepG2 cells other
procedures such as flow cytometry may detect low expression levels of different
viral antigens. Also the analysis of cytokine levels within infected cultures may
assist in characterizing KSHV infection in more detail.
In summary the HepG2 culture system allows studies into the interaction of
KSHV and EBV as well as KSHV infection alone of a liver cell line with liver
specific functions. Furthermore, HepG2 cells may also allow expression studies of
KSHV gL and gH to investigate their functional properties and allow
investigations into possible surface receptor(s) for KSHV.
8.3 The impact of a quantification assay
Since the identification of KSHV several serological assays have been developed
that vary in their sensitivity (see chapterl). Initially we were interested to evaluate
whether recombinant gH and gL could be included in such serological assay
system. This idea was soon dismissed in favor of a quantification assay based on
PCR amplification. The assay presented shares its design with other assays for the
quantification of HIV, HCV and HCMV, indicating its ability to allow reliable
quantification. The assay was modified to our purposes and several samples were
tested to evaluate its ability to quantif' KSHV. Using samples from a small cohort
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of 50 patients infected with HIV we demonstrated that 10% of the patients
exhibited detectable viral titers. This corresponds to the prevalence of KSHV
found by others when tested individuals with HIV but without KS (Gao et
a!. 1996; Kedes et a!. 1996; Martin et a!. 1998; Blackbourn et a!. 1999). Though we
only tested a limited number of samples, the data described here suggests that the
test can be used for further studies into the biology of KSHV. Indeed, this assay is
now being evaluated to assist studies of KSHV lytic replication and for inclusion
in diagnostic testing.
Viral quantification can be applied both diagnostically and for research purposes.
Measuring viral load within a patient can assist in monitoring disease progression
or the impact of anti-viral therapy. In drug development this assay can be used to
identif' the potency of a particular drug. Furthermore, quantification can be used
as a prognostic marker for disease development or for the detection of herpesviral
reactivation. There are a number of examples where quantitative methods have
been successfully applied and provided an insight into the association of viral
replication and disease progression, in particular in HIV research (Berger et
a!. 1997; Yamamoto et a!. 1995).
For KSHV specifically such an assay can support investigations of viral load and
the development of KS. KS is the most common neoplasm in individuals with
AIDS (Ensoli et a!. 1991; Beral et a!. 1990). Studies using qualitative PCR have
shown that the presence of KSHV in HIV-infected individuals predicts KS
development (Whitby el a!. 1995). Furthermore, 20-35% of homosexual or
bisexual men with AIDS are KSHV infected, compared to approximately 3% of
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the general population (Gao et a!. 1996; Kedes et a!. 1996; Martin et a!. 1998;
Blackboum et a!. 1999; Simpson et a!. 1996). It is therefore likely that KSHV is
involved in KS pathogenesis. Monitoring patients at risk for KS would allow early
responses as soon as an increase in viral load was detected and may achieve a
decline in HI V-associated KS in the future.
Analysing KSHV viral replication, and the influence that various factors may have
on it, can also be analysed conveniently with such an assay. A whole range of
studies would benefit from this assay; viral gene expression can be reliably
associated with viral load estimates or immunological responses such as antibody
production, furthermore seroconversion and viral load can be examined.
In summary, we have established an assay that can address a variety of questions
concerning KSHV reactivation, drug susceptibility, disease association and
epidemiology.
To conclude KSI-IV is most likely to play an important role in the development of
KS and PEL. Studying viral host-cell interactions offers the opportunity to
identit' new therapeutic targets that may lead to successful treatment or even
vaccine development. KSI-IV is unique as it encodes for a large number of
oncogenes, that allow to not only study viral pathogenesis but also to gain further
information about the cell cycle regulation and angiogenesis. This thesis includes
studies of several aspects of KSI-IV which can be the basis of more detailed
characterizations of molecular entry mechanism and may help in identif'ing target
cells. HepG2 cells appear to be susceptible to KSHV infection and may support
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studies into the interaction of related viruses within one cell. Finally, an assay that
is beneficial for both in depth epidemiological studies as well as diagnostic testing
has been established as part of this thesis.
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Solutions and Buffer
1 OxTris-Sal i ne
8.5% NaCI; 0.05% Tween-20
50x Tris Acetate EDTA (TAE), pH 8.1
242g/I Tris base; 57.lml/l glacial acetic acid; 37.2g/l EDTA,
Tris-EDTA (TE)
1mM EDTA; 10mM Iris-Cl, pH 8
PBS
150mM NaCI; 15mM KH,PO4; 63mM Na2 HPO4xH 2O; 26mM KCI; pH 7.2
Lysis buffer I (Iriton-X-lOO lysis buffer)
50mM Iris-HCI, pH 7.5; 140mM NaCI; 1% Triton-X-l00, 1mM PMSF
Lysis buffer II (SDS-lysis buffer)
50mM Iris-HCI, p1-16.8, 2% SDS
Flow cytometry
PBSFCSAzIde
PBS; 1% FCS; 0.05% sodium azide
Western Blot analyses
Towbin Transfer Buffer
25mM Iris, 192mM glycine, 20% methanol, 0.1% SDS, pH 8.3
TBSTT
20mM Tris-Cl; 500mM NaCI; (pH 7.5); 0.2% (v/v) Iween-20;
0.3% (w/v) Triton-X-100
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Tris-Marvel
20mM Tris-CI; 500mM NaCI; (pH 7.5); 5% Marvel; 0.3% (v/v) Tween-20
Tris-Casein
20mM Tris-Cl; 500mM NaCI; (pH 7.5); 1% Casein; 0.3% (v/v) Tween-20
Tris-BSA
20mM Tris-CI; 500mM NaCI; (pH 7.5); 2% BSA; 0.2% (v/v) Tween-20; 10% FCS;
5% Normal goat serum
Tris-NGS
20mM Tris-CI; 500mM NaCI; (pH 7.5); 10% Marvel; 0.2% (v/v) Tween-20; 10%
Normal goat serum; 5% FCS
ELA
EIA blocking buffer
6% BSA/0.05% Tween-20 in 20mM Tris/Azide
TMTFCS
4% low fat milk powder; 0.5% Tween-20; 20%; FCS in I xTBS
TMFGT
20% Goat Serum, 4% Marvel, 0.5% Tween-20 in Tris buffered saline
PCR and Cloning
lOxAnnealing buffer
200mM Tris-CI, pH 8.4; 500mM KCI; 15mM MgCl2
lOxExpand PCR reaction buffer
500mM Tris-CI, pH 9.2; 160mM (N1-1 4)2SO4; 22.5mM MgCI,; 20%(v/v) DMSO;
I %(v/v) Tween-20
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I OxUniversal buffer
IM KOAc; 250mM Tris-Acetate, pH 7.6; 100mM MgOAc; 5mM 13-mercaptoethanol;
I00tgIml BSA
Buffer I-I
50mM Tris-HCI, 10mM Mgcl 2, 100mM NaCl, 1mM Dithioerythritol, pH 7.5
lOxLigase buffer
300mM Tris-CI, p!-1 7.8; 100mM; MgCl 2 ; 100mM DT'T; 5mM dATP
SDS-PAGE
lOxPage buffer
25mM Tris-CI; 192mM glycine; 0.1% SDS
Sample buffer (Laemmli buffer)
l.43M beta mercaptoethanol; 125mM Tris-Cl, pH 6.8; 20% glycerol; 6% SDS;
0.004% bromphenolblue
Coomassie blue solution
0.25g Coomassie brilliant blue; 45% methanol; 10% glacial acetic acid; 45% water
Destaining solution
10% acetic acid; 40% methanol; 50% water
Blue Cell Assay
Blue cell assay staining solution
3mM Potassiumhexacyano(l l)ferrat; 3mM Potassiumhexacyano(I I l)ferrat; I mM
MgCl2
X-Gal
0.Smg/p.l X-Gal stock solution, diluted in staining solution to a final concentration of
5p.gperjJ
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Agarose gel electrophoresis
1kb DNA Marker (Life Technologies)
20.tl 1kb marker; diluted 200j.tl of TE and 8Op.l of loading dye
lOxLoading dye
40% sucrose; 0.1% orange G
Sequencing
l0xTrisBorateEDTA (TBE)
108 gIL Tris base, 55 gIL boric acid, 9.3 gIL EDTA, adjusted to pH 8.3
Quantitative Assay
I Ox1TA
50m1 Tween-20, I OmI Azide in I 000ml of I M Tris-CI
Sample diluent
5% (v/v) Casein blocking buffer (Genesis, Ltd.); 0.5% (v/v) Tween-20 in PBS
Probe diluent
5% (v/v) Casein blocking buffer (Genesis, Ltd.); 0.5% (v/v) Tween-20 in 2OxSSC
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Bacterial growth medium and cell culture medium
Luria-Bertani (LB) (for I000mi)
I Og bacto-tryptone, 5g bacto-yeast extract, I Og NaCI
Ampicillin stock solution
100mg/mi ampicillin in water, stored at -20°C
Complete medium DMEM
Dulbecco's Modified Eagle's Medium, 10% FCS, 5mM L-glutamine, iOOU/mi
penecil I in, I 00g/m I streptomycin, 0.075% sodium bicarbonate
Complete medium RPMI,
Dulbecco's Modified Eagle's Medium, 10% FCS, 5mM L-glutamine, IOOU/ml
penecillin, 100ig/ml streptomycin, 0.075% sodium bicarbonate
Selection medium, neomycin
Complete media supplemented with 500mg/mi geneticine
Selection medium, zeocin
Complete media supplemented with 200JLg/ml zeocin
Freezing Medium
10% DMSO, 40% FCS, 50% DMEM/RPMI
PB S/EDTA
25mM EDTA in PBS
356
Appendix II
357
0z0
a)
--
4-4 0
0-
a)
.
U,
UI
-0<0
	
-	 I-
	
U)	 bO
a)
U)
a)
E
- bO 0
U)
CnV)
a)
	
.	 a)
;,' U)
a)0
. •0Q Q+.
-a) c
> U)
'-, — a)
z
U a)
C)
•'; bO C
a)U)
.-
liD 
o •,
-. a.-0 >I-.- C)
>-.. a)
-
I- bO
z
8	 C)
w
-	 0
E >s
i	 0)
0.
0 - I	 E
0
'6	 oO. 0.
Nt-.
U)
(I)
I-	C
-
:	
0
0.	 1
E	 w
U)
0
C
U)
U)
U)I-
C
0
>'
E
0
II)
z
358
=•00
a)
C)
U0
C)
Cd,
I- >
C) -
C)0)	 .
—C
C) . -
5 .
I-.
o o
0
C) C.)
—I
U) ..
-C)
I-
0
-
0. 0.
0);	 -
.	 cz
.-C0).0.
0) -.C)C) C)
C)C)0	 0
a)
a)
Cd,	 —
1
0)	
—	 >
-	 =
=
-
z
C)0.
0
-
a)
t
a)
Cd,0
C
a)
E
C
-C
I
359
en
C
0
a-
E
'U
.-. V
I
'U
0
'1)
D•
'U20
O'U0 .
0
liD u
f_._. 
'U
°
.9
0)
+	 0) i-
- 0)
C)
'4- 0
-	
.	 C'
0)
C,, C'
—
— 0)
o	 0)
4— 4-0
0)
—
cV
.CI
-	 .O
Hu,..,
.	 ;-.
<00
-
0
,- 0 C
'4-
0)
o >- 04-
0 C)
C
- 0) —
o
C/D
U'
I-.
0)
cJ	 —
I-
U)
—	 U)0	
C)E
c2
a-
I	
>.
C
I-0
w
00
0)I.-0
4-'0
E0
a-
>C/)
01)0
CD
Co
ci)I.-
C
0
>'
E0U)
z
360
0)
a)
o	 0
C
Lu
.5
0
0
0.
E
ci:
a)
(1)
C)C
I-
0
E
0
I-
c.
N
0.
I
(9
C
0)
0
a)
0
E0
I-0.
0
C,)0
a)
0
E a)C)C
a)
(I)
Ci,
.3)
C
C)
0
a)
N
U)
a)
C)
a)
U)
0
::4
—. 0
— -a0..
I-.
c4_I C)0
0$-
C,,
a) tO
-	 c
a) —
U,
C)
:11
C)
C) U, .
—a
0
QQa)
Cl) In
•- 0
0
;.. -	 0
361
a)
U) U-
E	 0N
0.	 0
-	 Co
a)
a)4-.0
E0I-0.
>
()
a)0C
a)4-
U)
U)
a)
C
0
0.
E
C
0)
0
w
0
0
a,
C)
c
Co
U)
U)
C
C)
>'
E0
a,
z
0
E
0
0.
C)
>
C/)
>'
0
a-
I
I'
U)
a)
a)
U,
a)U,0
I-.
Oa)
-	 .
0
>-
_4 -
-	 .
a)
—
<0
o >-
E.
4-.
0
0*..
Cl)	 (I
r* 0
0
N
.-.. V
362
C' .!
>'I
Ex
- Co C
0)
I-
0
C
0)
0
a)
-a
0
E
0I-
0.
>(I)
U
a)
U0
I-
0
0)
4-
U)
a)
U)
U)
0)U
0)
-o
a)N
E
.4-.
0
0
4-
a)
U)
U)
0
4-U
0)
U)
C"
1
U0)
C')
U
4-.
E
a)
U
C')
U)
0)
I-.
>
-o
0)Ii
>01...
-
I-
a)0
E
0I-
0
>
0
-c
C-)
C
C,)
U)
a)I.-
C
C-)
E
I)
4-
C,)
D)
c
EI.-0
01)
4-
0
E
0
I.-
0
F—
I-
01)
C)
C
a)
0
U)
U)
I-
a)
D
U)
U)
0)
c..J
w
>
(9
C-)
a)
ci)
'1)0
C
U)
U)
U)
2
0
0
a)
NJ
.t
363
Appendix Ill
364
Manufacturers' addresses
Advanced Biotechnologies Ltd.	 Epsom, UK
Amersham Pharmacia Biotech UK Ltd.
	 Little Chalfont, UK
Becton Dickinson UK Ltd.
	
Oxford, UK
Bio-Rad Laboratories Ltd.	 Hemel I-lempstead, UK
Dako Ltd.	 Ely, UK
Harlan Sera-Lab UK Ltd.
	 Bicester, UK
JCN Pharmaceuticals Ltd.	 Basingstoke, UK
Invitrogen BV	 Groningen, The Netherlands
Life Technologies Ltd.
	 Paisley, UK
Merck Ltd.
	 Leiscester, UK
Molecular Probes Europe BV
	 Leiden, The Netherlands
Oswel DNA Service	 Southampton. UK
Perkin Elmer Biosystems
	 Warrington, UK
Promega	 Southampton. UK
Qiagen Ltd.
	 Crawley, UK
Roche (Boehringer Mannheim)
	 Lewes, UK
Sigma-Aldrich Company Ltd.
	 Poole, UK
Stratagene Ltd.	 Cambridge, UK
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LO
UNIV.
D L-'--t-	 J
DIRECT LINE: 	 0171 380 9191
FDT.dj
4th August 1999
ST. PETER'S HOSPITAL
(In Association wit/s The Institute of Urology & Nephrology)
THE MIDDLESEX HOSPITftL \
Mortimer Stit	 ...-
London WiN 8AA
TeLephone: 017! 436 6464
0171 380.........
Fax 0171 380 9199
Professor Richard Tedder
Head of Dept of Virology
Windeyer Building
Cleveland Street
I ,	 ,	 fr;
-	 T 
')9 •./
- - - - - - - - -: -
Dear Richard,
Re: Residual patient samples for KSHV DNA study
Thank you for submitting this proposal to the Ethics Committee. I am quite happy for this study
to proceed.
Yours sincerely.
Dr F D Thompson
Chairman. Ethics Committee
,j The University College London Hospitals
UCL University Colleg9 London Hospitals is an NHS Trust incorporating The Eastman Dental Hospital. The Hospital for
___________ Tropical Diseases, The Middlesex Hospital, The National Hospital for Neurology & Neurosurgery. The United
HOSPITALS	 Elizabeth Garrett Anderson Hospital and Hospital for Women, Soho, and University College Hospital.
Royal Free and University College Medical School
UNIVERSITY COLLEGE LONDON	 ____
UCLWINDEYER INSTITUTE OF MEDICAL SCIENCES
DEPARTMENT OF VIROLOGY
Windeyer Buildrng
46 aeveland Street
London WIP6DB
Telephone 0171 504 9490
Direct Line 0171 504
Fax 0171 5805896
7 July 1999
Dr F Thompson
Chairman
UCLH Ethics Committee
Department of Uro-Nephrology
Middlesex site
Dear Derek
Re: Residual patient samples for KSHV DNA study
As part of a UCLH Special Trustees-funded PhD studentship, Bianca Elzinger has developed a
quantitative assay for KSHV DNA. The assay was initially developed on material derived from
KSI-1 V-infected cell-lines maintained in tissue cultute. We wish now to investigate the utility of this
assay for the detection of cell-free viral DNA present in plasma and in serum. To confirm that both
materials will be suitable analytes for analysis, we need to access residual patient materials for
testing for KSHV DNA. We intend to use residual material held in the Department on HIV-infected
patients where the patient has been contemporaneously bled into a tube for clotted blood and a tube
for EDTA anti-coagulated blood. This occurs during the confirmation and final assessment of
patients transiting onto anti-retroviral therapy. It will be possible, retrospectively, to identify from
our patientlsample files those instances where contemporaneous serum and plasma residual samples
are held. We wish to test, randomly and entirely anonymously, pairs of plasma and serum samples
for the presence of KSHV DNA. Since this will be undertaken on patients anending consecutively
for starting anti-retroviral therapy, and it will be conducted anonymously, this will neither
compromise patient management nor lead to patient detriment through inadertent identification of
KSHV infection in an otherwise un-affected individual. The ownership of residual samples on
patients is vested in the Trust but for obvious principles of good practice I write to ask your
agreement, as Chairman of the Ethical Committee, that the above protocol for access and testing of
the samples as laid out as part of Bianca Elzinger's thesis, is appropriate and has your blessing. She
approaches the end of her 3rd year with some rapidity, and I would be etrernely grateful for a
response at your earliest opportunity.
Best wishes
Richard S Tedder
Head of Department of Virology
RST/eg
	 A
Professor of Medical Virology and Head of Department The Hon RichardS Tedder MA MB BChur MRCP FRCPath
